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 ABSTRACT 
 
   The work reported in this thesis focuses on the development of synthetic approaches 
to prepare novel triazole-containing nucleic acid (TCNA) monomers for subsequent 
incorporation into oligomers. The triazole moiety was designed to be prepared using 
“click chemistry”. Initial studies involved development of viable synthetic pathways for 
preparation of both the required azide component, derived from L-serine methyl ester 
and the nucleobase-containing alkyne component. The azide has been successfully 
synthesised from either protected or unprotected L-serine methyl ester by direct 
diazotransfer employing the novel ‘diazo donor’, imidazole-1-sulfonyl azide 152. 
Synthesis of the four protected nucleobase-containing alkyne components has been 
achieved in overall yields ranging from 55-89%.  The key step involved alkylation of 
the appropriately protected nucleobase with propargyl bromide. A series of model 
‘click’ reactions were performed in which it was found that the best yields of triazole 
products were obtained using CuSO4·5H2O and sodium ascorbate in a 1:2 ratio. These 
conditions have been applied to the ‘click’ reaction employing the thymine alkyne 
component 161 and L-serine derived azide 158 to afford the desired thymine-derivatised 
triazole product 246 in a 44% yield. Preliminary studies into converting the resulting 
triazole compound into the required phosphoramidite thyminyl TCNA monomer 252 
have been undertaken. 
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Introduction 
 
1.1 INTRODUCTION 
 
   Cancer is recognised as being one of the biggest killers in the developed world today. 
It is expected to affect all of us in some way, at some stage in our lives. Understanding 
why cancer arises in the body, how it can be prevented and how it can be ‘cured’ are the 
key aspects of current cancer research. Increased public awareness through education 
and publicity, advances in diagnostic testing and screening, and the development of new 
and improved treatments, has undoubtedly resulted in greater survival rates being 
observed. However, no widespread, single preventative measure or cure has been found. 
This failing is the driving force behind the extensive array of cancer research carried out 
in the world today and forms the basis from which our research group has stemmed. 
 
   This research will focus on the development of next generation anti-cancer 
therapeutics; by first establishing a greater understanding of current cancer treatments 
and then applying these findings to our own scientific endeavours. 
 
1.1.1 Latest cancer statistics 
 
   With 298,000 people being diagnosed with cancer in the UK each year, it is expected 
that greater than 1 in 3 people will develop some form of the disease during their 
lifetime.1 The twenty most common cancers identified in 2007 are shown in Graph 1. 
Although there are over 200 different types of cancer known, breast, lung, colorectal 
and prostate together account for over half (54%) of all new cases.1 
 
UK incidence of cancer in 2007
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Graph 1. UK incidence of cancer in 2007.  
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1.1.2 Cancer  
 
   Cancer involves loss of control of a number of processes and, ultimately, results in an 
abnormal growth of cells which proliferate in an uncontrollable fashion and, in some 
cases, metastasize. Eventually this unrestrained growth and division of cancer cells 
interferes with the normal functioning of the body and results in the death of the 
sufferer.  
 
1.1.3 The cell cycle 
 
   At the heart of cellular proliferation is the cell division cycle. This is the process by 
which a cell grows, replicates its DNA and then undergoes mitosis into two daughter 
cells.2 A simplified diagram of the four main stages of the cell cycle is depicted in 
Figure 1. 
 
 
M
G2
G1
S
G0
Mitotic
checkpoint
G2 DNA damage
checkpoint
S Phase DNA damage
checkpoint
Restriction
point (R)
G1/S DNA damage
checkpoint
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The stages of the cell cycle (redrawn from ref 2). 
 
   The two most important stages of this cycle are considered to be the S phase, when 
DNA replication occurs, and the M phase (mitosis) when the cell divides into two.2 The 
S phase is the longest part of the cell cycle and typically takes 10-12 hours of the 24 
hours normally required for one complete cycle.2 In the M phase, which is normally 
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complete within 1-2 hours, there is an ordered sequence of events that occur leading to 
the alignment and separation of duplicated chromosomes.2 In order to ensure that the 
integrity of the genome is maintained, DNA replication cannot begin until mitosis has 
ended and mitosis cannot commence until DNA replication is complete.2 Between these 
two phases are G1 and G2, which are two gap phases. G1 supersedes mitosis and is the 
point at which the cell is responsive to both negative and positive growth signals.2 It is 
here that the necessary proteins for DNA replication are synthesised.2 G2 follows on 
from the S phase and is where the cell prepares to enter mitosis.2 At this point, the cell 
undertakes the synthesis of key proteins required to assemble all of the machinery 
which is essential for mitosis.2 The fifth stage, G0 (or quiescence), is the point at which 
the cell may reversibly leave G1 if it is deprived of the appropriate growth-promoting 
signals.2  
 
   Transition from one phase to another through the cell cycle is monitored and regulated 
at various sites known as checkpoints.3 These checkpoints are sensor mechanisms, 
contained within the cell, which screen the cellular environment and establish if 
appropriate conditions have been satisfied before allowing further progression through 
the cycle.2 Every checkpoint consists of three components: (i) a sensor mechanism to 
identify aberrant or incomplete cell cycle events such as DNA damage; (ii) a signal 
transduction pathway to carry the signal from the sensor to the third component, and; 
(iii) an effector, which has the ability to induce a cell cycle arrest should a malfunction 
be found and need to be resolved.2  
 
   The first of these checkpoints occurs at the G1/S transition phase and is responsible for 
sensing DNA damage. The checkpoint at the G2/M transition phase monitors the fidelity 
of DNA replication and, like the G1/S transition, is also involved in detection of DNA 
damage.2 A third checkpoint, known as the spindle checkpoint, is initiated during 
mitosis if a functional mitotic spindle is formed incorrectly.2 In Figure 1, the restriction 
point, R, can be seen between mid and late G1. It is here that the cell ascertains whether 
it has received sufficient growth signals to exit G1 and enter the S phase, replicate its 
DNA and fulfil one successful round of cell division.2 If the cell fails this inspection, it 
will enter G0.  
 
   Cancer occurs when these checkpoints malfunction, allowing inappropriate 
proliferation to take place.  
Introduction 
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1.1.4 Chemotherapy 
 
   Many of the compounds which have been investigated as anticancer agents act at 
multiple sites in the cell cycle.4 Their action can be either cytostatic or cytotoxic 
depending on the status of the target’s cell cycle.4 There are three main classes of 
chemotherapeutic agents: 
 
(1) Antimetabolites: These are drugs that interfere with the formation of key bio-
molecules within the cell, e.g. nucleotides. These drugs interrupt DNA replication and, 
consequently, cell division. Examples of antimetabolites include; folate antagonists 
(methotrexate),5 purine antagonists (6-mercaptopurine)5 and pyrimidine antagonists (5-
fluorouracil).5
 
(2) Genotoxic drugs: These are drugs that interfere with DNA. These agents hinder 
DNA replication, and therefore, cell division. Examples of genotoxic drugs include the 
family of alkylating agents (mitomycin C), intercalating agents (doxorubicin), enzyme 
inhibitors (bleomycin) and groove binders (distamycin). 
 
(3) Spindle inhibitors: Such agents prevent correct cell division by interfering with the 
cytoskeletal components enabling one cell to divide into two. An example of a spindle 
inhibitor is Taxol® (paclitaxel). 
 
   The common side effects associated with chemotherapy include; nausea and vomiting, 
constipation or diarrhoea, dry skin or rashes, lung problems and difficulty breathing, 
bleeding or bruising, muscle and nerve problems, fertility and sexuality problems, 
anaemia, a low number of white cells in blood counts and hair loss. Although, the 
damaged normal tissue usually recovers and repairs, these unpleasant side effects are 
often found to be more debilitating to the patient than the cancer itself. The lack of 
specificity and selectivity of chemotherapeutic agents towards cancer cells only, is the 
main source of these current clinical therapeutic problems. Chemotherapeutics used in 
cancer treatment target all cells undergoing cell division. Cell types that rapidly divide, 
such as those found in the bone marrow and in the lining of the small intestine, are the 
most susceptible to attack. Sites in the body where there is a steady demand for new 
cells, such as the skin, hair and nails are also unwanted targets.  
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1.2 CURRENT CHEMOTHERAPEUTICS 
 
   As outlined in section 1.1.4, page 5, there are three main classes of chemotherapeutic 
agents: antimetabolites, spindle inhibitors and genotoxic drugs.  
 
1.2.1 Antimetabolites 
 
   Antimetabolites are drugs capable of being processed, within a cell, under the disguise 
of being a normal metabolite, and therefore, interfere with regular cell division and 
function.5 The majority of antimetabolite drugs currently used to treat cancer interfere 
with the production of either DNA or RNA.5 The main classes of antimetabolites are: (i) 
folate antagonists, and; (ii) purine/pyrimidine antagonists. 
 
(i) Folate antagonists 
 
   Folate antagonists (antifolates) inhibit the enzymes dihydrofolate reductase (DHFR) 
and thymidylate synthetase (used to generate thymidine monophosphate (TMP)), which 
participate in the formation of nucleotides.5 DHFR converts dihydrofolate (FH2) into 
tetrahydrofolate (FH4) and subsequently, 10-formyl tetrahydrofolate (CH2FH4). By 
blocking these enzymes, the folate antagonists prevent nucleotide production and hence 
DNA replication and cell division are disrupted.5 
 
   An example of a folate antagonist currently used clinically is methotrexate [Figure 2]. 
 
N
N N
N
NH2
H2N
N
N
H
O
OHO
OHO
1
 
 
 
 
 
 
Figure 2. Structure of methotrexate. 
 
Methotrexate is used to treat many different forms of cancer such as choriocarcinoma, 
breast, bladder, head and neck cancers, large cell and high grade lymphoma, acute 
lymphocytic leukaemia and osteogenic cancers.5 Methotrexate’s exact mechanism of 
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action is, as yet, uncertain.5 However, it is known to enter the cell through an active 
transport system, which is available to the natural substrate folate, and then bind to and 
inhibit the enzymes.5 
 
(ii) Purine/pyrimidine antagonists 
 
   Purine antagonists function by replacing purine nucleotides (adenine and guanine) in 
one or more normal cell functions.5 They are ‘decoys’ for the natural nucleotides. 
Purine antagonists inhibit DNA synthesis is two ways: (1) they inhibit the synthesis of 
purine nucleotides, and; (2) they may become incorporated into DNA during its 
synthesis and further interfere with cell division.5 An example of a purine antagonist 
drug which is currently used to treat many forms of leukaemia is 6-mercaptopurine 
[Figure 3].5 
 
N
N N
N
SH
H
2
 
 
 
Figure 3. Structure of 6-mercaptopurine. 
 
   Pyrimidine antagonists function by blocking the synthesis of pyrimidine-containing 
nucleotides (thymine and cytosine).5 As was the case for purine antagonists, they act as 
‘decoys’ of the natural nucleotides and their mode of action is identical too. An example 
of a pyrimidine antagonist which is used clinically is 5-fluorouracil [Figure 4]. 
 
N
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O
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H
3
 
 
 
 
Figure 4. Structure of 5-fluorouracil. 
 
1.2.2 Spindle inhibitors 
 
   Spindle inhibitors are different to the previous examples in that they do not alter DNA 
structure or function. Instead they act on the mechanics of cell division. 
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   As stated previously, mitosis is the process by which a cell is replicated and then 
divided into two separate daughter cells.6 This process involves spindle fibres which 
attach themselves to the replicated chromosome and facilitate the movement of one 
copy of the chromosome to each side of the dividing cell.6 Without such spindle fibres, 
the cell cannot divide and cell apoptosis results.6 
 
   Spindle inhibitor drugs act in a cell-cycle specific manner, halting cell division in the 
early stages of mitosis.6 Spindle fibres are composed of microtubules which are 
composed of smaller subunits of proteins known as tubulins.6 Certain types of spindle 
inhibitors associate with the tubulin monomers and prevent their synthesis.6 This 
complex stops the correct formation of such spindle microtubules and disables the 
transportation of chromosomes.6 The movement of replicated chromosomes is 
dependent on two processes: (1) the polymerisation of tubulins to form microtubules, 
and; (2) the breakdown of such microtubules.6 An example of a current spindle inhibitor 
drug is taxol® [Figure 5]. 
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Figure 5. Structure of Taxol®. 
 
The mode of action for Taxol® is to bind to microtubules and consequently prevent 
their breakdown.6 
 
1.2.3 Genotoxic drugs 
 
   Genotoxic anticancer drugs can be classified into three main groups: (i) alkylating 
agents; (ii) enzyme inhibitors, and; (iii) intercalators. 
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(i) Alkylating agents 
 
   Alkylating groups act by adding alkyl groups to negatively charged groups.7 They are 
extremely electrophilic compounds capable of reacting with nucleophiles to form strong 
covalent bonds.7 There are two types of alkylating agents: mono and dialkylating 
species. Monoalkylating agents react with one guanine nucleobase, and are less 
common clinically, as they have been superseded by more efficient dialkylating 
compounds. 
 
   Alkylating agents act by three different mechanisms to cause disruption of DNA 
function and results in cell apoptosis. The three mechanisms are outlined as follows:  
 
   In the first mechanism, alkylating drugs, attach alkyl groups to guanine nucleobases.7 
Repair enzymes attempt to restore the alkylated bases, and in so doing, cause the DNA 
to become fragmented.7  
 
   The second mechanism involves cross-linking between two guanine nucleobases on 
DNA and is only seen for dialkylating agents.7 These cross-links may occur within a 
single molecule of DNA (intrastrand cross-linking), or by bridging between two 
different molecules of DNA (interstrand cross-linking).7 Ultimately, this course of 
action prevents DNA from separating and therefore prevents transcription from 
occurring.7 
 
   The first alkylating agent used clinically, was the nitrogen mustard compound, 
mechlorethamine (Mustargen) [Figure 6].7 
 
N
Cl
Cl
5
 
 
 
Figure 6.  Structure of mechlorethamine. 
 
Mechlorethamine is an example of this second mode of action and is known as a 
bifunctional agent, as it is capable of binding and reacting at two different sites.7 The 
chloride ion is displaced intramolecularly by the nitrogen atom, to form a substantially 
electrophilic aziridine ion intermediate.7 This reactive intermediate then alkylates the 
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N7 of guanine in one or both strands of the DNA molecule, which results in cross-
linking between the guanine residues in DNA chains, and/or depurination which 
facilitates DNA strand breakages.7 It is currently used to treat Hodgkin’s lymphoma, 
non-Hodgkins lymphoma and some types of chronic leukaemia. 
 
   The third mechanism of action of alkylating agents involves inducing the mispairing 
of nucleotides resulting in mutations.7 Guanine nucleobases erroneously pair with 
thymine instead of its Watson-Crick base pair cytosine, and the resulting mismatch, if 
not corrected, has the potential to become a permanent mutation.7 Mitomycin C [Figure 
7] is an example of a current drug which alkylates using primarily, this third 
mechanism.  
 
6
O
H2N
O
N
O
NH2
OCH3
NH
 
 
 
 
Figure 7. Structure of mitomycin C 
 
It is derived from the bacterium Streptomyces caespitosus and is commonly used as an 
antibiotic, however, it can also function as an alkylating agent.7 
 
   Alkylating agents are not selective in their action, and therefore, have the ability to 
react with all nucleophiles in the body, such as proteins or other macromolecules.7 
Alkylation can occur in both cycling and resting cells and are cell-cycle non-specific.7 
However, proliferating cells are more susceptible to attack from these agents.7 For these 
reasons, it is vital that the alkylating agents are applied locally, targeting the tumour.7 
 
(ii) Enzyme inhibitors 
 
   Genotoxic enzyme inhibitors are drugs which interfere with key enzymes, e.g. 
topoisomerases, which are involved in DNA replication, thereby inducing DNA 
damage. Bleomycin (Blenoxane®) [Figure 8] is one such example of a compound. It 
has the ability to cleave the phosphodiester backbones of duplex DNA and, 
subsequently, avert the enzyme DNA ligase from repairing the damage.8 Bleomycin is a 
glycopeptide antibiotic, which is produced by the bacterium Streptomyces verticillus. Its 
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mode of action is to form complexes with iron, which go on to reduce molecular oxygen 
to superoxide and hydroxyl radicals. These radicals subsequently cause single- and 
double-stranded breaks in DNA.8 Further, these reactive oxygen species induce lipid 
peroxidation, carbohydrate oxidation and alterations in prostaglandin synthesis and 
degradation.9 Bleomycin is currently used to treat many forms of cancer e.g. Hodgkin’s 
lymphoma, non-Hodgkin’s lymphoma, testicular cancer, cancers of the head and neck 
and also, fluid on the lung. 
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Figure 8. Structure of Bleomycin. 
 
(iii) Intercalators 
 
   Intercalators bind in the spaces between nucleotide base pairs in the double helix of 
DNA.10 Their flat, π-electron chromophore binds tightly but reversibly to DNA through 
a combination of dipolar forces such as electrostatic, hydrophobic and hydrogen-
bonding interactions.10 Through binding, intercalating drug molecules alter the structure 
of DNA, which consequently prevents polymerases and other DNA binding proteins 
from functioning correctly.10 They interfere with transcription and replication and 
induce mutations in DNA.10 An example of an intercalating drug currently used 
clinically is doxorubicin (Adriamycin®) [Figure 9].  
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Figure 9. Structure of doxorubicin. 
 
Doxorubicin was first isolated from the fungus Streptomyces peucetius and is an 
anthracycline antibiotic. It acts as both an intercalator and an enzyme inhibitor and is 
used to treat many forms of cancer including Hodgkins and non-Hodgkins lymphoma, 
breast, lung, bladder, ovarian, testicular, gastric, thyroid cancer, soft tissue sarcoma, 
hepatoma, Wilm’s tumour, acute leukaemia and neuroblastoma.10  
 
   The main disadvantage for all the chemotherapeutic agents described in this section, is 
that they fail to demonstrate high specificity to cancer cells, mainly, as a result of them 
being small molecules. As stated previously, all forms of rapidly dividing cells are 
targeted, including normal healthy cells, and this results in the common side-effects of 
chemotherapy described in section 1.1.4, on page 5. They also fail to discriminate 
effectively between cancer-causing and normal genes. In order to address the later issue, 
selectivity must be improved. To develop drugs that inhibit specifically one particular 
gene, much larger compounds have to be employed (see the later section 1.7.1. on pages 
37-42). 
 
   The purpose of the research reported in this thesis was to develop the next generation 
of cancer chemotherapeutics which would be more selective for cancer cells. We were 
interested in regulating gene expression at the level of DNA. In order for us to discuss 
the specific drugs that target DNA, it is first necessary to understand the structure and 
function of DNA itself. 
 
1.3 THE COMPONENTS OF DNA  
 
   DNA is essentially a highly negatively charged biopolymer, the monomers of which 
are called nucleotides. A nucleotide consists of three components; a five-carbon sugar, a 
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heterocyclic base and a phosphate group. The sugar in DNA is 2-deoxy-D-ribose, a 
furanose, as shown in Figure 10. 
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Figure 10. Structure of 2-deoxy-D-ribose. 
 
   DNA consists of four unique, organic heterocyclic bases; adenine (A), guanine (G), 
thymine (T) and cytosine (C). As stated previously, adenine and guanine are bicyclic 
purines and cytosine and thymine are monocyclic pyrimidines, the structures of which 
are depicted in Figure 11. 
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Figure 11. DNA bases. 
 
At physiological pH (5 < pH < 9), the bases exist in the forms shown in Figure 11 
above; however, at pH greater than 3, keto-enol and amino-imino, tautomeric forms 
may also exist.6 These tautomeric forms are shown in Figure 12.  
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    Figure 12. Tautomeric forms. 
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The planar faces of each of the bases make them hydrophobic.6 The N-H groups are 
good hydrogen-bond donors while the sp2-hybridized electron pairs, on both the 
oxygens of the carbonyl groups and ring nitrogens, are much better hydrogen-bond 
acceptors than the oxygens of either the phosphate or the pentose sugar.6 The hydrogen 
donor/acceptor abilities of the nucleotide bases is illustrated in Figure 13 taking 
deoxycytidine as an example.6 
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Figure 13. Donor/acceptor ability of deoxycytidine.6 
 
    The nucleotide bases are attached to the sugar moiety through β-glycosidic links 
between C1 of the sugar and either N1 or N9 of a pyrimidine or purine base, 
respectively.6 The resulting structures are known generally as deoxyribonucleosides, 
and the four deoxyribonucleosides present in DNA are shown in Figure 14. 
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Figure 14. Structures of the deoxyribonucleosides. 
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   The name nucleotide is given to phosphate esters of nucleosides. In the case of DNA, 
it refers to a nucleoside bearing a 5’-phosphate group on C5 of the sugar ring, as shown 
in Figure 15. 
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(MP = 5’-monophosphate) 
 
Figure 15. Structures of the deoxyribonucleotides. 
 
1.3.1 Shapes of nucleotides 
 
   Nucleotides incur many interactions between non-bonded atoms as a result of their 
bulky substituents.6 In order to minimise these non-bonding interactions, nucleotides 
adopt compressed structures through use of sugar puckers and syn- and anti-conformers 
of the glycosidic bond. 
 
The sugar pucker 
 
   In order to minimize the interactions between non-bonded substituents, the furanose 
rings of nucleotides are twisted out of the plane.6 This ‘puckering’ is defined by 
identifying the main displacement of C’2 and C’3 from the median plane denoted by C’1-
O’4-C’4.6 The displacement of these two atoms is not equal.6 If for example, the endo-
displacement of C’2 is found to be greater than the exo-displacement of C’3, then the 
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conformation is called C2’-endo.6 The endo face of the sugar ring contains the 
nucleotide base together with C’5, and the exo face is the opposite side.6 The sugar 
puckers are positioned in the north and south domains of the pseudorotation cycle of the 
sugar ring.6 Fortuitously, the relative shape of the C-C-C-C bonds in the C2’-endo and -
exo- forms reflect the (S) and (N) designations.6 In regular dsDNA, the sugar moiety 
adopts the C2’-endo (S) pucker.6 The sugar puckers are shown in Figure 16. 
 
C5'
B
O3'
BO3'C5'
23 23a
 
 
 
Figure 16. Structures of C ’-endo (S) 23 and C ’-endo (N) 23a sugar puckers. 2 3
 
The syn-anti conformation of the glycosidic bond 
 
   Syn- and anti-conformers result from rotation about the glycosidic bond through the 
torsion angle χ.6 The heterocyclic bases are contained within a plane perpendicular to 
the furanose ring and approximately intersect the O’4-C’1-C’2 angle.6 As a result, the 
bases can reside in two orientations, the syn- conformer and the anti-conformer.6 For the 
anti-conformer, the H6 (pyrimidine) or H8 (purine) atom is positioned above the sugar 
ring [Figure 17] and in the case of the syn-conformer, it is the O2 (pyrimidine) or N3 
(purine) atom which is positioned above the sugar ring [Figure 17].6 In regular dsDNA, 
nucleotides adopt the anti-conformation.6 
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Figure 17. Structures of the syn- 24 and anti- 24a conformations. 
 
1.3.2 Secondary structure of DNA 
 
   DNA generally exists in the form of a double-stranded helix, with the exception of a 
few viruses where it is found as a single strand. Two polynucleotide chains, come 
together in an anti-parallel fashion to form a double helix and are stabilised by hydrogen 
bonding that ensues from complementary base pairing.11 The double helix of DNA is 
depicted on the next page in Figure 18.  
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Figure 18. Structure of the double helix (taken from www.tutorvista.com). 
 
From Figure 18, it can be seen that the sugar-phosphate backbone is on the outside of 
the molecule encapsulating the nucleobase pairs in the core of the structure. Two 
hydrogen bonds form between an adenine of one strand and a thymine on the other, 
when they are located opposite each other,6 whereas three hydrogen bonds form 
between a cytosine and a guanine. Adenine only base pairs with thymine and cytosine 
only base pairs with guanine. This base association shown in Figure 19, is known as 
Watson-Crick base pairing after the scientists who first reported the structure of DNA.6  
 
N
N
HN
N
O
N H
H
H
Guanine
N
N
N
O
H
H
Cytosine
dR
dR
N
NN
N
N
H
H
N N
O
O
H
Adenine Thymine
dR
dR
10 13 11 12
 
 
 
 
 
 
Figure 19. Watson-Crick base pairing, with hydrogen bond formation.
 
The flat base pairs arrange themselves in the structure of dsDNA in such a way, so as to 
eradicate water molecules. They achieve this by stacking and rotating slightly, relative 
to one another.6  
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B-DNA 
 
   B-DNA is the commonest form of dsDNA. Its key feature is that it has a major and 
minor groove of approximately equal intensity.6 The depth of the major and minor 
grooves are 8.8Å and 7.5Å respectively, and the width of the major and minor grooves 
are 11.7Å and 5.7Å respectively.6 The heterocyclic bases stack directly above their 
neighbours in the same strand and are perpendicular to the axis of the helix.6 As 
mentioned previously, the C2’-endo sugar pucker is the predominant conformation 
adopted by the sugar moiety and all the glycosides adopt the anti-conformation.6 
Phosphate groups in the same chain are 6.7Å apart and there are 10 base pairs per turn 
in B-DNA.6 
 
   The wide major groove of B-DNA is surrounded by a unimolecular surface of water 
molecules which interacts with all the C=O, N and NH groups that are present in this 
region, and is responsible for solvating the phosphate backbone.6 In the smaller minor 
groove, two water molecules per base-pair can be found, in a well-ordered zig-zag 
pattern.6  
 
   The average parameters for B-DNA are shown in Table 16 (page 21) and diagrams of 
its structure are shown in Figure 20 below. 
 
 
 
 
 
 
 
 
 
Figure 20. Structure of B-DNA (taken from www.somewhereville.com). 
 
   In addition to B-DNA, alternative secondary structures of DNA are known. These 
include A-DNA and Z-DNA.  
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1.3.3 Alternative secondary structures of DNA 
 
   There are several conformations that dsDNA can adopt apart from B-DNA as 
summarised in Table 1 on page 21.6 Of these, the two most important alternative double 
helical structures are; the A- and Z- form (Figure 22, page 20). It is believed, that both 
the A- and Z- form of the double helix may exist in localized sections of the 
chromosome, but not exclusively.1 
 
   The A-form arises when dsDNA becomes dehydrated.6 This causes the heterocyclic 
bases to tilt by 20 τo (propeller twist [Figure 21]) relative to the helical axis and the 
overall perception of the double helix to become stocky in shape.6 The A-form follows 
the Watson-Crick model with anti-parallel, right-handed double-helices.11 All the 
parameters for the A-form are shown in Table 1 on page 21.6 
 
 
 
 
 
 
 
Figure 21. Schematic diagrams of the propeller twist that arises in A-DNA (taken from 
www.ed.stanford.edu). 
 
   In the A-form, the major groove is deeper by 4.7Å and narrower by 9.0Å compared to 
B-DNA, there are 11 base pairs per turn and the C3’-endo sugar pucker is predominant.6 
The structure of A-DNA is shown in Figure 22 on page 20. 
 
   The Z-form of dsDNA is a left-handed double helical structure. This arises due to a 
switch in the glycosidic torsion angle, from the regular anti- to the atypical syn-
conformation, for one nucleoside (the purine) in each base pair.6 This anti-syn 
relationship alternates along the DNA backbone which, as a consequence, causes the 
phosphorous atoms to follow a zig-zag path.6 Further, the sugar pucker alternates from 
C2’-endo for the anti-residues to C3’-endo for the syn-nucleosides.6 It is the combination 
of these two changes that causes a significant difference to the base-stacking abilities of 
Z-DNA compared to the other forms of dsDNA.6 As a consequence of this, the minor 
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groove of Z-DNA is so cavernous that it contains both the helical axis and the major 
groove. The surface of the minor groove is also convex exposing the C5 of the cytosine 
residues and the N7 of the guanine C8 moieties.6 The major groove is shallower by 5.1Å 
and narrower by 2.9Å compared to B-DNA, there are 12 base pairs per turn and the C3’-
endo(syn) sugar pucker is predominant.6 The parameters for Z-DNA are shown in Table 
1 on page 21 and its structure is shown in Figure 22 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Structures of (a) B-DNA, (b) A-DNA and (c) Z-DNA (taken from 
www.nthu.edu). 
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Twist per 
bp t/o
Displacement
bp / Å 
Rise per 
bp / Å 
Base 
tilt 
τo
Sugar 
pucker 
Groove Width / 
Å 
minor        major 
Groove Depth / 
Å 
Structure 
Type 
Helix 
sense 
Residues 
Per turn minor        major 
A-DNA R 11 32.7 4.5 2.56 20 C-3’-endo 11.0              2.7 2.8            13.5 
B-DNA R 10 36 -0.2 to -1.8 3.3-3.4 -6 C-2’-endo 5.7             11.7 7.5             8.8 21
Z-DNA L 12 -9, -51 -2 to -3 3.7 -7 C-3’-
endo(syn) 
2.0               8.8 13.8             3.7 
 
     Table 1. Average helix parameters for the major DNA conformations. 
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1.3.4 Higher order DNA structures 
 
   DNA in eukaryotic cells exists as a DNA-protein complex known as chromatin. Small 
basic proteins called histones, abundant in the amino acids arginine and lysine, bind to 
the phosphate groups on the DNA backbone through formation of ionic bonds.6 Four of 
these proteins, H2A, H2B, H3 and H4, (two of each) come together to form an octamer 
protein complex called a nucleosome core [Figure 23].6  
 
 
 
 
 
 
 
 
 
Figure 23. Structure of a nucleosome (taken from www.accessexcellence.org). 
 
The DNA duplex (red) wraps around the block of eight histones (grey) to give 1.75 
turns of a left-handed superhelix.6 Each successive nucleosome core is linked via an 
intervening stretch of linker DNA of length 30-40 base-pairs. The structure that results 
is termed ‘beads on a string’ and is shown schematically in Figure 24 on page 23. 
Although this process condenses the DNA molecule, further compaction is still 
required.6 The nucleosomes form a 10 nm fibre which is further condensed by a fifth 
histone, H1 (green), to form what is known as the 30 nm fibre or a solenoid.6 This fibre 
is arranged as long loops attached to a central chromosomal protein scaffold, which 
forms the highly dense chromosome structure. Chromosomes are located in the nucleus 
of a cell. 
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Figure 24. Hierarchy of chromatin (taken from www.themedicalbiochemistrypage.org). 
 
   When cells divide, each chromosome must be carefully replicated to ensure that each 
daughter cell obtains a complete and accurate set of information. 
 
1.4 DNA REPLICATION 
 
   Double-stranded DNA (dsDNA) replication is known to be semi-conservative, in that 
the two original parental strands are separated and act as a template for synthesising the 
new strand.6 As a result of this, there is precise duplication of DNA in terms of both 
quantity and sequence.6  
 
   Firstly, the two original polynucleotide chains of dsDNA, parental strands, are 
separated at the origin of replication by the enzyme helicase (Figure 25, page 24). 
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Figure 25. Semi-conservative DNA replication (taken from www.britannica.com). 
 
Due to the vast length of DNA and the fact that it is attached to protein structures 
(previously described in section 1.3.4, page 22), separation presents a topological 
problem known as overwinding.12 This results in the formation of positive supercoils 
that if unrelieved, would halt strand separation and therefore DNA replication.12 Such 
supercoils are removed by topoisomerases enzymes of which there are two types; type I 
and type II, there action is summarised in Table 2 below. 
 
          Topoisomerase            Action on DNA                       Effect on supercoiling 
              Type I                      Cuts one DNA strand              Relaxes positive and 
                                                                                               negative supercoils. 
 
              Type II (gyrase)      Cuts two DNA strands             Relaxes positive supercoils 
                                                                                                but cannot insert negative 
                                                                                                supercoils. 
                                               
Table 2. Summary of the types of topoisomerases and their action. 
 
   At the point at which the two strands are separated, the replicative fork [Figure 25], 
DNA is synthesised at a rate of 50 base pairs per second.12 There are hundreds of 
origins of replication situated along the chromosome, allowing for replicative forks to 
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work in both directions.12 Enzymes called DNA polymerases catalyse the 
polymerisation of nucleotides into DNA.12 DNA polymerase can only synthesis DNA in 
a 5’- to 3’- direction, which creates a problem due to the two parental strands running in 
anti-parallel directions, hence, only one strand has the required directionality.12 From 
Figure 25, the leading strand is synthesised continuously in the 5’- to 3’- direction and 
the lagging strand is synthesised discontinuously in a 5’- to 3’- direction.6  
 
   DNA polymerase cannot initiate chain synthesis as it is unable to join together two 
free nucleotides. This problem is overcome by the preliminary links, phosphodiester 
bonds, being prepared by an RNA polymerase known as primase.12  
 
   As elongation of the leading strand continues, a greater portion of the lagging strand 
becomes single-stranded.6 DNA polymerase then acts on this lagging strand to synthesis 
short, complementary strands called Okazaki fragments6 [Figure 25]. As DNA unwinds, 
primase repeats the initiation section on the lagging strand, to which these Okazaki 
fragments become attached [Figure 25].12 The lagging strand is synthesised as a series 
of these Okazaki fragments in which the gaps between have been filled by DNA 
polymerase. Another enzyme called DNA ligase, then joins the fragments together 
forming the complete DNA strand.12 
 
   Due to the necessity for a short segment of single-stranded DNA, on both the leading 
and lagging strand close to the replicative fork, this area is protected by single-strand 
binding proteins.6 Single-stranded binding proteins, which themselves have no base 
sequence specificity, bind to the separated strands, the energy release of which drives 
strand separation to completeness.12 A product of the ssb gene, these proteins also 
protect this highly susceptible region from hydrolysis by nucleases.6 DNA polymerase 
displaces these proteins in the process of synthesising a new complementary strand and 
the overall result is the production of two daughter double helices containing identical 
genetic content to their parent.6 
 
1.5 GENE EXPRESSION 
 
   The genetic code, derived from the sequence of the four bases, A, T, C and G, is used  
to direct the assembly of each of the twenty amino acids required to produce the protein 
for which a specific gene is responsible.12  
Introduction 
 
   A gene does not directly participate in protein synthesis. In eukaryotes, the DNA is 
enclosed inside the nuclear membrane whilst the protein-synthesising machinery is 
situated in the cell cytoplasm.12 Instead, a copy of the code is transcribed into mRNA 
transcripts through a process known as transcription.12 The manner in which mRNA 
transcripts guide the correct sequencing of amino acids to synthesise proteins is called 
translation.6 The overall flow of genetic information involved in gene expression is 
shown schematically in Figure 26 below. 
 
                                                      Transcription              Translation 
DNA        Æ          mRNA          Æ        Protein  
 
 
Figure 26. Schematic diagram showing the flow of genetic information involved in gene 
expression. 
 
1.5.1 Transcription 
 
   Transcription is the first step in the biosynthetic process of protein synthesis within a 
cell and, as stated above, is the process of transcribing the information stored in DNA to 
mRNA transcripts. The strand of DNA double helix that is copied by base pair 
complementarity is known as a the template strand [Figure 27].12 
 
DNA
5' C G A T G C A T 3' Non-template strand
(coding or sense)
3'G C T A C G T A 5' Template strand
(non-coding or non-sense)
5' C G A U G C A U 3' mRNA strand
 
 
 
 
 
 
 
 
 
Figure 27. The relationship between mRNA and the template/non-template strands of 
DNA. 
 
   As previously mentioned in section 1.3.4, page 22, DNA undergoes a great degree of 
packing in order to fit its vast length into the nucleus of a cell. Before (or during) 
transcription, the higher order structure of DNA must selectively loosen at a particular 
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gene to be transcribed.  This is achieved by a large number of protein transcription 
factors assembling on the 5’- side of a gene at the promoter site and recruiting RNA 
polymerase from the surrounding medium, to bind to this complex.  Together, the 
protein transcription factors and RNA polymerase facilitate the opening of the DNA 
double helix at a specific gene.  The progression from this initiation to the actual 
synthesis of mRNA is complicated and to date, incompletely understood.  However, 
RNA polymerase is known to move along the template strand in a 3’- to 5’- direction.  
In doing so, the enzyme reads the exposed DNA nucleotide bases and assembles the 
corresponding Watson-Crick complementary ribonucleotide (supplied as triphosphates) 
to the RNA strand being formed.  When RNA polymerase reaches the end of the gene, 
it synthesises the sequence AAUAAA (which is coded for by the template strand).  The 
enzyme continues to transcribe beyond this point and then terminates by an as yet not 
understood mechanism.  A separate enzyme cuts the RNA transcript a short distance 
beyond this termination signal and then another enzyme adds adenine nucleotides to 
form a polyA tail.  As many as 200 adenines are added to the 3’-end of the mRNA 
transcript and the main reason for this is believed to be to protect the transcripts from 
rapid degradation from 3’- to 5’- exonucleases.  Further, it may also be necessary for 
the transport of the mRNA transcripts and in their subsequent translation.  
12
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12
12
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   The initial mRNA (pre-RNA) produced by transcription is proportionate in length to 
the size of the protein to which it codes.12 It is divided into several segments linked by 
intervening stretches of RNA which do not code for the amino acid sequence.12 These 
intervening stretches of RNA are called introns and the coding segments are called 
exons.12 There are between 2 and 500 introns in every gene, which vary in length from 
50 to 20,000 base pairs, in contrast to exons which are normally less than 1000 base-
pairs in length.12 Due to pre-RNA being longer than that required for subsequent 
translation, following transcription, a maturation procedure takes places to remove the 
introns and thus shorten the molecule.12 The process by which the introns are eliminated 
and the exons are linked together is known as RNA splicing12 and is depicted in Figure 
28 on page 28. 
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Figure 28. mRNA splicing (redrawn from www.unm.edu). 
 
   mRNA, once prepared, immediately undergoes a modification at the 5’-end known as 
capping.12 The first nucleotide triphosphate incorporated into the RNA simply accepts 
the nucleotide on its 3’-OH group, which results in the initial triphosphate being 
unchanged.12 The capping process removes the terminal triphosphate and replaces it 
with a GMP residue from GTP, the 5’-5’triphosphate which results, is extremely rare in 
nature [Figure 29].12 The guanine nucleobase is then methylated at the N7 position and a 
methyl group is added to the sugar 2’-OH of the second, and occasionally third, 
nucleotide.12 The purpose of this ‘cap’ is to both protect the mRNA from exonucleases 
and to facilitate the initiation of translation.12  
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Figure 29. Structure of the 5’-cap in eukaryotic mRNA.
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   Unlike DNA, which to a large extent is immortal in cellular terms, mRNA has a half-
life of twenty minutes to several hours.6 This means that mRNA has to be continuously 
produced.6 Destruction of mRNA molecules in the cytoplasm marks the end point of the 
synthesis of the specific proteins encoded by the gene.6  
 
   mRNA is not the only form of RNA that is produced from transcription of a gene: 
Ribosomal RNA (rRNA) for use in the synthesis of ribosomes (see the later section 
1.5.2, page 30); transfer RNA (tRNA) used to transport amino acids to the growing 
polypeptide chain (see the later section 1.5.2, page 30); small nuclear RNA (snRNA) 
used in the processing of the primary transcripts produced from transcription of mRNA, 
rRNA and tRNA to functional molecules exported to the cytosol; small nucleolar RNA 
(snoRNA) that have a variety of functions and are located in the nucleolus of the cell; 
and microRNA (miRNA) that regulate the expression of mRNA molecules are also 
synthesised through transcription.12 However, it is mRNA that is translated into a 
polypeptide. 
 
1.5.2 Translation 
 
   The second step in the sequence of genes directing the synthesis of proteins is 
translation and is summarised in Figure 30 below. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Schematic diagram of translation (taken from www.le.ac.uk). 
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   Translation is a three step process involving the use of mature mRNA, ribosomes and 
tRNA. Proteins are synthesised from twenty different varieties of amino acids and the 
sequence of bases in the mRNA, designates the sequence of amino acids in the 
protein.12 A codon is a triplet of bases which represents each amino acid included on the 
mRNA.12 Identification of the codons responsible for each amino acid can be found in 
the genetic code, a list of all these constituents12 [Appendix A].  
 
   Proteins are synthesised on particles called ribosomes.12 In every cell, there is a large 
quantity of these multi-subunit particles, they are ~20 nm in diameter and are composed 
of both ribosomal rRNA and a ribosomal protein, called ribonucleoprotein (RNP).6 
rRNAs conform to a highly folded, compact structure and are associated with the 
formation of numerous proteins.6 
 
   Due to no direct link, either physically or chemically, being established between the 
association of a codon and its corresponding amino acid, it was postulated that an 
adaptor molecule known as tRNA was involved.12  
 
   tRNAs are small RNA molecules of less than 100 nucleotides in length.12 They 
constitute a cloverleaf structure, with the unpaired nucleic bases arranged as a direct 
consequence of the internal base-pairing that exists. The complete structure is called an 
anticodon and is depicted in Figure 31 below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. The cloverleaf structure of tRNA (taken from www.interscience.wiley.co.uk). 
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   The tRNA molecules have two main sections; an anticodon and an amino acid 
accepting site.12 The anticodon is situated at a hairpin bend and is a triplet of unpaired 
bases complementary to a codon.12 These bases are therefore available for hydrogen 
bonding to a complementary codon on mRNA.12 At the 3’-accepting site, the sequence 
CCA marks the point at which the ribose sugar becomes covalently bound to the amino 
acid through the formation of an ester linkage.12 
 
   The synthesis of a protein molecule can be divided into three phases; initiation, 
elongation and termination.12 
 
Initiation 
 
   As discussed in section 1.5.1 on page 28, mRNAs are ‘capped’ with a methylated 
guanine nucleotide at the 5’ end.12 A collection of eukaryotic initiation factors (EIF) and 
an amino acid containing-tRNA (in this case Met) [Figure 32], attach to the cap, and are 
joined by a 40 S ribosomal subunit.12 
 
   The ribosome in the initiation complex is situated at the cap site, some distance from 
the AUG start codon.12 The 40 S subunit complex advances along the mRNA to the 
initiating AUG codon and at this point, the 60 S subunit joins the complex which 
completes the initiation process.12 After initiation is achieved, polypeptide synthesis 
proceeds involving two cytosolic elongation factors.12 
 
Elongation 
 
 
 
 
 
 
 
 
 
Figure 32. Elongation in eukaryotes (taken from www.emcmaricopa.edu). 
 
 31
Introduction 
 
 32
   The P site only accepts tRNAs charged with an amino acid from the initiation process 
[Figure 32].12 All subsequent aminoacyl-tRNAs enter the A site after being complexed 
in the cytosol with the elongation factor EF1α.12  
 
   The aminoacyl groups on the two tRNA molecules in the P and A sites are in the 
vicinity of the catalytic site of the enzyme peptidyl transferase. This RNA molecule is 
responsible for transferring the amino acid in the P site (Met) to the free amino group of 
the aminoacyl-tRNA in the A site (Pro), the result of which is a dipeptide (Met-Pro) 
attached to the tRNA [Figure 32].12 
 
   Once this first peptide bond is synthesised, the A site is filled with a peptidyl-tRNA 
and the P site contains the uncharged tRNA.12 The ribosome is repositioned one codon 
further along the mRNA in a process known as translocation.12 The discharged tRNA is 
transported to a third exit site and the peptidyl-tRNA in the A site is moved to the P 
site.12 The elongation process continues in an infinite fashion until a stop codon is 
encountered on the mRNA.12  
 
Termination 
 
   At the end of the mRNA, one of three stop codons; UAG, UAA or UGA is 
encountered.12 Once this occurs, a specific cytoplasmic protein release factor attaches 
and envokes the release of the final protein from the tRNA.12 Hydrolysis of the ester 
bond occurs and the ribosome detaches from the mRNA and dissociates into subunits 
ready for the next initiation process.12  
 
1.6 METHODS FOR CONTROLLING GENE EXPRESSION 
 
   Gene expression can be controlled in two ways using either antisense therapy or 
antigene therapy. 
 
1.6.1 Antisense therapy 
 
   Antisense oligonucleotides are short single-stranded DNA molecules, of 
complementary sequence to a target mRNA strand, which are capable of specifically 
binding to and thereby inhibiting translation of this mRNA [Figure 33]. 
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Figure 33. Schematic diagram of Antisense therapy (taken from www.csbsju.edu). 
 
   In the 1970s, it was discovered that an oligodeoxynucleotide, bearing a 
complementary sequence to part of the Rous Sarcoma virus’s mRNA, was capable of 
preventing its translation and, therefore, its viral production.13 These findings afforded 
researchers with a new drug-design strategy to treat diseases that arose from over-
expression of unwanted genetic information.14 Thus, providing the sequence of the gene 
is known, then a synthetic oligonucleotide can be prepared to form a stable Watson-
Crick base paired duplex with the target mRNA and, subsequently, avert its translation.  
 
   Once bound to the mRNA target, inhibition can occur through three main modes of 
action; cleavage by RNase H, translational arrest and directed alternative splicing.15 
Figure 34 depicts these modes of action. 
 
 
 
 
 
 
 
 
 
 
Figure 34. Translation modes of action (taken from www.journalsprous.com). 
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   Of  these modes of action, gene inhibition is substantially due to endogenous RNase 
H. This ubiquitous endonuclease recognizes mRNA-oligonucleotide duplexes and 
cleaves the RNA strand, leaving intact the antisense strand, which is then free to bind 
other molecules of the mRNA target.15 Due the antisense strand remaining intact during 
this process, an antisense approach to exploit this mode of action would be catalytic.15  
 
   Translational arrest [Figure 34] results in hybrid arrest or the inhibition of the 
initiation complex (see the previous section 1.5.2, page 31) and therefore, translation is 
halted.15 
 
   Directed alternative splicing [Figure 34] involves the re-establishment of correct 
splicing sites by oligonucleotides that target incorrect mutant splicing sites.15 The result 
of this process is to alter the protein produced and not, as in the case of the other two 
modes of action, prevent its production.15 
 
   Although inhibition of gene expression is predominantly the biological mechanism, 
non-antisense effects may also contribute to the overall response.15 
 
   The main targets for antisense therapy include numerous cancers, viral infections and 
some maladies that start from parasites and bacteria.  
 
   Any potential modified oligonucleotides designed to act as antisense drugs, have to 
fulfil the following criteria: 
 
(1) bind to target mRNA with high affinity and sequence selectivity; 
(2) be resistant to enzyme degradation; 
(3) be soluble in aqueous media; 
(4) be able to penetrate cells, and; 
(5) be able to halt the in vivo translation of mRNA. 
 
Requirement four has proved problematic with respect to transporting the antisense 
oligonucleotides to their specific target. The preferred methods for a synthetic 
oligonucleotide to pass through the cell membrane in cell cultures (in vitro) are: (i) by 
active or passive transport;13, 16, 17 (ii) synthesis of antisense RNA within the target 
cell;18 or (iii) by external microinjection into a single cell. Although such techniques are 
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worthwhile under laboratory conditions, none have valuable or practical applications in 
vivo.  
 
   Another limitation of antisense oligonucleotides is that they tend to be easily degraded 
by nucleolytic enzymes. 
 
   The flexibility and selectivity of antisense therapy makes it a valuable research tool 
and an exciting new class of therapeutic compounds for serious diseases with known 
genetic etiologies but poor therapeutic alternatives.19  
 
1.6.2 Antigene therapy 
 
   In the antigene strategy, gene expression is specifically inhibited at the transcriptional 
level through a DNA-binding agent. The main advantage of antigene therapy over the 
antisense strategy (see previous section 1.6.1, pages 32-34) is that there are only two 
copies of the target sequences of DNA per duploid cell, compared to thousands of 
copies of the target mRNA sequence.20 This potentially reduces the quantity of DNA-
binding agent required for activity.20 As a result, this should increase efficacy and 
reduce side effects. Further, by blocking transcription the re-population of mRNA is 
prevented and therefore the DNA-binding agent would not have to be re-administered.20 
 
   Unfortunately, the potential benefits of antigene therapy are currently counteracted by 
several common restrictions that apply to all oligonucleotide-based treatments.20 These 
include bioinstability, poor cellular permeability, and non-specific binding of the 
oligonucleotides used.20 
 
   Despite these disadvantages, the capability for many cellular functions to be 
controlled by antigene therapy is still very attractive. Antigene therapy forms the basis 
from which the work reported in this thesis has developed.  
 
1.7 GROOVE BINDERS 
 
   The design and synthesis of molecules capable of gene discrimination and down-
regulating the expression of any required gene(s) associated in a disease process, would 
be a major accomplishment. Historically, there have been two broad approaches 
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described in the literature to achieve this: (1) to devise molecules that interact non-
covalently in the minor groove of DNA, and; (2) to use oligonucleotides targeted to the 
major groove of DNA, which form triple helical structures.  
 
1.7.1 Minor groove binders 
 
   Several natural products have been found to bind in the minor groove of DNA with 
some degree of sequence specificity. Although the structures of such groove binders are 
diverse they all share a common feature, a crescent shape. Examples of minor groove 
binders with antitumour capabilities are distamycin and netropsin [Figure 35].21 
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Figure 35. Structures of distamycin 26 and netropsin 27. 
 
   Although distamycin and netropsin are too toxic for clinical use, they have been 
extensively studied.22 They are characterised by the presence of an oligopeptidic 
pyrrolecarbamoyl frame ending with an amidino moiety, which reversibly binds to the 
minor groove of DNA by hydrogen-bonding, Van der Waals contacts and electrostatic 
interactions, with a strong preference for adenine-thymine (AT)-rich regions containing 
at least four AT base pairs.21 They block the binding of transcription factors required for 
the initiation of transcription by RNA polymerase (see the previous section 1.5.2, page 
31).21 
 
   Their mode of binding was first revealed from an x-ray crystal structure of netropsin 
binding to a B-DNA dodecamer of sequence d(CGCGAATTCGCG).22 Binding in the 
minor groove caused the displacement of water molecules from the spine of hydration, 
which aid the stabilisation of B-DNA, and were replaced with the covalently bonded 
backbone chain of the drug molecule.22 The amide NH participates in hydrogen-
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bonding, to bridge the DNA, with the N3 of adenine and O2 of thymine present on 
adjacent base pairs and opposed helical strands.22 As a consequence of the narrowness 
of the minor groove, netropsin was found to locate itself symmetrically in the midpoint 
of the groove with the two pyrrole rings, to some extent, non-coplanar.22 Drug binding 
forces the minor groove to open by 0.5-2.0Å and causes the helical axis to bend by 8o at 
the binding region.22 Although netropsin has an intrinsic twist that favours insertion into 
the minor groove, this is further enhanced upon binding, to produce the final structure in 
which the two pyrrole groups are twisted 33o relative to one another.22 
 
   The structure of distamycin is different to netropsin in that the guanidinium tail has 
been replaced by another pyrrole ring and a terminal NH-CHO.22 Therefore, the optimal 
distamycin binding site encompasses five base pairs, as opposed to the four observed 
with netropsin, as a direct result of the additional amide NH.22 
 
   In an attempt to tailor base specificity, Kopka et al. decided to substitute the 
methylpyrrole in netropsin for methylimidazole.22 It was hoped that by replacing the 
ring CH by N, the drug molecule would then favour guanine-cytosine (GC) regions by 
being able to accommodate the NH2 on the purine and a hydrogen bond acceptor.22 
 
   Kopka et al.22 therefore prepared the lexitropsin molecule shown in Figure 36 below. 
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Figure 36. Structure of Lexitropsin 28. 
 
This imidazole analogue of netropsin was shown to exhibit a mild decrease in 
specificity towards AT rich regions, and a concomitant increase in the acceptance of GC 
sites.22 This finding implied that new hydrogen bonds formed between the 2-amino 
group of guanine and the N3 imidazole nitrogen.22  
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   The number of lexitropsins that have since been prepared and evaluated is vast.23 In 
general, they all exhibit some ability to recognise GC base pairs, although they also 
retain AT recognition.23 The lack of GC specificity was initially ascribed to the 
differences in molecular electrostatic potential between AT and GC minor groove 
regions, with the strongly negative potential well of the later preferring the formally 
dicationic charged netropsin-based lexitropsins.23 However, recent experimental and 
theoretical data on the thermodynamics of netropsin binding has indicated that Van der 
Waals interactions may be responsible instead of electrostatics.23 In addition, 
lexitropsins commonly demonstrate reduced overall DNA affinity.23 
 
   As stated previously, it has been estimated that 15-17 base pairs have to be 
specifically targeted to inhibit gene expression of a single gene. As the natural minor 
groove binders’ netropsin and distamycin are sequence selective for much shorter 
segments of DNA, Dervan et al.24 decided to investigate if longer sequences could be 
targeted using extended distamycin structures. Thus, they prepared a series of six 
pyrroleimidazole polyamides, containing three to eight rings, designed to bind to 5-10 
base pair sites respectively.24 The DNA binding sites were based on the 5’-TGACA-3’ 
core sequence and contained sequential AT base pair inserts in the central region of the 
binding site to enable recognition by the additional pyrrolecarboxamides.24 The results 
of their study showed that DNA sequences of up to nine base pairs can be specifically 
recognised by pyrroleimidazole polyamides, containing 3-7 rings, by a 2:1 polyamide-
DNA complex formation in the minor groove.24 The maximum binding affinity was 
seen for the polyamide containing five rings and the subsequent addition of up to two 
more rings, had no further effect.24 The polyamide containing eight rings failed to 
recognise a ten base pair site.24 On closer inspection of their x-ray crystal structure, 
Dervan et al. discovered that upon binding of the eight ring polyamide, the minor 
groove widened by 4Å and consequentially, the major groove was compressed.24 
Further, an 18o bend in the helix towards the major groove was also observed.24 Figure 
37 on page 39 shows the structure of their eight ring pyrrolepolyamide and also a 
schematic ball and stick model of its binding with the target sequence. 
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Figure 37. Structure of the eight ring pyrrolepolyamide 29 and the schematic ball and 
stick model of its binding with the binding target. 
 
Since these discoveries in the 1980s, Dervan et al.25 have continued their search for a 
polyamide capable of recognising and binding to a longer sequence of bases. In 1998, 
they reported on ImPy-β-ImPy-β-ImPy-β-PyPy-β-Dp [Figure 38], a pyrrole-imidazole 
polyamide dimer that was able to distinguish the 16 base pair sequence 5’-
ATAAGCAGCTGCTTTT-3’ which is present in the regulatory region of the HIV-1 
genome.25  
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Figure 38. Structure of ImPy-β-ImPy-β-ImPy-β-PyPy-β-Dp 30. 
 
   Their results showed that this polyamide bound to the target sequence as a cooperative 
antiparallel dimer.25 Further, the high binding affinity together with the affinity cleavage 
pattern observed for the polyamide/DNA complex, implicated that the eight pairs of 
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amide residues formed a completely overlapped core, which correctly positioned the six 
Im-Py pairs for recognition of the six GC base pairs and two β/β pairs for recognition of 
the two AT base pairs.25  
 
   The minor groove binding strategy, thanks to the work by the Dervan group, now has 
the potential to produce viable antigene therapeutics. However, despite several 
promising analogues exhibiting antitumour properties in preclinical trials and having 
entered clinical phase trials, for example, adozelesin,26 carzelesin,27 bizelesin28 and 
tallimustine29 [Figure 39], their clinical efficacies have yet to be established.30 
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Figure 39. Structures of adozelesin 31, carzelesin 32, bizelesin 33 and tallimustine 34.  
 
   An example of a minor groove binder used currently in the treatment of advanced soft 
tissue sarcoma is trabectedin [Figure 40, page 41].31 
 
 
 
 
 
 40
Introduction 
 
 
35
HO
O
NH
S
O
O
N
N
O
O HO
O
O
O
HO
 
 
 
 
 
 
 
Figure 40. Structure of trabectedin. 
 
Trabectedin was originally derived from the Caribbean marine trunicate Ecteinascidia 
turbinate but can now be prepared synthetically.31 Although its mode of action is as yet, 
not clear, it appears to bend DNA away from the site of action, unlike other minor 
groove binders that bend DNA towards the site of action.31 Trabectedin is thought to 
interfere with the transcription-coupled nucleotide excision repair pathway and in 
addition to this, blocks the G2/M phase of the cell cycle.31 In vitro and in vivo studies 
have demonstrated activity against a range of solid tumour cell lines, human tumour 
explants (soft tissue sarcoma, prostate, ovarian, renal cancers, melanoma, breast and 
non-small cell lung cancer) and human xenografts.31 
 
1.7.2 Major groove binders 
 
   The commonest example of major groove binders are ss-oligonucleotides that are 
capable of binding to dsDNA through Hoogsteen hydrogen bonding to form triple 
helices. This ability was first discovered by Felsenfeld et al.32 and much research has 
since been carried out. The information contained within this sub-section should be 
regarded as a précis. 
 
   Although third strand binding was found to be weaker than double-stranded Watson-
Crick binding, it has been shown to be sequence-specific and easily stabilised by 
divalent cations.33 It is this potential for sequence-specific binding that has led to an 
extensive study of molecules capable of forming triple helices. Such triplex targets 
include genomic duplex DNA and ss-mRNA.33 Third strand binding to these targets can 
be achieved by natural and modified ssDNA oligonucleotides and ssDNA 
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oligonucleotide mimics such as peptide nucleic acids (PNAs) (see the later section 
1.9.5, pages 63-65).33 
 
   Triple-helix forming oligonucleotides (TFOs) are typically 10 to 30 nucleotides in 
length.33 Even though the sequence of TFOs can be composed of either polypurine or 
polypyrimidine molecules, TFOs are limited by their inability to recognise anything 
other than purine bases.33 This limitation arises as a direct consequence of purines 
containing two vacant Hoogsteen hydrogen bonding sites compared to one in the case of 
pyrimidines and therefore, means that purines are bound more efficiently. The 
formation of triple-stranded structures is for that reason, restricted to areas of dsDNA 
which are abundant in homopurine sequences.34  
 
   A typical triple helix motif occurs as a direct result of a polypurine target duplex being 
recognised by a pyrimidine-rich third strand.35 Such an oligonucleotide orientates itself 
parallel to the polypurine strand in the dsDNA target in the major groove and forms 
complementary T-A-T and C+-G-C Hoogsteen base triplets (where C+ indicates the N3-
protonated cytosine) [Figure 41].35 
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Figure 41. Hoogsteen hydrogen bonding. 
 
   The T-A-T base triplet involves formation of two Hoogsteen hydrogen bonds between 
the thymidine in the third strand and the adenine residue in the Watson-Crick A-T base 
pair. Compared to the C+-G-C base triplet involving formation of two Hoogsteen 
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hydrogen bonds between a protonated cytosine in the third strand and the guanine 
residue in the Watson-Crick G-C base pair. The prerequisite for prior protonation of the 
cytosine residue is a pH-dependent process and therefore, restricts the formation of 
these triplexes in living cells. Further, as a result of the electrostatic repulsion which 
occurs when two protonated cytosines are located next to each other in the third strand, 
the ensuing triplex would be destabilised.36 It is for this reason that several pH-
independent cytosine analogues have been designed and synthesised in order to allow 
for the formation of such parallel-stranded pyrimidine-purine-pyrimidine recognition 
motifs at physiological pH.  
 
   One example is that reported by Xiang et al.37 involving the pyrimidine nucleoside 
m5oxC [Figure 42]. This was found to permit G-C base pair recognition under slightly 
acidic, neutral and slightly basic conditions.37  
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Figure 42. Structure of m5oxC 36 and the fully protected m5oxC 37 G-C base triplet. 
 
   m5oxC includes: (i) A pyrimidine-like ring system to minimize anomalous 
conformational changes in the backbone of the triplex strand; (ii) a bidentate hydrogen 
bond donor to interact effectively with the O6-oxygen and N7-nitrogen of the target G-
C base pair, and; (iii) a 5-methyl group to contribute to the formation of a potentially 
important, stabilising, hydrophobic spine.37 The nucleoside was prepared and then 
incorporated into a series of 15-mer oligonucleotides, of which the triplex formation 
was studied using a 25-mer dsDNA target containing four G-C base pairs.37 The triplex 
stabilities were assayed at five different pHs i.e. 6.4, 7.0, 7.5, 8.0 and 8.5, and their 
results showed that for the cytosine-containing 15-mer control reaction, the Tm values 
(described in more detail in the later section 1.8 on page 44) for the resulting triplex 
decreased from 39.0 oC at pH 6.4 to 14.0 oC at pH 8.5. However, the m5oxC-containing 
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15-mer oligomer, showed pH-independent triplex transitions that varied by only 2 oC 
over the entire pH range investigated (28 oC at both pH 6.4 and 8.5).37 The triplex 
containing m5oxC was less stable at all pHs compared to the triplex containing the 
control third strand. 
 
   The ability to develop the potential uses of TFOs as therapeutics is currently hindered 
by a limited recognition alphabet. In attempt to overcome this problem, Brown et al.38 
have recently reported on the three nucleobases shown below in Figure 43. 
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Figure 43. Structures of MP 38, AEP 39 and APP 40. 
 
   MP was designed primarily to assess the suitability of the 3H-pyrrole[2,3-
d]pyrimidin-2(7H)-one core for GC recognition. By incorporating an acyclic amino 
group, as in the cases of AEP and APP, it was hoped that this moiety would increase the 
hydrogen bonding potential with N7 or O6 of guanine, and/or participate in electrostatic 
interactions with the anionic phosphate groups and, thereby, increase stability.38  
 
   From their results shown in Table 3 on page 45, the 3H-pyrrole[2,3-d]pyrimidin-
2(7H)-one core was found to recognise GC base pairs and the 18-mer TFO 
5’TCTCTCTTXTCCTCCTCC-3’ formed stable triplexes with the target duplexes 5’-
AGAGAGAGGYAGGAGGAGG-3’ and 5’-CCTCCTCCTZTTCTCTCT-3’.39 The 
control thymine oligomer Tm was 44.5 oC at pH 5.5 when Y=C and Z=G, compared to 
MP, AEP and APP which had melting temperatures of 46.4, 45.6 and 47.1 oC 
respectively.39 Attempts to increase the thermodynamic stability by including pendant 
protonated amino groups, as in the case with AEP and APP, failed to increase the 
thermodynamic stability of the resulting triplexes.39 From Table 3, it can be seen that 
the differences in melting temperatures of the triplexes studied are negligible apart from 
when Y=C and Z=G.39 
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                                                               Tm/oC 
X                               YZ =                  AT                  TA                  GC                  CG 
   T                                                          54.5                39.2                 43.7                44.5 
   MP                                                       42.7                38.7                41.4                 46.4 
   AEP                                                      40.4                37.8                 40.2                45.6 
   APP                                                      42.1                37.6                 41.4                47.1  
 
Table 3. Melting temperatures of T, MP, AEP and APP. 
 
1.8 TECHNIQUES FOR DETERMINING THE BINDING AFFINITIES AND 
SELECTIVITIES OF OLIGONUCLEOTIDE ANALOGUES 
 
   The binding affinity and selectivity of any newly synthesised oligonucleotide 
analogues are normally investigated by melting temperature experiments (Tm). 
 
The melting temperature experiments, Tm
 
   The melting temperature (Tm) of a double stranded nucleic acid complex is the 
temperature at which 50% of the duplex has dissociated into two separate strands.40 The 
Tm depends on the length of the molecule, its specific sequence composition, the 
concentration of the oligonucleotide and the properties of the solvent that it is contained 
within.40 This parameter gives an excellent indication of the degree of affinity that a 
species has for binding to target oligonucleotides.40 The Tm is directly proportional to 
the guanine-cytosine content within the molecule i.e. the greater the guanine-cytosine 
content, the higher the Tm value.40 This is due to the difference in hydrogen bonding 
capacities of guanine-cytosine base pairs, compared to adenine-thymine pairs.40 
 
   A common way to deduce the Tm of a nucleic acid complex is to use a thermostatted 
cell in a UV spectrophotometer. A plot of temperature versus absorbance affords an S-
shaped curve containing two plateaus [Graph 2, page 46]. The temperature is gradually 
increased over the range 20 oC to 90 oC whilst the absorbance is monitored at a 
wavelength of 260 nm.40 The absorbance measurement at the half-way point between 
the two plateaus yields the Tm value.40 
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Graph 2. Denaturation behaviour of DNA (taken from the what is life website). 
 
   Melting temperature experiments can also be used to prove triplex formation. In this 
case, two Tm values will be observed as the third strand first dissociates to yield the 
Watson-Crick duplex, and then further desolves to afford the two single strands [Figure 
44]. 
 
                                                       Tm                   Tm
                                           Triplex → duplex → single strand 
 
Figure 44. Schematic transition of DNA composition during denaturation. 
 
1.9 OLIGONUCLEOTIDE ANALOGUES 
 
1.9.1 Natural oligonucleotides 
 
   Natural strands of oligodeoxyribonucleotides cannot be used as therapeutic agents due 
to the fact that their sugar-phosphodiester backbone, is readily hydrolysed by 
intracellular enzymes, namely nucleases.6 They are easily degraded and cleared in vivo 
and generally, have poor bioavailability.18  
 
   In order to overcome the problems associated with natural oligonucleotides, their 
analogues have been the focus of much attention in recent years. To date, these studies 
have typically involved modification of one of the four components of an 
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oligonucleotide i.e. the base, the sugar moiety, the phosphate group, or the sugar-
phosphate moiety. A selection of the most promising modifications reported will be 
discussed over the next few sections. 
 
1.9.2 Base modifications 
 
   The inclusion of unnatural nucleobases into oligonucleotides has been extensively 
researched. For example, Kool et al.41, 42 have created a range of base-expanded 
nucleobases in order to evaluate their effect on Watson-Crick base pairing.34 These 
analogues have been categorised into three main classes: xDNA (“expanded DNA”);43-
48 yDNA (“wide DNA”)49-51 and yyDNA (“double wide DNA”)52 and these will be 
discussed below.  
 
   In the case of xDNA [Figure 45 on page 48], the width of the nucleobase was 
increased by 2.4Å by adding a phenyl ring to each of the four natural bases.41 
Subsequently, the expanded adenine nucleotide dxA, together with the natural 
thymidine nucleotide dT, was incorporated into the 10-mer oligomer of sequence 5’-
d(xATxAxATxATTxAT). The hybridisation ability of the oligomer was then 
investigated and it was found that it formed a more thermodynamically stable duplex 
with itself compared to the corresponding natural oligonucleotide i.e. the Tm for xDNA 
was found to be 54.9 oC compared to 20.1 oC for the natural dsDNA.53 Even though the 
helical diameter of this modified 10-mer homoduplex had increased by approximately 
3.0Å (as shown by CD studies), NMR solution studies uncovered that it bore several 
structural similarities relative to natural DNA.41 In particular, the homoduplex 
containing the expanded xA nucleobase was found to be of B-DNA type, the helix was 
right-handed, the deoxysugar conformations were C2’-endo and the glycosidic bonds 
were in the anti conformation.34, 41  
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Figure 45. Expanded nucleobases (xDNA set). 
 
   Regarding studies of yDNA, the benzohomologated nucleotide dyC [Figure 46, page 
49] has been incorporated into an 18-mer self-complementary oligonucleotide sequence 
as shown in Table 4 below.54 Comparisons with the corresponding natural dsDNA 
showed that the yDNA complex was more stable (∆Tm = 17.7 oC).34, 41and further, 
studies have shown that yDNA selectivity was also greater than that of the natural DNA 
control.54 
 
   When the oligomer containing dyT was investigated, it too was found to form a 
complex with increased stability [Table 4].54 This complex exhibited a Tm which was 43 
oC higher than natural DNA and had an estimated Gibbs’ free energy which was 11 kcal 
mol-1 more favourable.34, 41 
                                             Sequence                         Tm/oC 
                 yDNA                  5’-yCyCyCGyCGGG         71.1 
                                              3’-GGGyCGyCyCyC 
                   DNA                  5’-CCCGCGGG                53.4 
                                              3’-GGGCGCCC      
                 yDNA                   5’-yTyTyTAAyTAyTAA    58.2 
                                               3’-AAAyTyTAyTAyTyT 
                    DNA                  5’-TTTAATATAA            15.2 
                                              3’-AAATTATATT     
Table 4. yDNA containing dyC, dyT and control DNA sequences with their Tm. 
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Figure 46. Structures of dyC 45 and dyT 46. 
 
   yyDNA is derived from the class of naphtho-homologated nucleobases.34 This set of 
compounds represents the limit, in terms of size, that a DNA-like molecule can have.41 
dyyT and dyyC [Figure 47] have been incorporated into an oligonucleotide of sequence 
5’-dXCGCGCG, where X is either dyyT or dyyC respectively. The corresponding Tm of 
the oligomers when bound to 3’-AGCGCGC and 3’-GGCGCGC, were 66.3 oC and 60.8 
oC respectively.55 The doubly widened nucleobases were found to stabilise the resulting 
duplexes by 1.4 - 1.6 kcal/mol (37 oC) compared to their smaller yDNA homologues.55 
Surprisingly, yyT and yyC were also found to show negligible sequence selectivity 
towards the four natural bases.55 The reason for this is  thought to be due to their larger 
size which may prevent Watson-Crick-like base pairing from occurring.55 
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Figure 47. Structures of dyyT 47 and dyyC 48. 
 
   In addition to these expanded nucleobases reported by Kool et al.41 a vast number of 
other base-modified nucleosides have been reported in the literature for inclusion into 
oligonucleotide analogues. A selection of these modified bases are shown in Figure 48 
on page 50. 
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Figure 48. A selection of base-modified nucleosides.40 
 
   In general, the oligomers bearing the above base-modified nucleosides have been 
found to form less stable duplexes with complementary oligonucleotides than those 
formed from natural oligonucleotides of the same sequence.40 As a result of this, their 
incorporation into antisense or antigene therapeutics is hindered.40 
 
   The base modifications described in this section should be regarded as a précis and by 
no means a comprehensive outline of current research in this area. For a more detailed 
discussion, the reader is referred to the review article by Uhlmann et al.40 
 
1.9.3 Sugar modifications 
 
   There are many reasons as to why the deoxyribose component of a nucleic acid is a 
popular site for modification. It is hoped that manipulation at this site will lead to 
increased enzymatic stability, improved nucleic acid-protein binding and, generally, 
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additional functionality in DNA. Thus, there is an enormous quantity of literature 
available on sugar modifications which have been investigated to date.34,56 The 
information contained within this sub-section should be regarded as a brief outline, with 
specific focus on acyclic sugar modifications as these have direct bearing on the 
research work reported in this thesis.  
 
   In an attempt to overcome the common problem reported in the literature, of acyclic 
oligonucleotide analogues not forming duplexes with natural oligonucleotides of 
acceptable stability, Rana et al.57 decided to impart backbone rigidity into serinol 
derived acyclic analogues by introducting substituents in the acyclic backbone.57 They 
therefore, synthesised and studied oligomers bearing either the (1R,2R)- or (1S,2S)- 
stereoisomers of the serinol derived acyclic analogue 57 [Figure 49].57  
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Figure 49. Structure of 2-amino-1-phenyl-1,3-propandiol. 
 
The oligonucleotides examined are shown in Table 5 below. Oligomer (1) is the fully 
unmodified 18-mer control whereas oligomers (2)-(5) contain the serinol derived 
monomer x.  
Oligonucleotide sequences 
 
                                    (1) 5’-TTCTTCTTCTTTTCTTTT-3’ 
                                    (2) 5’-TTCTTCTTCTTTTCTTxT-3’ 
                                    (3) 5’-TTCTTCTTCxTTTCTTTT-3’ 
                                    (4) 5’-TxCTTCTTCTTTTCTTTT-3’ 
                                    (5) 5’-TTCTTCTTCTTTTCxxxT-3’ 
                                                   (x = modified monomer) 
 
Table 5. Oligonucleotide sequences. 
 
The abilities of these oligomers to form duplexes and triplexes were explored using UV 
melting experiments. From their results, it was found that incorporating the chiral, 
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acyclic phenyl derivative into the oligonucleotides did not hinder the formation of either 
duplexes or triplexes.57 These findings also demonstrated that the SS-diastereoisomer 
was slightly better than the corresponding RR-stereoisomer with respect to forming 
stable triplexes with dsDNA at pH 5.8 (∆Tm = 4 oC).57 The reason for their modified 
oligonucleotide not interrupting the formation of stable duplexes and triplexes is 
reportedly due to the phenyl substituent enforcing conformational rigidity of the acyclic 
chain, and also by it causing local hydrophobic dissolvation in the major groove.57 
Further, the location in the major groove of the phenyl substituent in the SS-
diastereoisomer may be more favourable than that corresponding to the RR-
stereoisomer. 
 
   Vandendriessche et al.14 have incorporated two different types of acyclic nucleosides 
into oligonucleotides; those with the 3S,5-dihydroxypentyl side chain 58 and those with 
the 4R-methoxy-3S,5-dihydroxypentyl side chain 59 [Figures 50].  
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Figure 50. Structure of the 3S,5-dihydroxypentyl side chain 58 and 4R-methoxy-3S,5-
dihydroxypentyl side chain 59. 
 
Both acyclic nucleosides lack the C4’-O-C1’ moiety of natural DNA sugar. Their reason 
for investigating these nucleosides was that it had been postulated that the ribose sugar 
oxygen may be involved in the recognition processes of both exo- and endonucleases. 
Thus, by removing it, it was hoped that the nuclease stability of the resulting acyclic 
derivative would be enhanced. In the second acyclic nucleoside 59 studied, the ribose 
sugar oxygen is disguised within a methoxy group.14 A common feature of both acyclic 
nucleosides 58 and 59 is the lack of a glycosidic linkage.56 However, both the number 
of bonds between the nucleobase and the primary and secondary hydroxyl groups, and 
the configuration of the stereocentres are consistent with those found in natural 2’-
deoxy-D-ribose.56  
 
   Both acyclic nucleosides were incorporated into oligomers and their nuclease 
stabilities were studied. Their results showed that both a 13-mer and 12-mer 
homoadenine oligomer, composed entirely of the 3S,5-dihydroxypentyl or 4R-methoxy-
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3S,5-dihydroxypentyl-nucleosides respectively, were stable towards snake venom 
phosphodiesterase for more than two hours.56 The corresponding unmodified natural 
homoadenine oligonucleotides, when treated under the same conditions, showed 
complete degradation after 3.1 minutes.56 In addition to this result, the 3S,5-
dihydroxypentyl-nucleoside when incorporated at the centre of their oligonucleotide, 
demonstrated hyperchromicity values of approximately 50% that demonstrated by the 
unmodified oligonucleotide.56 In attempt to understand their finding, they postulated 
that the 13-mer oligomer was being degraded to a 7-mer oligomer, which was 
subsequently stabilised by the presence of the 3S,5-dihydroxypentyl-nucleoside at its 3’-
end.56  
 
   The ability of heteroligonucleotides bearing acyclic nucleosides 58 and 59 to 
hybridise to complementary ss-oligonucleotides has been studied using melting 
temperature experiments. The data showed that the 13-mer homo-adenine oligomer 
containing a single 4R-methoxy-3S,5-dihydroxypentyl-nucleoside at the centre had a Tm 
of 26.7 oC when hybridised to the complementary unmodified oligomer.56 The 
corresponding control experiment had a Tm of 33.3 oC, indicating that incorporation of 
this analogue was destabilising (∆Tm = -6.6 oC). A lesser degree of destabilisation was 
observed when two 4R-methoxy-3S,5-dihydroxypentyl-nucleosides were incorporated 
at each end of the homo-adenine oligomers as the melting temperature observed was 
30.9 oC which afforded a net ∆Tm of -2.4 oC.56 Further, the 4R-methoxy-3S,5-
dihydroxypentyl analogues were shown to destabilise the resulting S-heteroduplex 
formed with the corresponding ss-oligonucleotide, slightly more than the 3S,5-
dihydroxypentyl analogues.56 Incorporation of a single 3S,5-dihydroxypentyl-nucleoside 
at the centre of the 13-mer homo-adenine oligomers had a Tm of 28.6 oC (∆Tm = 1.9 oC 
compared to the 4R-methoxy-3S,5-dihydroxypentyl analogue) and a Tm of 28.5 oC (∆Tm 
= 1.7 oC compared to the 4R-methoxy-3S,5-dihydroxypentyl analogue) when 
incorporated at either end of the homo-adenine oligomers.56  
 
   Vandendriessche et al.14 hypothesised that due to the conformational mobility of their 
acyclic nucleosides, the base pairing properties may be different from Watson-Crick 
base pairing and this could contribute to the destabilisation observed.56 Increased 
flexibility may prevent the acyclic nucleosides from successfully discriminating 
between the natural bases.56 
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   Schneider et al. have prepared and introduced flexible acyclic nucleosides of the type 
60 [Figure 51] into the centre of a series of oligonucleotides (Table 6, page 55).58  
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Figure 51. Flexible nucleoside t. 
 
   The ability of these oligomers to hybridise to ss-oligonucleotides was studied (Table 
6, page 55). Their observations showed that the stabilities of the resulting complexes 
formed from oligomers bearing the modified acyclic nucleoside 60 decreased relative to 
the corresponding unmodified dsDNA. The Tm values of these heteroduplexes were 
found to decrease by 9-15 oC for each flexible nucleoside incorporated.58 Although the 
effect was not additive, duplexes formed from oligomers containing two adjacent, 
acyclic monomers 60 were slightly more destabilised than for those generated from 
oligomers containing the two acyclic monomers 60, separated by a natural nucleoside.58 
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Sequence                                                 Tm / oC 
 
(1) 5’-CTTTTTTTG-3’                             40.0 
                                         3’-GAAAAAAAC-5’ 
(2) 5’-CTTTtTTTG-3’                               25.0 
                                         3’-GAAAAAAAC-5’ 
(3) 5’-CTTtTtTTG-3’                                 13.0 
                                        3’-GAAAAAAAC-5’ 
(4) 5’-CTTttTTTG-3’                                 11.0 
                                        3’-GAAAAAAAC-5’ 
(5) 5’-CTTTTTTTG-3’                                21.0 
                                        3’-GAAAGAAAC-5’ 
(6) 5’-CTTTTTTTTTTTG-3’                      55.0 
                                        3’-GAAAAAAAAAAAC-5’ 
(7) 5’-CAAATAAAG-3’                            37.0 
                                        3’-GTTTATTTC-5’ 
(8) 5’-CAAAtAAAG-3’                              25.0 
                                        3’-GTTTATTTC-5’ 
(9) 5’-CAAtAtAAG-3’                               12.0 
                                        3’-GTTATATTC-5’ 
(10) 5’-CAAttAAAG-3’                             11.0 
                                          3’-GAAAAAAAC-5’ 
(11) 5’-CTTTtTTTG-3’                              12.0 
                                          3’-GAAAGAAAC-5’ 
 
Table 6. Table of sequences and Tm values. 
 
   In attempt to explain their findings, they hypothesised that, by incorporating a flexible 
nucleoside analogue into an oligonucleotide, the ability to form duplex structures was 
decreased. This was due to the entropy lost upon going from two oligonucleotides to a 
duplex being larger in a system containing flexible nucleosides, opposed to one 
containing natural oligonucleosides.58 
 
   Recently, Meggers et al59, 60 have reported the design and synthesis of glycol nucleic 
acid (GNA) (Figure 52, page 56).  
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Figure 52. Structures of (R)- 61 and (S)- 62 glycol nucleic acid (GNA). 
 
   This propylene glycol phosphodiester backbone is conceivably the most atom 
economical example of modifications to natural DNA. The acyclic glycol nucleosides 
were prepared by stereospecific and regioselective nucleophilic ring opening of epoxide 
64 by the appropriately protected nucleobase as shown in Scheme 1 below.60 
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Scheme 1. Formation of (S)-T 68a, U 68b, C 68c and A 70d. 
 
63 was tritylated to give 64, which was then ring opened in the presence the appropriate 
nucleobase, thymine, uracil or N4-benzoylcytosine.59 The pyrimidine nucleosides 65a, 
65b and 65c were then directly converted into the corresponding phosphoramidites 68a, 
68b and 68c, in the presence of 2-cyanoethyl-N,N-diisopropylchlorophosphoramidite 66 
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and Hünig’s base 67.59 The adenine nucleoside 65d was benzoylated to give 69d as 
shown in Scheme 2, and then directly converted to its corresponding phosphoramidite 
70d (Scheme 1, page 56).59 
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Scheme 2. Benzoylation of 65d. 
 
   To synthesise the guanine nucleoside 76, natural guanine was substituted with 
commercially available 2-amino-6-chloropurine 71 for reasons discussed in more detail 
in chapter 2, section 2.3.4, page 111.59 Treatment with 63 gave intermediate 72 to which 
the exocyclic amino group was subsequently protected with an isobutyryl group to 
afford 74.59 This was then tritylated and treated with Hünig’s base as in the previous 
cases, to afford the corresponding phosphoramidite [Scheme 3].59 
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Scheme 3. Synthesis of (S)-G 76. 
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   Subsequently, seven 18-mer oligonucleotides consisting entirely of each enantiomer 
were prepared in high yields [Table 7]. 
 
                        3’-TTTTAAATTTTAATATAT-2’   a     Antiparallel duplex 
                        2’-AAAATTTAAAATTATATA-3’ b         (Tm = 63 oC) 
 
                        3’-TAAAATTTATATTATTAA-2’   c      Antiparallel duplex 
                        2’-ATTTTAAATATAATAATT-3’   d         (Tm = 63 oC) 
 
                       3’-TAAAATTTATATTATTAA-2’   c       Parallel duplex 
                       3’-ATTTTAAATATAATAATT-2’   e          (No Tm) 
 
                       3’-TAAAATTTATATTATTAA-2’   c      One mismatch 
                       2’-ATTTTAAATTTAATAATT-3’   f         (Tm = 55 oC) 
 
                       3’-TAAAATTTATATTATTAA-2’   c      Two mismatches 
                       2’-ATTTAAAATTTAATAATT-3’   g         (Tm = 44 oC) 
 
Table 7. Table of 18-mer GNA oligomers prepared. 
 
   Temperature-dependent UV spectroscopy at 260 nm was carried out to investigate the 
ability of these GNA oligomers to hybridise to themselves.59 It was found that, for 1:1 
mixtures of two complementary (S)-GNA strands i.e. a and b and c and d [Table 7], 
sigmoidal curves with melting temperatures of 63 oC were observed.60 Furthermore, the 
thermal stability of the resulting GNA duplex formed from oligomers c and d, 
noticeably surpassed the thermal stabilities of both the analogous DNA duplex (Tm 40.5 
oC) and RNA (Tm 42.5 oC, where U was used in place of T).60 This was a surprising 
result as nucleic acids normally require a cyclic structure (such as a ribose) to impart 
structural rigidity into the nucleic acid backbone and enable hybridisation to occur.59 
The requirement for the two GNA strands to bind in an antiparallel orientation was 
demonstrated since no sigmoidal melting or only weak hyperchromicities were observed 
for solutions containing the single strands of the 18-mer (S)- or (R)- GNA 
oligonucleotides alone.60 In order to confirm that the (S)- or (R)- GNA homoduplexes 
relied entirely on the formation of Watson-Crick base pairs, mismatch experiments were 
performed on an 18-mer GNA duplex derived from oligomers c and f, which included a 
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single T:T mismatch [Table 7]. It was found that the Tm value for this duplex was 
reduced by 8 oC compared to the corresponding fully complementary homoduplex. 
When two mismatches were incorporated, one T:T and one A:A, as in the case with 
oligomers c and g (Table 7, page 58) the Tm decreased by 19 oC.60 Similar results were 
obtained for the analogous enantiomeric (R)-GNA oligomers.60  
 
   Both the (S)-GNA and (R)-GNA homochiral duplexes formed from oligomers c and d 
[Table 7], have been evaluated using circular dichroism (CD).The CD spectra recorded 
displayed strongly amplified CD bands at 205, 220 and 275 nm upon mixing of 
oligomers c and d in a 1:1 fashion. These findings clearly showed that helical duplexes 
had formed.60 It was further found that the CD signal was strongest for a 1:1 ratio of 
GNA oligomers c and d and that the Cotton Effect decreased as the temperature 
increased, additional evidence of homoduplex formation.60 The analogous (S)-GNA and 
(R)-GNA homochiral homoduplexes exhibited mirror image CD spectra and both were 
distinguishable from the CD spectra recorded for a DNA duplex of the same sequence.60 
Meggers et al.60 have postulated that GNA strands c and d exhibited a large Cotton 
Effect due to pre-organisation of the GNA backbone taking place in the single strand 
prior to hybridisation.60  
 
   The antiparallel cross pairing between (S)-GNA, (R)-GNA, DNA and RNA has also 
been investigated.60 It was found that complementary (S)-GNA and (R)-GNA oligomers 
do not undergo antiparallel cross-pairing with each other, and nor do they form stable 
antiparallel cross-pairs with complementary ssDNA.60 Interestingly, however, (S)-GNA 
oligomers were shown to hybridise to complementary RNA. This was apparent from 
their UV melting temperature experiment curves, for duplexes with the sequences c and 
d of RNA, (S)-GNA and the RNA/(S)-GNA hybrid.60  
 
   Other acyclic sugar modified nucleosides which have been reported to date for 
inclusion into oligonucleotide analogues include the acyclic nucleoside Tβ, 77 which is 
conformationally restricted about the C=C double bond [Figure 53].  
 ThymineHO
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Figure 53. Structure of 1-[3-hydroxy-2-(hydroxymethyl)prop-1-enyl]thymine (Tβ). 
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It was thought that this compound would be an effective mimic of a natural nucleoside 
according to molecular modelling and geometry calculations.15, 61 These theoretical 
studies implied that compound 77 would be able to replace natural thymidines in both 
A- and B-type DNA helices, with no disruption to their resulting helical structure.15, 61 
However, preliminary hybridisation studies on oligonucleotides in which one or two 
thymidines had been substituted for 77, with complementary ssDNA or RNA targets in 
fact showed reduced binding affinities compared to the corresponding unmodified 
oligonucleotides.15 When one Tβ nucleoside was incorporated into the centre of the 
oligonucleotide of sequence dT7TβT6, the Tm of the resulting duplex decreased from 
36.0 oC to 31.0 oC. This change in Tm was also observed when Tβ was located near the 
end of the oligonucleotide (dT11TTβT).15, 61 Thus, it can be concluded from this example 
that merely restricting the conformational freedom of the acyclic nucleoside using a 
C=C double bond is not sufficient to produce stable hybridisation. 
 
   Despite an already vast sum of research having been carried out, there is still scope to 
improve both resistance to enzymatic degradation and to enhance binding capabilities in 
this area. Having learnt from the work reported by Vandendriessche et al.14 and 
Schneider et al.58 in particular, that increased flexibility may lead to both acyclic 
nucleosides unsuccessfully discriminating between their natural bases, and that 
decreased ability to form duplex structures may arise due to the entropy lost being larger 
in a system containing flexible nucleosides, opposed to one containing natural 
oligonucleosides. Future endeavours within this research area are of benefit.  
 
1.9.4 Phosphate modifications 
 
   As stated previously, a major problem that has been encountered in the use of natural 
phosphodiester oligonucleotides as potential regulators of gene expression is that they 
are readily degraded (t1/2 = 30 minutes) by nucleolytic activities in cells and culture 
medium.62 Therefore, in recent years, substantial effort has gone into trying to develop 
oligonucleotide analogues which show increased resistance towards nucleases. Due to 
the phosphorus centre being the main site of attack for nucleases, it is not surprising that 
many modifications have been made to the natural internucleotide linkage.62 Of the 
modifications which have been reported to date, methylphosphonates63 and 
phosphorothioates62 have been extensively evaluated. These modifications have been 
shown to increase stability of the resulting oligomers to both exo- and endo-enzymatic 
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degradation.62 The reviews by Goodchild,64 Varma65 and Uhlmann and Peyman.40 
provide excellent accounts of the progress achieved to date in this research field. 
 
(i) Methylphosphonates 
 
   Methylphosphonates [Figure 54] are oligonucleotide analogues in which the non-
bridging oxygen of the natural phosphodiester linkage has been substituted for a methyl 
group.  
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Figure 54. Structure of a methylphosphonate linkage. 
 
They were the first example of an antisense, backbone modified oligonucleotide which 
displayed increased enzymatic stability compared to the natural counterpart.66 
Methylphosphonates are much more lipophilic than natural oligonucleotides due to their 
lack of a formal negative charge and this results in increased binding affinities as a 
direct consequence of having removed electrostatic repulsion.66  
 
   Miller et al.66 have demonstrated that oligomethylphosphonates are accomplished 
inhibitors of Vesicular Stomatitis Virus (VSV) and type 1 Herpes Simplex Virus (HSV-
1) in tissue culture, using an antisense approach. An eight residue oligomer 
d(TpCCTCCTG) (all nucleotides linked through methylphosphonate linkages apart from 
the 5’-thymidine residue) was designed to be complementary to the acceptor splice 
intersection of HSV-1 IE.66 It was shown that, not only did this 8-mer oligomer inhibit 
HSV-1 viral replication in a sequence specific and dose-dependent fashion (IC50 = 25 
Μm; IC90 = 75 μM),66 but that it was also stable to nucleases and exhibited increased 
cell permeability compared to the complementary control.66 Oligomethylphosphonates 
enter cells in a passive manner, unlike active transport in the case of charged 
oligonucleotides.66  
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   The use of methylphosphonate oligonucleotides is limited by weak hybridisation.66 
This problem has been overcome by employing oligonucleotides bearing alternating 
methylphosphonate and phosphodiester linkages.67 Thus, a chimera of sequence 
pCpUpCpCpCpGpGpApCpUpCpApGpApU where p = methylphosphonate and p = 
phosphodiester linkage was prepared which was complementary to the upper hairpin 
region of the HIV virus TAR RNA.67 The 15-mer was found to form a stable duplex 
with its complementary RNA target and had a Tm  of 71 oC.67  
 
   Methylphosphonates have been superseded by phosphorothioates. 
 
(ii) Phosphorothioates 
 
   Phosphorothioates [Figure 55] are oligonucleotide analogues in which the non-
bridging oxygen of the natural phosphodiester linkage has been substituted for a 
sulphur.  
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Figure 55. Structure of a phosphorothioate linkage. 
 
   Phosphorothioates are relatively easy to prepare. The phosphorothioate linkage is 
typically synthesised as a mixture of a pair of diastereoisomers (i.e. Rp and Sp), and 
these are not subsequently separated.68 Different nucleases show differing preferences 
for Rp or Sp linkages depending on the nature of the active site of the enzyme.69 
 
   Phosphorothioates afford the best hybridisation properties of the phosphate 
modification studied to date.68 In an antisense approach, Hoke et al.62 prepared a 21-mer 
oligonucleotide phosphorothioate compound, ISIS 1080, of sequence 
A*C*C*G*A*G*G*T*C*C*A*T*G*T*C*G*T*A*C*G*C which was complementary 
to the internal AUG codon of UL13 mRNA in HSV-1. They found that by incorporating 
this oligonucleotide, the ability to form stable hybrids with mRNA was reduced.62 The 
Tm of the control phosphodiester oligonucleotide was 68.9 oC and the Tm of the modified 
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oligomer was 61.1 oC.62 The corresponding ∆Tm of 7.8 oC was thought to be as a direct 
result of incorporating the phosphorothioate linkage.62 Thus, there was an overall loss in 
hybridisation stability when ISIS 1080 was incorporated. This loss in stability led to a 
reduction in the infectious yield of HSV-1 in HeLa cells, to 9.0% ± 11% by supporting 
RNase H cleavage of the HSV mRNA to which it was targeted.62  
 
   Phosphorothioate modified oligonucleotides are known to affect the stability of 
triplexes, formed from an antigene perspective, with complementary single stranded 
DNA, in different ways depending on the environment of the modification.66 
Phosphorothioates linkages 5’- to a purine increases triplex stability, whereas 
phosphorothioate linkages 5’- to a pyrimidine decreases triplex stability.66 
 
   An example of a TFO with phosphorothioate linkages is described by McGuffie et 
al.69 They report on the phosphorothioate oligonucleotide of sequence 5’-
TGGGTGGGTGGTTTGTTTTTGGG-3’, which is a mixed purine-pyrimidine 
oligonucleotide designed to bind in antiparallel orientation to the purine strand of the 
target duplex. This oligonucleotide formed a triplex in vitro with the target site shown 
below [Figure 56], and was sufficiently taken up by leukaemia cells where it remained 
intact for up to 72 hours.69 
 
TFO target site 5’-TCCCTCCCTCCGTTCTTTTTCCC-3’ 
          3’-AGGGAGGGAGGCAAGAAAAAGGG-5’ 
 
Figure 56. Target TFO binding site. 
 
   Electrophoretic mobility shift assays (ESMA) were used to determine that a triplex 
had formed between the target site and the phosphorothioate oligonucleotide.69 This 
involved labelling the 5’- end of the oligonucleotide corresponding to the pyrimidine 
strand of the duplex DNA with 32P and annealing it to the complementary purine 
strand.69 Their oligonucleotide was shown to inhibit endogenous c-myc gene expression, 
reduce cell proliferation, disrupt cell cycle progression and induce cell apoptosis.69 
 
   The limitations associated with phosphorothioate modifications are that they are toxic 
as a direct result of non-specific binding interactions with numerous enzymes and they 
are degraded by nucleases over a period of time.70  
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   As stated previously, the number of examples available in the literature for phosphate 
modifications is vast. Figure 57 depicts a selection of other such modifications. 
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Figure 57. A selection of phosphate modifications. 
 
1.9.5 Sugar-phosphate backbone modifications 
 
   In attempt to impart synthetic oligonucleotides with resistance towards intracellular 
enzymes, namely nucleases, numerous analogues have been designed in which both the 
sugar and phosphate groups in the backbone have been altered together at the same 
time. Due to the extent of research already carried out in this field, only the most 
promising example reported to date will be discussed here. The reader is referred to a 
review by Varma for a more comprehensive insight into this research field.65  
 
Peptide nucleic acids (PNAs) 
 
   Peptide nucleic acids are analogues of DNA in which the conventional sugar-
phosphate backbone has been replaced with an achiral polyamide backbone composed 
of 2-aminoethyl glycine subunits [Figure 58].71  
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Figure 58. Schematic diagram of the structure of PNA. 
 
   The structure of PNA, although radical at the time, was designed to maintain key 
features of DNA such as the base-to-base and base-to-backbone distances. Egholm et 
al.72 discovered from computational models, that the optimal number of bonds between 
two nucleosides was six (consistent with the number of bonds between two nucleosides 
in natural DNA) [Figure 59]. Further, the optimum number of bonds between the base 
and a backbone is two or three.72 
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Figure 59. Schematic comparison of the structures of DNA and PNA (B = base). 
 
   PNAs stiff, achiral, polyamide structure allows for excellent sequence specific binding 
with high affinity to ssDNA, RNA and dsDNA.71 The tertiary amide linker of PNA is 
conformationally labile and exists as both the E- and Z-rotameric forms in uncomplexed 
PNA.71 Due to the lack of charge repulsion and the gain of entropy, following on from 
the pre-organisation of PNA, DNA/PNA complexes exhibit closely packed binding 
structures.71 
 
   Since their development, PNAs have demonstrated that they possess numerous 
significant functional properties and these have resulted in them being useful tools in 
molecular biology, prebiotic chemistry and antisense/antigene research.71 
 
   PNA is limited by its reduced aqueous solubility and consequent minimal uptake by 
cells.73 To overcome these problems, PNA is generally synthesised as C-terminal lysine 
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amides.74 The binding affinity and aqueous solubility are therefore aided as a result of 
this positive charge having been incorporated.74 
 
   PNAs form triplexes with homopurine ssDNA (or RNA) targets and two 
complementary homopyrimidine PNA strands, (PNA•DNA•PNA or PNA•RNA•PNA). 
These hybrids exhibit unprecedented high thermal stability, resulting in a Tm increase of 
1 oC per base for DNA/PNA hybrids and 1.5 oC per base for DNA/RNA complexes 
compared to DNA binding to itself.75 Such hybrids can be formed in either parallel or 
antiparallel conformations, but the latter are more stable by 1-2 oC.76 
 
   Nielsen et al75 have previously shown77, 78 that PNA binds to homopurine targets in 
dsDNA by a novel mechanism, triplex-invasion, and not by the more conventional 
formation of DNA2/PNA triplexes in the major groove through Hoogsteen hydrogen 
bonding.  
 
   Triplex-invasion involves homopyrimidine PNAs binding through Watson-Crick base 
pairing to its complementary oligonucleotide strand in an antiparallel orientation, 
resulting in the displacement of the non-complementary strand, to afford the PNA/DNA 
heteroduplex and the displaced strand.79 A second strand of PNA then binds in the 
major groove to give a PNA2/DNA triplex. Triplex-invasion is depicted schematically in 
Figure 60 on page 67. 
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Figure 60. PNA triplex invasion (redrawn from the Kobenhavens University website). 
 
   As mentioned previously, PNA oligomers can potentially be used as 
antisense/antigene therapeutics. However, they are substantially hydrophobic in nature, 
 66
Introduction 
 
 67
compared to the hydrophilicity observed for peptides or oligonucleotides, and it is for 
this reason that they are not readily taken up by cells.76 This therefore, has restricted 
their utility in such applications to date. 
 
1.10 RESEARCH OUTLINE 
 
   This purpose of this chapter was to gain a greater understanding of the structure, 
replication and molecular interactions of DNA. As well as the processes by which gene 
expression leads to the synthesis of proteins in cells. Having achieved this, it was 
decided to investigate further the role that antigene therapy can play in the future of 
drug research, through inhibition of gene expression. The focus of the work reported in 
this thesis relates specifically to improving the regulation of gene expression in a 
sequence-selective manner.  
 
   As already discussed in section 1.7.2 on pages 41-45, one potential approach for 
achieving this involves the use of triplex-forming oligonucleotides. These 
oligonucleotides bind in the major groove of the double-stranded target via Hoogsteen 
hydrogen bonding to form a triple helix. This complex subsequently interferes with 
regulatory proteins binding to the same and effectively inhibits transcription. Such 
compounds could find clinical value as antiviral and anticancer agents. 
 
   With a view to developing novel TFOs, we were inspired by the findings reported by 
Meggers et al.59, 60 (detailed on pages 54-58) on the structurally simplified glycol 
nucleic acid (GNA) mimics. As stated earlier, these researchers have demonstrated that, 
in addition to forming stable homochiral GNA:GNA duplexes, (S)-GNA oligomers 
hybridised to complementary, anti-parallel ssRNA; however, no binding to 
complementary, anti-parallel ssDNA was observed. The reason for this is perhaps due to 
the fact that, in GNA, both the base-to-backbone and base-to-base intrastrand distances 
are shorter than those found in natural DNA [Table 8]. 
 
Nucleic acid            base-to-base/No of bonds                base-to-backbone/No. of bonds 
         (S)-GNA                                       5                                                2 
            DNA                                          6                                                3 
     
Table 8. Base-to-base and base-to-backbone distances of (S)-GNA 62 and DNA 86. 
Introduction 
 
Figure 61 shows the structure of (S)-GNA 62 and DNA 86.  
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Figure 61. Structures of (S)-GNA 62 and DNA 86. 
 
   These bond distances, and in particular the base-to-base intrastrand distance, are 
important and should be carefully considered in the design of oligonucleotide 
analogues. As stated previously, Egholm et al.72 discovered from computational models 
that the optimal number of bonds between two nucleosides was six, and that the optimal 
number of bonds between the base and the backbone was two or three (see the previous 
section 1.9.5, page 64). 
 
   In seeking to improve upon the findings reported by Meggers et al.80 by simply 
increasing the number of bonds in both the base-to-base and base-to-backbone of GNA, 
to mirror those found in DNA, the number of degrees of flexibility of the molecule 
would also increase as a consequence. This may have a detrimental effect on its binding 
due to entropic reasons. Since it is generally assumed that nucleic acid analogues 
containing a phosphodiester backbone must be cyclic in order to produce the required 
conformational preorganisation for duplex formation.80 It was already astonishing that 
the thermal stability of the GNA duplex noticeably surpassed that of the analogous 
DNA duplex.80  
 
   By adhering to the optimal number of base-to-base and base-to-backbone bonds 
outlined by Egholm et al.72 and in attempt to prevent any consequential entropic issues, 
we designed the triazole-containing nucleic acid (TCNA) phosphoramidite monomer 
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shown in Figure 62 below, to explore side chain and backbone expanded analogues of 
GNA. 
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Figure 62. Structure of our TCNA phosphoramidite monomer. 
 
   As the name suggests, a triazole group is included. This was incorporated in an 
attempt to counteract any entropic problems that may accrue from increasing the side 
chain length and therefore, flexibility, by restricting the side chains movement. Further, 
the added advantage of using a triazole moiety is that it can be incorporated using the 
increasingly popular “click chemistry” approach, which was first discovered by 
Sharpless et al.81 ‘Click’ chemistry, for our purpose, is a CuI-catalysed variant of the 
Huisgen 1,3-dipolar cycloaddition of terminal alkynes and azides. This reaction will be 
discussed in greater detail in chapter 2, (section 2.4.2, page 128). 
 
   The six bonds between the bases of our TCNA analogue are consistent with those in 
DNA. It is hoped that this will prevent the bases from becoming out-of-phase with each 
other and, therefore, aid its hybridisation with DNA. The number of bonds between the 
base and the backbone, however, has been increased to five in our TCNA compared to 
three in regular DNA. Although the number of bonds between these two moieties is 
larger, the actual distance is reflective of the incorporation of the triazole group and not 
the analogous carbon-carbon distance. The combined crude bond distance for the 
shortest part of the triazole group (N1-C5=C4) is 2.72Å, and the analogous crude C-
C=C distance is 2.88Å. Thus, the actual distance between the base and the backbone is 
shorter than first anticipated. 
 
   The work reported in this thesis will, therefore, focus on the development of viable 
synthetic approaches for the preparation of the required novel triazole-containing 
phosphoramidite monomers, for incorporation into TCNA oligomers. The main aims 
were: (1) to develop a suitable synthetic pathway for the synthesis of the azide 
component; (2) to develop an appropriate synthetic route for the preparation of the 
nucleobase-containing alkyne component; (3) to investigate the use of the ‘click 
 69
Introduction 
 
 70
reaction’ for coupling our azide and alkyne components, and; (4) to develop a viable 
route for the construction of the TCNA monomers. Finally, if time permitted, it was 
planned to examine the introduction of the TCNA phosphoramidite monomers into 
oligomers using solid phase synthesis. Our progress towards achieving these objectives 
will be detailed in the next chapter. 
 
Results and discussion 
 
  71
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Results and Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results and discussion 
 
2. RESULTS AND DISCUSSION 
 
2.1 INTRODUCTION 
 
   As discussed in our research outline in chapter 1 (section 1.10, pages 67-70), the aim 
of this research was to design a synthetic approach to all four novel, triazole-containing 
phosphoramidite monomers [Scheme 4] required for integration into oligomers. 
 
   It was envisaged that the triazole unit required for these monomers could be easily 
prepared using “click chemistry” (see later section 2.4, pages 125-147) which was first 
introduced by Sharpless et al.81 in 2001. There are many processes which have been 
identified that fall into the category of ‘click’ chemistry, but for our purposes, we 
focused on the CuI-catalysed variant of the Huisgen 1,3-dipolar cycloaddition of 
terminal alkynes and azides. Using this approach, we proposed that the phosphoramidite 
monomers 88 could be simply prepared from the retrosynthetic analysis, shown in 
Scheme 4, using the appropriate nucleobase-containing azide 91 and alkyne component 
92. [Scheme 4] 
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Scheme 4. Retrosynthetic analysis pathway of phosphoramidite monomer 88. 
 
   This chapter will focus on: (i) the development of a viable synthetic route to the azide 
component 91; (ii) development of synthetic routes to each of the four nucleobase-
containing terminal alkyne components, 92, and; finally, (iii) the development of the 
‘click’ reaction to afford the target TCNA phosphoramidite monomers. 
  72
Results and discussion 
 
2.2 DEVELOPMENT OF A SYNTHETIC ROUTE TO AZIDE COMPONENT 
(91) 
 
   It was envisaged that the azide component 91 could be prepared according to the 
retrosynthetic analysis pathway shown in Scheme 5 below. In route A, the azide 91 
undergoes a functional group interconversion to the differentially protected triol 93 
which can be obtained from naturally occurring glycerol 94. In route B, the azide 91 
undergoes a functional group interconversion to afford the amine alcohol 95 which can 
be obtained from the carboxylic acid 96, which is commercially available serine. 
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Scheme 5. Retrosynthetic analysis pathway of the azide component 91. 
 
2.2.1 Glycerol route (route A) 
 
   In order to obtain the required azide component 91, we decided to investigate the four 
step reaction pathway shown in Scheme 6 on page 74, starting from commercially 
available (4S)-2,2-dimethyl-1,3-dioxolane-4-methanol 97. [Scheme 6] 
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Scheme 6. Reagents and conditions: (i) TBDPSCl, DMAP, TEA, DCM, rt, 24 h; (ii) 
TFA, THF/water, rt, 45 h; (iii) DMTrCl, DBU, DCM, rt, 27 h; (iv) (1) MsCl, DCM, rt, 
24 h, (2) NaN3, DMF, rt, 24 h. 
 
The first step involved protecting the primary alcohol with a TBDPS group to afford 98. 
The acetal protecting group was then removed to form diol 99, which subsequently had 
the primary alcohol function selectively protected over the secondary alcohol with a 
DMTr group to give 100. The final step in this reaction scheme was to convert the 
remaining alcohol to azide 101 via an in situ mesylation nucleophilic substitution. 
 
   Scheme 6 was based on work reported by Xiang et al.82 These researchers had 
successfully obtained the cytosine analogue 102, containing a conformationally flexible 
acyclic linker, starting from the alternative isomer (4R)-2,2-dimethyl-1,3-dioxolane-4-
methanol 97a [Scheme 7]. 
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Scheme 7. Synthesis of 102. 
 
Inspired by their finding, we decided to apply the same conditions for the preparation of 
98. Thus, DMAP and TEA were added to a stirred solution of 97 in dry DCM at rt 
followed by tert-butyldiphenylsilyl chloride. After aqueous work-up and purification by 
flash chromatography, 98 was afforded in a 97% yield. Formation of 98 was confirmed 
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from the 1H NMR spectrum recorded which showed a singlet at 0.92 ppm 
corresponding to the nine protons of the tert-butyl group attached to the silicon 
functionality, and two multiplets at 7.16-7.29 ppm and 7.50-7.58 ppm, corresponding to 
the ten aromatic protons of the TBDPS protecting group.  
 
   Acetals are typically cleaved under acidic conditions. However, we were aware of the 
fact that TBDPS groups can be labile under certain acidic conditions because Edwards 
et al.83 had reported the successful removal of the equivalent silicon group in a 76% 
yield using a 3% methanolic solution of HCl at rt [Scheme 8]. Therefore, less harsh 
acidic conditions were sought.  
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Scheme 8. Reagents and conditions: 3% HCl in CH3OH, rt. 
 
   Lewbart et al.84 described the successful removal of an acetal protecting group from 
5β,21-pregnane-3α,17,20β,21-tetrol 3-acetate, 105 using the milder organic acid, acetic 
acid. [Scheme 9] 
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Scheme 9. Synthesis of 5β,21-pregnane-3α,17,20β,21-tetrol 3-acetate, 106. Reagents 
and conditions: 60% acetic acid, 4 h, rt. 
 
   This group of researchers treated compound 105 with a 60% acetic acid solution for 
5.5 hours at rt to afford 106 in a 97% yield. Inspired by their work, we decided to apply 
the same conditions for the removal of the acetal protecting group on 98. Unfortunately, 
in this case the acetal protecting group was not cleaved and only unreacted starting 
material 98 was recovered. Further attempts at this reaction including increasing the 
reaction time to a maximum of 24 hours and heating the reaction to 60 oC for a 
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maximum of 6 hours, also failed to afford the desired diol, 99. We therefore sought 
another method. 
 
   Leblanc et al.85 had described the successful cleavage of an acetal protecting group on 
107 using TFA to afford the diol, 108 in an 83% yield. Interestingly, the TBDPS 
protecting group was unaffected by these conditions. [Scheme 10] 
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Scheme 10. Diol preparation. Reagents and conditions: TFA, THF/H2O, 0 oC, 24 h. 
 
Thus these conditions were applied to our compound 98. A solution of 98 in THF and 
H2O was stirred at 0 oC, and TFA was added before leaving the resulting solution to stir 
overnight. After work-up and purification by column chromatography, diol 99 was 
afforded in an 11% yield. This finding was after one addition of reagents. 
 
   We were aware of the fact that this step was an equilibrium process and therefore, we 
decided to explore whether the equilibrium could be driven in favour of diol formation 
by periodically evaporating the reaction mixture in vacuo and adding fresh reagents. 
The results of this investigation are shown in Table 9. It was found that three repetitions 
afforded the best balance between a clean reaction and a good percentage yield of 64%. 
No. of 
repetitions 
% Yield 
of 99 
% Yield 
of SM 98 
% Yield 
of TBDPSOH 
1 11 86 0 
2 34 62 0 
3 64 31 5 
4 59 10 30 
5 50 13 35 
6 45 16 39 
7 33 22 44 
 
Table 9. No. of repetitions, % yield and % of recovered materials. 
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Graph 2. No. of repetitions versus % yield of materials recovered. 
 
   The formation of the desired product 99 was confirmed by 1H NMR spectroscopy. 
The spectrum recorded showed a broad singlet at 2.26 ppm integrating to two protons 
which was assigned to the diol protons. Further, the nine protons corresponding to the 
tert-butyl group were observed as a singlet at 0.91 ppm, and the ten aromatic protons 
from the diphenyl constituent were observed as two multiplets at 7.18-7.33 ppm and 
7.45-7.53 ppm. The presence of both of the later signals confirmed that the TBDPS 
group had remained intact. 
 
   The next step in the synthetic pathway involved protecting the primary alcohol of 99 
with a DMTr protecting group. This ensured that the triazole-containing monomers 
were protected with the same group used in DNA/RNA synthesis and so these 
monomers could be incorporated into nucleic acid oligomers. 
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ection. Reagents and conditions: DMTrC
 Xiang et al.82 showed that a DMTr protecting group could be introduced into alcohol 
Scheme 11. DMTr prot l, pyridine, rt, 4 h. 
 
  
109 using DMTrCl in the presence of pyridine [Scheme 11]. Their DMTr protected 
compound 110 was obtained in a 92% yield. Therefore, a solution of our diol 99 in 
anhydrous pyridine was treated with DMTrCl at rt and the progress of the reaction was 
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monitored periodically by TLC. Unfortunately, after 24 hours, only a spot 
corresponding to starting diol 99 could be observed and there was no indication of any 
product formation. Therefore, we decided to apply heat to the reaction and so the 
mixture was gradually warmed to a maximum of 70 oC over 12 hours. Following work-
up and purification by flash chromatography, still no product could be identified from 
the 1H NMR spectra collected for the fractions obtained. Only the starting diol 99 was 
recovered in a 96% yield. 
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 Chaudhary et al.86 reported that the primary alcohol of α-methylglucoside 111 could 
cheme 12. Sele
 Thus, these conditions were applied to diol 99. Following work-up and purification by 
 It was hypothesised that this tritylation reaction should occur by preliminary 
111
O
  
be selectively tritylated to give 112 in an 88% yield [Scheme 12]. This was 
accomplished by treating a solution of 111 in DMF with DMTrCl in the presence of 
DMAP and TEA. 
 OH OH
 
 
 
S ctive tritylation of α-methylglucoside. Reagents and conditions: 
DMTrCl, DMAP, TEA, DMF, rt, 24 h. 
 
  
flash chromatography, none of the 1H NMR spectra recorded for each of the fractions 
isolated corresponded to the desired DMTr protected product 100. Again, only 
unreacted diol 99 could be identified.  
 
  
formation of the N-tritylpyridinium salt 115 [Scheme 13]. 
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cheme 13. Proposed mechanism for formation of 115. Reagents and conditions: 
 It was thought that if this salt had not formed in situ, or if its formation was rate 
cheme 14. Preparation of DMAP, DMTrCl, DCM, 
hus, salt 115 was prepared by reaction of DMAP with DMTrCl in DCM at rt for 30 
 Subsequently, salt 115 was dissolved in DCM and treated with diol 99 and the 
S
DMAP, DMTrCl, DCM, rt, 30 mins. 
 
  
determining then this could be the source of our problems. In order to avoid this issue, 
we decided to explore the procedure reported by Hernandez et al.87 They had described 
the preparation and isolation of 115 prior to its subsequent use in the immediate 
tritylation of primary alcohols [Scheme 14]. 
 
 
 
 
 
S  115. Reagents and conditions: (i) 
rt, 30 mins. 
 
T
minutes. The 1H NMR spectra recorded on the white solid isolated after addition of 
Et2O to the reaction mixture, confirmed that alkylation of the heterocyclic nitrogen had 
occurred.  
 
  
reaction was left for 24 hours. Unfortunately, following work-up and purification by 
flash chromatography, still no alkylated product 100 was observed. Again, unreacted 
starting diol 99 was recovered quantitatively. The outcome of this reaction suggested 
115114
N
NN Cl
DMTr
N
+ DMTrCl
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that our alkylation problems did not lie with the formation of the required DMAP salt. 
There had to be underlying issues. Thus, our attempt to make the ‘electrophile more 
electrophilic’ had failed.  
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 In order to explore other possible reasons which may be preventing DMTr alkylation 
 An alternative procedure for performing this reaction has been reported by Messager 
cheme 15.  conditions: DBU, 
 Thus, we decided to apply the same reaction conditions for DMTr protection of diol 
116
H3C
  
of diol 99, we decided to investigate the substitution of DMAP for NaH in the hope that 
use of this stronger base would deprotonate the alcohol and increase the speed of the 
rate determining step. Thereby, making the ‘nucleophile more nucleophilic’. Therefore, 
one equivalent of NaH was added to a stirred solution of diol 99 in DCM followed by 
DMTrCl and the reaction was left at rt for 24 hours. Regrettably, only unreacted starting 
diol 99 was again recovered. The same result was achieved when two equivalents of 
NaH were added.  
 
  
et al.88 They describe a convenient method for the preparation of trityl ether 117 from 
the secondary alcohol 116 in an 81% yield using DBU as a sterically hindered amidine 
base [Scheme 15]. 
 H3C ODMTrOH + DMTrCl 
 
 
S Tritylation from secondary alcohols. Reagents and
DMTrCl, DCM, rt, 27 h. 
 
  
99. Therefore, 99 was added to a solution of DMTrCl and DBU in DCM. Following 
work-up and purification by flash chromatography, 100 was afforded in a 49% yield 
[Scheme 16]. Although this yield was poor, it was sufficient to progress with the 
synthetic scheme and could be optimised at a later date. The 1H NMR spectrum 
recorded of the product 100 showed two multiplet signals corresponding to the aromatic 
protons of the DMTr substituent at 6.56-6.83 ppm and 7.06-7.67 ppm, a singlet at 3.71 
ppm corresponding to the methoxy protons and a third multiplet at 3.53-3.69 ppm 
corresponding to the CH and CH2 groups near the OH and silicon protecting group 
respectively. 
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cheme 16. DBU, DMTrCl, DCM, rt, 27 h. 
 Having successfully obtained 100, the final step in our synthetic scheme was to 
 
cheme 17. Azide formation via mesylation. Reagents and conditions: (i) MsCl, DCM, 
 From our initial inspection of the literature, a method involving two reactions being 
cheme 18. rmediate. Reagents 
 It was decided to follow the strategy of Mohapatra et al.89 however, not initially as a 
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S DMTr alkylation. Reagents and conditions: 
 
  
convert the remaining secondary alcohol in 100 to azide 101 via a mesylation and 
nucleophilic substitution with azide [Scheme 17]. 
S
rt, 24 h; (ii) NaN3, DMF, rt, 24 h. 
 
  
carried out in one pot by Mohapatra et al.89 was appealing. They described the in situ 
conversion of (1S,2S)-cyclopropyl alcohol 118 into the corresponding mesylate 
followed by its immediate transformation into azide 119 in an overall 92% yield 
[Scheme 18]. 
 
 
 
 
S Alcohol to azide conversion via an in situ mesylate inte
and conditions: (i) MsCl, TEA, DCM, 0 oC, 6 h; (ii) NaN3, DMF, 60 oC, 24 h. 
 
  
one-pot reaction. Instead we sought to isolate and characterise the intermediate mesylate 
product 100a and once certain of its formation, continue with its conversion to azide 
101. Having established that both steps were successful individually, the one-pot 
reaction would then be carried out. 
 
OTBDPSOTBDPS
100
DMTrO
(i) (ii)HO MsO N3
DMTrO
100
OTBDPS OTBDPSDMTrO OTBDPS
100a 101
118
(i) MsCl, TEA
(ii) NaN3, DMF
Ph
OH
H
H Ph H
N3
H
119
Results and discussion 
 
  82
   In order to isolate the mesylate product 100a, alcohol 100 was dissolved in DCM and 
cooled to 0 oC. TEA and MsCl were added and the reaction mixture was stirred at rt for 
24 hours. Regrettably, after work-up and purification of the crude product by flash 
chromatography, no mesylate product 100a was obtained. Only the starting alcohol 100 
was recovered quantitatively. Despite several repeat attempts of this reaction [Table 10], 
we were never able to isolate 100a. The reason for this failure is currently uncertain. 
The reaction conditions attempted are shown in Table 10. 
 
Experiment 
No
Reaction 
Time/hours 
Reagent equivalents 
Alcohol          MsCl          TEA 
% Yield 
of 100a 
1 24         1                   3                 6 0 
2 48         1                  3                  6 0 
3 62         1                  3                  6 0 
4 24         1                  4                  6 0 
5 24         1                  5                  6 0 
6 24         1                  6                  6 0 
7 48         1                  4                  6 0 
8 48         1                  5                  6 0 
9 48         1                  6                  6 0 
 
Table 10. Mesylate reaction conditions attempted. 
 
   The synthetic scheme faced problems throughout its entirety; the difficulty in 
removing acetal 98 to afford diol 99, albeit that this was overcome, the problems 
involved in protecting the primary alcohol with DMTr and the low percentage yield 
obtained when the DMTr product 100 was finally achieved. These difficulties coupled 
with the fact that the mesylate could not be produced in our hands, led us to abandon the 
synthetic route to afford azide 101 (Scheme 6, page 74) and focus our efforts on 
designing and developing a new synthetic scheme. 
 
2.2.2 Serine route (route B) 
 
   The alternative route B to target azide 91, as described in our retrosynthesis in Scheme 
6, (see the previous section 2.2.1, page 74) starts from commercially available L-serine 
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methyl ester 120 and involves reduction of the ester to the primary alcohol 95, followed 
by a diazotransfer reaction to azide 91. Scheme 19 shows our initial synthetic pathway 
to target azide 91.  
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Scheme 19. Reagents and conditions: (i) BnBr, NaHCO3, THF/DMF, reflux, 14 h; (ii) 
TBDMSCl or (a) TBDPSCl, imidazole, DCM, rt, 6 h; (iii) LiBH4, THF, rt, 24 h; (iv) 
MEM-Cl, NaH, THF, rt, 24 h; (v) H-cube (see later discussion for details); (vi) ‘diazo 
donor’, K2CO3, CuSO4·5H2O, MeOH, rt, 24 h. 
 
This scheme preliminary involved protecting the free amine of L-serine methyl ester 
120 with a benzyl group to afford 121, the alcohol of which was then protected with a 
silyl group to afford 122. The choice of silyl protecting group was uncertain at this stage 
as we were unsure about the ability of TBDMS to withstand the following reduction 
conditions. Therefore, TBDMS and TBDPS were tested. Subsequently, the ester of 
122/a was reduced using LiBH4 to give alcohol 123/a. The third step involved 
protection of the newly formed alcohol using MEM-Cl to give 124. This was followed 
by hydrogenation to remove the benzyl protecting groups and give 125. The final step in 
this synthetic scheme used a diazotransfer reaction to produce azide 126. The protecting 
groups were carefully selected in order to afford a means of removing each substituent 
independently of each other; benzyl group removal by hydrogenation should not 
interfere with the silicon or MEM protecting groups and likewise the silicon removal 
with fluorides should not interfere with MEM or benzyl groups. 
 
   The first three steps in our synthetic scheme use similar conditions to those reported 
by Laїb et al.90 for the preparation of (2R)-2-(N,N-dibenzylamino)-3-O-[(tert-
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butyldimethylsilanyl)oxy]propionaldehyde 129 from commercially available D-serine 
methyl ester 120a [Scheme 20]. 
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Scheme 20. Synthetic route to 129. Reagents and conditions: (i) NaHCO3, BnBr, 
DMSO/THF, reflux, 15 h; (ii) TBDMSCl, DMF, imidazole, rt, 15 h; (iii) LiBH4, Et2O-
MeOH, 0 oC-reflux, 3 h; (iv) Swern. 
 
   The first step in our synthetic scheme followed the procedure reported by Laїb et al.90 
for the quantitative synthesis of 121a with the exception of using DMF instead of 
DMSO. Therefore, L-serine methyl ester 120, NaHCO3 and BnBr were dissolved in a 
1:1 mixture of THF and DMF and heated to reflux for 14 hours. Following work-up and 
purification by flash chromatography, 121 was afforded in a 91% yield. 
Characterisation data for this compound was found to be consistent with that recorded 
by Laїb et al.90 
 
   The next step in our reaction scheme was to protect the primary alcohol 121 using a 
silicon group. Laїb et al.90 had chosen to protect the equivalent alcohol using a TBDMS 
group and it was decided to follow their approach. Therefore, 121 was suspended in 
DCM and treated with TBDMSCl and imidazole for 15 hours at rt. After work-up and 
purification by flash chromatography, 122 was given in a 64% yield as opposed to the 
90% yield reported by Laїb et al.90 The reason for the difference in yields may be due to 
DCM being used as solvent instead of DMF. The characterisation data for our 
compound 122 was comparable to their data reported. When the exact reaction 
conditions by Laїb et al.90 were followed, i.e. DMF as solvent, an unidentifiable 
impurity was present alongside product 122. The source of this impurity was thought to 
be from the DMF used and therefore, it was decided to alter the solvent choice. 
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   An investigation into the order of these two reactions was then carried out to ascertain 
whether by reversing these two steps, the percentage yields could be optimised.  
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Scheme 21. Route 1 and 2 with percentage yields. Reagents and conditions: (i) BnBr, 
NaHCO3, THF/DMF, reflux, 14 h; (ii) TBDMSCl, imidazole, DCM, rt, 6 h. 
 
   In route 1, the first two reaction steps were carried out in the order described by Laїb 
et al.90 In route 2, the first two steps were reversed.  
 
   From scheme 21 above, it is can be seen that route 1 gave product 122 in an overall 
yield of 60% whereas route 2 gave 122 in an overall yield of 44%. Thus route 1 
represented the optimised ordering of these two steps. 
 
   The next step in our synthetic scheme involved reduction of the methyl ester of 122 to 
give the primary alcohol 123. The conditions for this step reported by Laїb et al.90 
seemed the obvious choice. Therefore, LiBH4 and MeOH were added to a solution of 
ester 122 in dry Et2O at 0 oC and the resulting mixture was heated to reflux for 3 hours. 
After this time, as no new product spot was observed by TLC, the mixture was heated at 
reflux for a further 3 hours. Following work-up and purification by flash 
chromatography, the only material that was recovered was the unreacted starting ester 
122. This was surprising given that Laїb et al.90 had reported a 99% yield for their 
corresponding reaction. This reaction was attempted several times under different 
conditions (including increased reaction time at reflux and increased equivalents of 
reagents added) but these reactions similarly failed to afford the alcohol 123. Drying 
ether is problematic in terms of being able to remove all traces of water. It was reasoned 
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that the presence of the remaining water may have influenced the outcome of the LiBH4 
reaction. Therefore, we sought different reduction conditions in which the water content 
could be reduced more efficiently. 
 
   We were inspired by a procedure by da Costa et al.91 which reported the successful 
reduction of the ethyl ester 131 to primary alcohol 132 in a 96% yield using NaBH4 as 
the reducing agent [Scheme 22]. 
 
 
131
O O OH
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Scheme 22. Ester reduction to primary alcohol. Reagents and conditions: NaBH4, 
MeOH, THF, 70 oC, 20 min. 
 
Thus, we decided to apply this method to our ester 122. Therefore, NaBH4 was 
suspended in THF, added to 122 and the mixture was heated to reflux. After one hour, 
MeOH was carefully added and the reaction mixture was maintained at reflux for a 
further four hours and the progress was monitored periodically by TLC. However, 
although no new product was observed after this time, it was decided to work-up the 
reaction. Following purification of the residue by flash chromatography, only starting 
ester 122 was recovered. This finding coupled with the outcome of the LiBH4 reaction, 
implied that borohydrides alone were not suitable reducing agents for ester 122 in our 
hands. 
 
   A procedure reported by Walker et al.92 using LiAlH4 was then attempted in the hope 
that use of this stronger reducing agent would overcome our difficulties. Walker et al.92 
had demonstrated the successful use of LiAlH4 for the reduction of methyl ester 133 to 
the corresponding diol 134 in an 83% yield [Scheme 23]. 
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Scheme 23. LiAlH4 ester reduction. Reagents and conditions: LiAlH4, THF, 0 oC-rt,  
24 h. 
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   Thus, a solution of ester 122 in THF was added dropwise to a stirred suspension of 
LiAlH4 in THF at 0 oC. After 24 hours at rt, the reaction mixture was quenched by 
careful addition of saturated aqueous Et2O solution. Despite using a stronger reducing 
agent, following work-up and purification by flash chromatography, unreacted starting 
ester 122 was still recovered in a 46% yield. Further, TBDMSOH and the desilylated 
alcohol 123 were recovered in a 24% and 28% yield respectively. It was unclear at this 
stage whether desilylation had occurred before or after the reduction had taken place. 
 
   Our initial doubt with regard to the ability of the TBDMS protecting group to 
withstand our reduction conditions had been confirmed. It was therefore decided to 
incorporate a TBDPS protecting group in order try and minimise desilylation from 
occurring.  
 
   Thus, the reaction conditions reported by Laїb et al.90 were followed with the 
exception of TBDPSCl having been used instead of TBDMSCl (Scheme 20, page 84). 
Again, an investigation into the optimal reaction order was carried out, the results of 
which are shown below in scheme 24. 
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Scheme 24. Route 1 and 2 with percentage yields. Reagents and conditions: (i) 
TBDPSCl, imidazole, DCM, rt, 6 h; (ii) BnBr, NaHCO3, THF/DMF, reflux, 14 h. 
 
   In route 1, the primary alcohol of L-serine methyl ester 120 was protected using 
TBDPSCl to afford 135, with the intention of then protecting the NH2 group with BnBr, 
to determine the optimal reaction order in terms of percentage yields. In route 2, the 
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previously synthesised benzyl protected 121 (see Scheme 21, page 86) was protected 
with a TBDPS group to afford 122a. 
 
   The first step of route 1, involved L-serine methyl ester 120, being taken up in DCM 
and treated with TBDPSCl and NaHCO3 for 6 hours at rt. This resulted in a 43% yield 
of 135 being achieved. TBDPS protection was identified by the nine proton singlet at 
0.89 ppm corresponding to the tert-butyl group and the two multiplets at 7.18-7.30 ppm 
and 7.50-7.52 ppm corresponding to six and four protons respectively, for the aromatic 
portion of the TBDPS protecting group. 
 
   The next step involved protecting the NH2 group of 135 with BnBr to afford 122a. 
This was not carried out due to the percentage yield attained for step one in this route, 
being lower than the corresponding step in route 2, to which it was being compared. Our 
efforts were therefore concentrated on route 2. 
 
   In route 2, the previously prepared benzyl protected serine derivative 121 was 
subjected to the silylation conditions described previously on page 86. Alcohol 121 was 
dissolved in DCM and treated with imidazole and TBDPSCl for 6 hours at rt. Following 
work-up and purification by flash chromatography, product 122a was afforded in a 66% 
yield. Evidence of the silicon protection was observed from the nine proton singlet 
situated at 0.89 ppm corresponding to the tert-butyl group and the two multiplets at 
7.06-7.34 ppm and 7.45-7.51 ppm corresponding to the aromatic portion of this species.  
 
   Having obtained TBDPS protected 122a the subsequent reduction with LiAlH4 could 
be compared. Thus, LiAlH4 in THF was added slowly to a stirred solution of ester 122a 
dissolved in THF at 0 oC. The reaction mixture was then stirred at rt overnight and 
following work-up and purification by flash chromatography, no desired product was 
observed. Starting ester 122a was recovered quantitatively.  
 
   It was apparent from this result that reduction of 122 must have taken place after 
desilylation had occurred, in the case of the TBDMS scheme (page 87). Increasing the 
stability of the silicon protecting group by employing TBDPS had prevented 
desilylation taking place, and consequently stopped the ester reduction. In other words, 
steric crowding of the silicon protecting group was inhibiting alcohol formation. 
Alternative ester reduction conditions were therefore sought. 
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   A second procedure reported by Walker et al.92 in which they successfully converted 
136 to 137 in a 99% yield [Scheme 25] was then followed. 
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Scheme 25. LiBH4/B-methoxy 9-BBN ester reduction. Reagents and conditions: LiBH4, 
B-methoxy 9-BBN, THF, 0 oC-rt, 24 h. 
 
   These reduction conditions were further supported by Brown et al.39 in which they 
had reported that ester reduction with LiBH4 could be enhanced using B-methoxy 9-
BBN. The ester reduction is understood to occur by first activating the B-methoxy 9-
BBN 138, to form its hydride 139 and then this species acts as the reducing agent 
[Scheme 26]. 
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Scheme 26. Activation of B-methoxy 9-BBN. Reagents and conditions: LiBH4, THF. 
 
   Thus, we were inspired to try this strategy for our reduction. Ester 122a in dry THF 
was added to a stirred solution of LiBH4 in dry THF at 0 oC. Subsequently, a solution of 
B-methoxy 9-BBN in hexane was added and the reaction mixture was left to stir at rt 
overnight. Following work-up and purification by flash chromatography, the desired 
product 123a was afforded in a 48% yield (unoptimised). From the 1H NMR spectrum 
recorded of 123a, a nine proton singlet at 1.08 ppm, a sixteen and a four proton 
multiplet at 7.20-7.49 ppm and 7.57-7.75 ppm respectively, corresponding to the 
aromatic protons were observed, which concluded that the tert-butyl group was 
untouched. The broad singlet at 1.65 ppm was indicative of the OH group generated. 
 
   The next step in the synthetic pathway was to protect the newly formed primary 
alcohol of 123a with a MEM group. This reaction was attempted by dissolving alcohol 
123a in dry THF with NaH. After an hour, MEM-Cl was added and the reaction mixture 
was stirred at rt for 24 hours. Following work-up and purification by flash 
chromatography, the desired product 124 was afforded. However, from the 1H NMR 
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spectrum recorded and subsequent TLC analysis of the product isolated, it was 
discovered that the desired material had co-eluted with another unidentifiable side 
product. Product 124 was identified by a three proton singlet at 1.26 ppm for the MEM 
CH3 group and a ten proton multiplet at 3.45-3.95 ppm, encompassing overlap of the 
four benzyl CH2 protons and six protons from the remaining three MEM CH2 groups. 
Several attempts using a number of different solvent systems were used to separate the 
product from the impurity, but unfortunately these two compounds always co-eluted 
from the column together. 
 
   Alternative MEM protection reactions were investigated in order to see if formation of 
the side product could be prevented. Firstly, the reaction was repeated without the 
addition of NaH. After the reaction mixture was quenched with aqueous NaHCO3 
solution, the pH was increased to 7.0 using aqueous NaOH solution. Following work-up 
and purification by flash chromatography, the impurity was still observed in the 1H 
NMR spectrum recorded.  
 
   We were then inspired by conditions reported by Corey et al.93 in which they 
successfully prepared several MEM ethers from primary, secondary, tertiary and 
hindered alcohols. Their MEM ethers were prepared by treating the alcohol with DIPEA 
and MEM chloride in DCM. The percentage yields for all their examples reported were 
above 95% and the reactions were complete within 30 to 60 minutes. Thus, a solution of 
alcohol 124 in dry DCM was cooled to 0 oC and DIPEA along with MEM-Cl were 
added. The reaction mixture was stirred at rt for 24 hours and the progress was 
monitored periodically by TLC. Unfortunately, following work-up and purification by 
flash chromatography, the impurity could still be observed alongside the desired 
product 124 in the 1H NMR spectrum recorded. At this point, since it did not seem to be 
possible to prepare or separate the desired MEM compound 124 from this side product, 
it was decided to continue with the subsequent step in the synthetic pathway in the hope 
that this impurity could be separated at a later stage. 
 
   The next step in our strategy for preparing the azide component involved removing 
the benzyl protecting groups to afford amine 125 (see the previous Scheme 19, page 
83). This was attempted using the in-house H-cube® hydrogenator, which combines 
continuous flow microchemistry with on demand hydrogen generation from electrolysis 
of H2O. Thus, a solution of impure 124 in absolute EtOH was cycled once through the 
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system at 0.5 mL/min. The temperature of the hydrogenator was set to 50 oC and the 
catcart® used was 10% Pd/C. The 1H NMR spectrum recorded of the crude product no 
longer showed the presence of benzyl protons which had appeared at 3.49-4.05 ppm, 
7.20-7.49 ppm and 7.57-7.75 ppm as multiplet signals in the 1H NMR spectrum 
recorded for impure starting material 124. The newly generated NH2 group of amine 
125 was observed as a broad singlet at 4.40 ppm. Having envisaged that the subsequent 
step to form azide 126 would need further purification, it was decided to continue with 
the next step and then attempt to separate the unknown impurity from the product, in 
order to keep the quantity of product lost to a minimum. 
 
   The next step in our synthetic pathway was to transform the amine into an azide 
through a diazotransfer reaction [Scheme 19]. The proposed mechanism of such a 
reaction is shown below in Scheme 27.94 
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Scheme 27. Proposed mechanism for the diazotransfer reaction (redrawn and adapted 
from ref 95) 
 
Firstly, the copper (II) catalyst 140 binds reversibly to the NH2 group of the organic 
amine staring material 141 to give 142. The ‘diazo donor’ 143 then associated itself 
reversibly with this complex, to form 144. Loss of one of the copper ligands L, 
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produces complex 145 which can then either break up to regenerate the ‘diazo donor’ 
143 and species 147 or form the desired azide 146. In order to carry out this 
transformation, a ‘diazo donor’ species is commonly used. Two such donors are: (1) 
trifluoromethanesulfonyl azide (TfN3) 151, and; (2) imidazole-1-sulfonyl azide 
hydrochloride, 152. 
 
   TfN3 151 can be prepared from commercially available triflic anhydride 15095 
[Scheme 28].  
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fN Tf2O T 3
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Scheme 28. Preparation of TfN3 151. Reagents and conditions: NaN3, toluene/H2O, 0 – 
10 oC, 2.5 h. 
 
   151 is the commonest ‘diazo donor’ for the CuII catalysed conversion of an amine to 
an azide, and it generally produces high yields and preserves the stereochemistry of the 
starting material in the product.96 However, neat 151 is explosive in nature and has a 
poor shelf life, which necessitates it being prepared in solution and used immediately.96 
Further, it is known that preparation of 151 from the expensive starting reagent, 
trifluoromethanesulfonic anhydride (Tf2O) 150, affords inconsistent yields and 
therefore, the reagent must be used in a liberal excess.96  
 
   At the time of this research, imidazole-1-sulfonyl azide hydrochloride 152 was 
emerging as an alternative, efficient, inexpensive and shelf-stable diazotransfer 
reagent.96 Goddard-Borger et al.96 designed and prepared this new diazotransfer reagent 
which had the potential to surpass TfN3 as a ‘diazo donor’ in terms of its stability, ease 
of use and reproducible yields.96 Further, this crystalline reagent can be easily prepared 
[Scheme 30] in a one-pot reaction on a large scale (several grams) from relatively 
inexpensive starting materials NaN3 153, sulfuryl chloride 154 and imidazole.96 
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Scheme 30. Synthesis of imidazole-1-sulfonyl azide hydrochloride 152. Reagents and 
conditions: (i) SO2Cl2, MeCN, rt, 24 h; (ii) imidazole, rt, 3 h; (iii) HCl in EtOH, 0 oC,  
1 h. 
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This involves treating 153 with sulfuryl chloride in pyridine and subsequent addition of, 
imidazole. Acidification of the reaction mixture then precipitates 152 as a hydrochloride 
salt.96 
 
   An example of 152 being used as a ‘diazo donor’ has been described by Goddard-
Borger et al.96 Here 156 from 155 was successfully prepared in a 65% yield using this 
reagent [Scheme 31]. 
 
155 156
EtO2C CO2Et
EtO2C CO2Et
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Scheme 31. Synthesis of diazo compound 156  using 152. Reagents and conditions: 
154, CuSO4·5H2O, H2O, MeOH, rt, 16h. 
 
   We were inspired by this new, safe diazotransfer method, and we decided to 
investigate the conversion of amine 125 to azide 126 using 152 in an analogous manner. 
In order to accomplish this, 152 first had to be prepared. This was achieved following 
the procedure described by Goddard-Borger et al.96 Firstly, sulfuryl chloride 154 was 
added dropwise to a cooled suspension of sodium azide 153 in dry pyridine and the 
resulting mixture was left at rt overnight. Imidazole was then added to the cooled 
mixture and the slurry was stirred for a further 3 hours at rt. Subsequent work-up and 
acidification afforded 152 as a white solid in a 69% yield. This compared favourably to 
the 63% yield reported by Goddard-Borger et al.96 The I.R. signal corresponding to the 
azide was of strong intensity at 2172 cm-1 and the 1H NMR spectrum recorded of 152 
confirmed the presence of the imidazole moiety. Finally, the purity of 152 was verified 
by elemental analysis. 
 
   Having successfully prepared azide 152, we were now in a position to use this in our 
diazotransfer reaction to form azide 126 from amine 125. Therefore, a solution of azide 
152 in MeOH was added to amine 125 in the presence of K2CO3 and CuSO4·5H2O and 
stirred at rt overnight according to the procedure by Goddard-Borger et al. 96 [Scheme 
31]. Following work-up and purification by flash chromatography, formation of the 
desired azide product 126 was confirmed by I.R. spectroscopy on the material afforded. 
The spectrum showed a strong signal at 2096 cm-1 which corresponded to the presence 
of an azide group. Furthermore, the 1H NMR spectrum recorded of 126 no longer 
showed a broad singlet at 4.40 ppm which had been attributed to the NH2 group in the 
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starting material 125. The impurity that had been produced during the MEM reaction 
(page 91), despite our best endeavours to remove it at that purification stage, was 
disappointingly still present alongside azide 126, following the purification step in this 
diazotransfer procedure. We therefore decided to abandon this pathway in search of an 
alternative approach avoiding MEM protection. 
 
Alternative serine approach 
 
   It was realised that the methyl ester of 120 could be viewed as a protected hydroxyl 
function, and if this was the case, then this would avoid having to use an alcohol 
protecting group such as MEM in our pathway. Therefore, it was reasoned that Scheme 
19 (page 83) could be both modified and shortened so that following protection of the 
side chain hydroxyl group of 120 with a silicon protecting group to give 135 (previously 
prepared), the diazotransfer reaction could then be achieved to generate the desired 
azide 157 [Scheme 32]. This could then be employed in the subsequent ‘click’ reactions 
with the appropriate alkyne components before liberating the hydroxyl function to 
produce our TCNA monomer. 
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Scheme 32. Direct diazotransfer. Reagents and conditions: 152, K2CO3, CuSO4·5H2O, 
MeOH, rt, 16h. 
 
Thus, direct diazotransfer was carried out using previously prepared 135 (Scheme 24, 
page 88). The amine group of 135 was converted into azide 157 following the same 
reaction procedure described previously. Thus, amine 135, azide 152, K2CO3 and 
CuSO4·5H2O were taken up in MeOH and stirred at rt overnight. Following work-up, 
the I.R. spectrum recorded of 157 showed a strong azide signal at 2110 cm-1. From the 
crude 1H NMR spectrum recorded of 157, it appeared that some of the silicon protecting 
group had been removed. In light of this finding, it was then decided to employ 
previously prepared TBDMS protected 130, as this silicon protecting group was deemed 
to be more stable to these reaction conditions [Scheme 33].97  
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Scheme 33. Direct diazotransfer. Reagents and conditions: 152, K2CO3, CuSO4·5H2O, 
MeOH, rt, 16h. 
 
Therefore, amine 130 was subjected to the same diazotransfer conditions as 135, and 
following the work-up, the crude I.R. spectrum recorded for 158 showed a strong signal 
at 2117 cm-1 corresponding to the azide. From the 1H NMR spectrum recorded for 158 
it was evident that the silicon protecting group was untouched. 
 
   Further investigation into desilylation in the presence of CuSO4·5H2O and K2CO3 was 
carried out by Whittingham et al.98 in our research group. It had initially been thought 
that the copper catalysts may be responsible for desilylation. However, the results of 
this investigation, confirmed that K2CO3 was responsible. TBDPS groups are removed 
quickly in the presence of this base, and furthermore the results suggested that, if left for 
long enough, TBDMS groups may also be removed, contrary to that described by 
Kocienski.97 Although we had seen no evidence for TBDMS desilylation having 
occurred, it was decided to investigate if the alcohol of 120 needed to be protected in 
order for a successful diazotransfer reaction to occur. Therefore, the direct diazotransfer 
of 120 was investigated [Scheme 34]. 
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Scheme 34. Direct diazotransfer. Reagents and conditions: 152, K2CO3, CuSO4·5H2O, 
MeOH, rt, 16h. 
 
Thus, having subjected 120 to the same reaction conditions and following work-up, the 
crude I.R. spectrum recorded of 159 showed a strong azide signal at 2110 cm-1. The 
crude 1H NMR spectrum recorded of 159 showed singlets at 3.64 ppm, 3.70 ppm and 
3.82 ppm which confirmed the methoxy CH3, the CH2 and CH substituents respectively, 
and the OH group was identified as a broad singlet at 5.74 ppm. 
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   Azides 158 and 159 were then immediately used in the subsequent ‘click’ reactions 
described in section 2.4.4 on pages 138-140. 
 
2.2.3 Conclusions 
 
   In order to develop a suitable synthetic pathway to afford our azide component, we 
initially investigated route A (Scheme 6, page 74) derived from commercially available 
glycerol 94. This scheme unfortunately afforded limited results.  
 
   The first problem faced in this synthetic pathway was to remove the acetal protecting 
group of 98 to generate the diol 99 without desilylation occurring simultaneously. This 
difficulty was overcome using a procedure reported by Leblanc et al.85 and having 
carried out an optimisation investigation into the number of repetitions of fresh reagents 
added, diol 99 was afforded in a 64% yield.  
 
   Difficulties in selectively alkylating the newly generated primary alcohol 99 using 
DMTrCl were then encountered. After two main investigations into the appropriate 
conditions for such a task: (i) making the ‘electrophile more electrophilic’ by both 
isolating and creating in situ, the 4-dimethylamino-N-dimethoxytritylpyridinium 
chloride salt 115 required for such an alkylation, and; (ii) making the ‘nucleophile more 
nucleophilic’ by employing NaH to deprotonate alcohol 99 and thereby increasing the 
speed of the rate determining step. Unfortunately, the alkylated species 100 could not be 
obtained. A procedure reported by Messager et al.88 was then investigated and this 
allowed us to successfully afford 100, albeit in an unoptimised yield of 49% using the 
sterically hindered base DBU.  
 
   The final step in this reaction pathway was to obtain azide 101 and this again proved 
problematic. It was decided to first investigate the one-pot conversion of alcohol 100 to 
azide 101 via an in situ mesylate from which we had been inspired by Mohapatra et al.89 
Having decided to first isolate the mesylate product 100a to verify its production, and 
then subject it to the subsequent azide conversion, in our hands, the mesylate product 
could not be obtained. Several attempts to obtain this product were carried out, for 
example, increasing the reaction time and altering the equivalents of reagents added, but 
despite this, all attempts failed to afford us with the desired product 101. In light of all 
these problems faced with this synthetic pathway, it was decided to focus our efforts on 
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route B, which had also been outlined as a potential way to achieve our azide 
component, at the time of our retrosynthetic analysis of azide 91. 
 
   The second synthetic pathway to achieve azide 126 was route B (Scheme 19, page 
84), starting from commercially available L-serine methyl ester 120. The first three 
steps of this scheme had been inspired by Laїb et al.90 in which they had carried out the 
same processes on D-serine methyl ester 120a, and we were confident that these 
conditions could be applied to our starting material. However, this was not the case.  
 
   The first step to protect the amine moiety with a benzyl group was successful in a 
92% yield and the subsequent protection of the alcohol function also was successful in a 
64% yield. However, the third step to reduce the methyl ester to the corresponding 
primary alcohol 123 was not as straightforward. In our hands, using the conditions 
reported by Laїb et al.90 the reduction was unsuccessful, despite considerable effort. 
Investigation into use of another borohydride was then undertaken, but to no avail. It 
was then decided to explore the use of a stronger reducing agent, LiAlH4, which had 
been described by Walker et al.92 However, despite the reduction having taken place, 
this had unfortunately the detrimental affect of removing the silicon protecting group. 
What wasn’t clear at this stage was whether desilylation had occurred prior to, or after, 
the reduction of the methyl ester.  
 
   In an attempt to prevent the loss of the silicon group, we substituted the TBDMS 
moiety for a TBDPS protecting group, as this silicon group was deemed to be more 
stable under these reaction conditions. The outcome of this investigation was that no 
reduction had taken place. This allowed us to conclude that in the example with the 
TBDMS protecting group, reduction of the ester had taken place after desilylation had 
occurred. It was postulated that perhaps the silicon protecting group was sterically 
hindering the reduction reaction taking place and that by employing the more labile 
TBDMS group, this reduction was achieved on the corresponding desilylated alcohol. 
This problem was later overcome by employing conditions reported by Walker et al.92 
and further confirmed by Brown et al.39 for the enhancement of LiBH4 in reduction 
reactions by use of B-methoxy 9-BBN. These conditions allowed us to produce alcohol 
123a in an unoptimised yield of 49%. Although this yield was low, it was decided to 
continue with the next steps in the reaction pathway and optimise the individual steps at 
a later date.  
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   Therefore, an investigation into protecting the newly generated alcohol 123a with 
MEM-Cl was then carried out. Despite this reaction having been successful in terms of 
protecting the alcohol function of 123a, the desired product could not be separated from 
an unidentifiable product which had co-eluted. Despite trying to find a solvent system 
that allowed for the two species to be separated, we had no success. The impurity was 
not U.V. active and was thought to be a MEM type derivative, although this could not 
be verified. In an attempt to eradicate the side reaction from occurring, the reaction was 
repeated without NaH being present. Unfortunately this did not solve our problem. We 
were then inspired by a different procedure reported by Corey et al.93 which employed 
DIPEA along with MEM-Cl. Again however, co-elution of the impurity with the 
desired product occurred.  
 
   At this point, it was decided to pursue the subsequent step in the reaction pathway in 
the hope that the impurity could be removed in a later purification step. Thus, the next 
step to remove the benzyl protecting groups was investigated using an in-house 
hydrogenator and afforded amine 125 quantitatively. No purification was carried out at 
this stage in attempt to keep product loss to a minimum as purification of the subsequent 
step was envisaged.  
 
   The final step in this reaction pathway was to convert the amine into an azide using a 
diazotransfer reaction. We were inspired by Goddard-Borger et al.96 on the development 
of the ‘diazo donor’ 152 for use in such a conversion. Thus, this reagent was prepared 
and used together with our amine 125. From 1H NMR spectroscopy, it was clear that the 
desired product had been formed, but unfortunately, despite considerable effort to 
separate the product, the previously prepared impurity had been carried through. Given 
that we could not isolate the desired azide, due to the unidentified impurity that always 
co-eluted with the product. In the interest of time, it was decided to abandon this route, 
and focus our efforts on a new synthetic scheme which would avoid the need to use 
MEM-Cl.  
 
   The alternative route designed investigated the viability of direct diazotransfer to take 
place on the previously prepared TBDPS protected compound 135. Under these 
conditions, the silicon protecting group was labile (initially it was thought that the 
copper catalyst was responsible for such cleavage) and in light of this finding, the 
reaction was repeated using the previously prepared TBDMS protected species, as this 
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was reported by Kocienski97 to be more stable to these conditions. Analysis of the 1H 
NMR spectrum recorded for 135 showed that the silicon group had been untouched, 
however, an investigation carried out by Whittingham et al.98 in our research group, 
concluded that removal of the TBDMS silicon protecting group may also result if given 
long enough time. As a result of this separate investigation, it was decided to ascertain 
whether direct diazotransfer could occur in the presence of the alcohol moiety contained 
within L-serine methyl ester 120, and hence prevent the silicon removal being an issue. 
Direct diazotransfer was once again successful and azides 158 and 159 were now ready 
to be coupled with the nucleobase-containing alkyne component in a subsequent ‘click’ 
reaction (see the later section 2.4.4, pages 139-141). 
 
   Having successfully obtained our azide components, the focus of this chapter now 
moves to the development of the alkyne component synthesis. 
 
2.3 DEVELOPMENT OF THE ALKYNE COMPONENT SYNTHESIS 
 
   The four natural nucleobases were synthetically modified to include an alkyne moiety, 
in order to make them suitable components for the ‘click’ reaction. The target alkyne 
components we envisaged preparing for our ‘click’ reaction are shown below in Figure 
63. 
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Figure 63. The target alkyne components. 
 
From Figure 63, 160 is benzoylated in the N3 position for reasons discussed later in 
section 2.3.1, (pages 100-103). It was essential to protect the exocyclic NH2 groups on 
161 and 162 with a benzoyl group, not only to increase the lipophilicity of the 
monomer, but also to adhere to the traditional protecting group strategy when 
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incorporating the monomers into oligomers. In the case of 183, the exocyclic NH2 is 
alternatively protected with an isobutyryl group for reasons discussed later in section 
2.3.4. 
 
   This section will focus on the individual synthetic approach for each nucleic base and 
the problems we encountered and overcame. 
 
2.3.1 Thymine alkyne component synthesis 
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Scheme 35. Reagents and conditions: (i) BzCl, CH3CN/C5H5N (1:1), rt, 24 h; (ii) 
HC≡CCH2Br, NaH, DMF, rt, 48 h; (iii) BnOH, 90oC. 
 
   Scheme 35 shows the planned synthetic scheme designed to prepare the alkyne 
component. The N3 position is first protected using BzCl to increase the lipophilicity of 
the compound and also to eradicate any possibility of N3 alkylation in the subsequent 
step. Alkylation is then carried out in the N1 position using commercially available 
propargyl bromide to give 161 and finally, debenzoylation is carried out (optional) to 
form 162. 
 
   Therefore, the first step involved treating a suspension of commercially available 
thymine 13, in a mixture of CH3CN and pyridine, with BzCl. Following work-up, the 
crude yellow solid afforded was purified by recrystallisation to give 160 in a 73% yield. 
N3 benzoylation was confirmed by x-ray crystallography. As shown in Figure 64 on 
page 101, two molecules were found to reside within the asymmetric unit which 
differed slightly in the orientation of both the phenyl and methyl substituents.  
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Figure 64. Ball and stick representation of the crystal structure of 160 (red = oxygen, 
white = hydrogen, grey = carbon and blue = nitrogen). 
 
From this crystal structure, the angle between the two rings was found to be 84.39o and 
one of the carbonyl oxygens forms a close contact with the nitrogen in the ring, which 
results in a dimer (information obtained from Dr Georgina Rosair, HWU). 
 
   The next step in the synthetic pathway involved alkylation of the N3 benzoylated 
derivative 161. We decided to adapt a procedure found in a paper by Choi et al.99 Thus, 
a solution of 160 in dry DMF was treated with NaH. Subsequently, propargyl bromide 
was added and after 24 hours in the dark, the TLC analysis showed that, unfortunately, 
no reaction had occurred. Therefore, it was decided to heat the reaction. The 
temperature was gradually raised in 10 oC increments up to a maximum of 80 oC over a 
four hour period. Regrettably, following work-up, the 1H NMR spectrum recorded of 
the crude reaction mixture confirmed that the reaction had failed and only unreacted 
starting material could be identified.  
 
   An extensive search of the literature provided evidence for use of both Cs2CO3100 and 
K2CO3101 as bases for alkylation purposes. Due to Cs2CO3 generally being more soluble 
in organic solvents than K2CO3, we substituted, NaH for Cs2CO3. After work-up, the 
crude residue was purified by flash chromatography, to successfully afford 161 in a 
55% yield. From the I.R. spectrum recorded of 161, we could see a weak alkyne stretch 
at 2129 cm-1 and three strong carbonyl signals at 1747 cm-1, 1696 cm-1 and 1644 cm-1. 
The 1H NMR data obtained, displayed a clear triplet at 2.67 ppm which was assigned to 
the terminal propargyl proton and a doublet at 4.56 ppm which was attributed to the 
propargyl ‘CH2’ attachment. The absence of the N-1H, which had previously been 
observed at 11.58 ppm in the 1H NMR spectrum recorded for 161, was further proof 
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that N1 alkylation had taken place. From the crystal structure obtained [Figure 65], 
alkylation had occurred exclusively at the desired position and there was only one 
molecule within the asymmetric unit. 
 
 
 
 
 
 
 
 
Figure 65. Ball and stick representation of the crystal structure of 161 (red = oxygen, 
white = hydrogen, grey = carbon and blue = nitrogen). 
 
From this crystal structure, it was observed that a twist angle of 84.06o exists between 
the planes defined by the two rings (information obtained from Dr Georgina Rosair, 
HWU). 
 
   The final step in our synthetic strategy to 162 involved removal of the N3 benzoyl 
protecting group of 161. There are a number of ways to do this reported in the literature. 
We were attracted to the simple approach described by Maguire et al.102 These 
researchers had reported that the benzoyl group can be easily removed by heating the 
compound 163 to reflux in benzyl alcohol [Scheme 36].  
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Scheme 36. Debenzoylation. Reagents and conditions: BnOH, reflux, 24 h. 
 
   Thus, 161 was dissolved in benzyl alcohol and heated to reflux for 30 hours. Removal 
of the solvent and purification using flash chromatography afforded 162 in an 82% 
yield. From the 1H NMR spectrum recorded, the absence of the aromatic protons and 
the new ‘NH’ proton signal at 8.12 ppm proved that debenzoylation had taken place. 
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Further, from the I.R. spectrum recorded, there were only two strong carbonyl signals 
observed at 1701 cm-1 and 1698 cm-1, in contrast to the three observed at 1747 cm-1, 
1696 cm-1 and 1644 cm-1 for 162. This compound was then directly subjected to our 
‘click’ conditions as described in the later section 2.4.4 (pages 139-141). 
 
2.3.2 Cytosine alkyne component synthesis 
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Scheme 37. Reagents and conditions: (i) BzCl, C5H5N, rt, 24 h; (ii) HC≡CCH2Br, 
DMF, DBU, rt, 24 h. 
 
   Scheme 37 shows the planned synthetic scheme designed to prepare the cytosine 
alkyne component 165. The initial step in Scheme 37 involves the benzoylation of 
commercially available cytosine 12 to afford 165. The exocyclic NH2 group must be 
protected in order to prevent interference in later oligomerisation steps. Usually the 
protecting group for cytosine (based on oligodeoxynucleotide chemistry) is a benzoyl 
group. We decided to keep the protecting group the same for our purposes. The final 
step involves alkylating 165, using propargyl bromide, to obtain the final cytosine 
alkyne component 166.  
 
   Thus, the first step investigated towards our target cytosine derivative 165 involved 
suspending commercially available cytosine 12 in dry pyridine in the presence of BzCl; 
these conditions had been previously used in order to benzoylate the N3-position of 
thymine (Section 2.3.1, pages 98-100). Following work-up and purification by 
recrystallisation, 165 was obtained in a 92% yield. This product proved to be insoluble 
in all deuterated solvents available in the laboratory and therefore, structural verification 
by NMR analysis could not be carried out. However, the I.R. spectrum recorded 
indicated the presence of a medium NH stretching band at 2964 cm-1 and two strong 
carbonyls bands at 1738 cm-1 and 1699 cm-1. Elemental analysis also afforded results 
within experimental parameters and mass spectrometry showed that the desired 
molecular ion peak was present in 100% relative abundance. Although none of these 
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techniques proved the site of benzoylation, elemental analysis and mass spectrometry 
results proved that mono-alkylation had occurred. Our elemental analysis was consistent 
with that reported for the same compound by Brown et al.103 Their elemental analysis 
found C 61.2, H 4.0, N 19.7 and our data was found to be C 61.4, H 4.2, N 19.4. The 
required data for C11H9O2N3 was C 61.4, H 4.2, N 19.5. Based on evidence reported by 
Nielsen et al.75 on their Cbz protection of N4-cytosine [Scheme 38], we surmised that 
the benzoyl group was most likely attached to the exocyclic N4-amino group. 
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Scheme 38. Cbz protection of N4-cytosine. Reagents and conditions: PhCH2OCOCl, 
C5H5N, rt, 24 h. 
 
   The next step in our synthetic pathway to 166 was alkylation using propargyl 
bromide. Initially, we were inspired by conditions reported by Guillarme et al.104 in 
which 165 was alkylated with the Michael acceptor 169 to give 170 in a 72% yield 
[Scheme 39]. 
 
N
N
H
NH
O
O
N
N
NH
O
O
CO2Et
EtO2C
CO2Et
OH
169
165 170
 
 
 
 
 
Scheme 39. Preparation of 170. Reagents and conditions: 169, DBU, DMF, rt, 24 h. 
 
We decided to investigate employing the same conditions for the preparation of 165. 
Thus, 12 was suspended in dry DMF in the presence of DBU and propargyl bromide 
overnight at rt. Following work-up and purification by flash chromatography, none of 
the desired product 165 was present in any fractions obtained, according to 1H NMR 
spectroscopy. Unfortunately, only the starting material was recovered. 
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   During a search of the literature to find viable alternative routes, we discovered a 
report by Lindsell et al.105 in which it was described how competing O2 alkylation had 
hampered N1 alkylation during their attempts to prepare a series of cytosine derivatives. 
These problems were alleviated by starting from the commercially available N4-
acetylcytosine 171 [Scheme 40].  
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Scheme 40. Cytosine derivatives. Reagents and conditions: 171, a or b, K2CO3, DMF, 
rt, 24 h. 
 
We decided that use of this compound for the preparation of our cytosine monomer may 
be worthy of exploration, in order to investigate whether the nature of the N4-
acetylcytosine protecting group of cytosine could influence N1-alkylation. Thus, we 
devised a new synthetic scheme to our cytosine alkyne component 166 starting from 
N4-acetyl cytosine as shown below in Scheme 41. 
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Scheme 41. Reagents and conditions: (i) HC≡CCH2Br, DMF, K2CO3, rt, 24 h; (ii) 5% 
(v/v) methanolic ammonia solution, 24 h, rt; (iii) BzCl, C5H5N, rt, 24 h. 
 
This new synthetic route involved first alkylation of the commercially available starting 
material 171 to afford 173 followed by removal of the acetyl protecting group to 
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unmask the exocyclic amino function 174, and finally, re-protection using benzoyl 
chloride to generate the target compound 166.  
 
   Thus, 171 was suspended in dry DMF and to this anhydrous K2CO3 and propargyl 
bromide were added. Following work-up and purification by recrystallisation from 
water, 173 was afforded in the slightly reduced yield, compared to the reported yield, of 
40%. Full characterisation of this compound was consistent with that published by 
Lindsell et al.105 From the 1H NMR spectrum recorded, the alkyne CH proton of 173 
was observed as a triplet at 3.45-3.48 ppm and the alkyne CH2 protons were present as a 
doublet at 4.63 ppm.  
 
   The second step in this new synthetic scheme was also based on the work reported by 
Lindsell et al.105 They had successfully removed the acetyl protecting group of 173 with 
a methanolic ammonia solution to afford 174 quantitatively [Scheme 41]. Therefore, it 
was decided to employ these conditions for our purposes. Thus, 173 was dissolved in a 
5% (v/v) methanolic ammonia solution and the resulting mixture was left to stir at rt for 
24 h [Scheme 41]. Following solvent removal under reduced pressure, 174 was afforded 
in a 94% yield. Again, full characterisation of this compound was consistent with that 
published by Lindsell et al.105 The NH2 group was observed as a broad singlet at 7.16 
ppm in the 1H NMR spectrum recorded of 174. Further, a crystal structure of 174 
[Figure 66] was obtained which clearly confirmed that alkylation had indeed occurred at 
the N1 position exclusively. 
 
 
 
 
 
 
 
 
Figure 66. Ball and stick representation of the crystal structure of 174 (red = oxygen, 
white = hydrogen, grey = carbon and blue = nitrogen). 
 
   The final step in this strategy involved re-protection of the exocyclic amine of 174 
with a benzoyl group, to afford our final cytosine alkyne component 166 [Scheme 41]. 
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As before, the reaction conditions previously used to protect the N3 position of thymine 
were applied to 174. Thus, BzCl was added to a cooled solution of 174 in dry pyridine 
and the solution was stirred at rt overnight. Following work-up and purification by flash 
chromatography, 166 was afforded in an 84% yield. The 1H NMR spectrum recorded of 
166 showed five aromatic protons as two multiplet signals at 7.46-7.67 ppm and 7.98-
8.02 ppm. In addition to the spectral data collected for 166, we obtained a crystal 
structure [Figure 67] in which it was observed that there was only one molecule within 
the asymmetric unit and that the single benzoyl group was attached to the desired N4-
amino group. 
 
 
 
 
 
 
 
 
 
 
 
Figure 67. Ball and stick representation of the crystal structure of 166 (red = oxygen, 
white = hydrogen, grey = carbon and blue = nitrogen). 
 
From this crystal structure, it was observed that ribbons formed between the NH···N 
hydrogen bonds forming a ring R2,2(8) and alternating with a R4,4(12) NH···O and 
NH···N. Furthermore, the pyrimidine ring is coplanar with the alkyne constituent and 
the layers stack in a herringbone array (information obtained from Dr Georgina Rosair, 
HWU). 
 
2.3.3 Adenine alkyne component synthesis 
 
   In the design of the adenine alkyne component synthetic scheme, our approach in 
terms of protection and alkylation was slightly different to the previous two cases of 
thymine and cytosine. This was mainly due to the regioselective problems associated 
with adenine. The order that the exocyclic amine protection and alkylation steps are 
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carried out is crucial in influencing the regioselective outcome. It is generally known 
from the literature, that alkylation must be carried out first on commercially available 
adenine 10 in order to afford mainly, the N9 alkylated product. Protection of the 
exocyclic amine may then be achieved. Bearing this in mind, we designed the synthetic 
scheme 42 below to afford the adenine alkyne component 176. 
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Scheme 42. Reagents and conditions: (i) HC≡CCH2Br, DMF, NaH, rt, 24 h; (ii) BzCl, 
C5H5N, rt, 4 h. 
 
This strategy initially involves the selective alkylation of the N9 position of 
commercially available 10 with propargyl bromide to afford 175. The subsequent step 
involved protecting the exocyclic amine group with a benzoyl group to obtain our target 
adenine alkyne component 176. Again, the benzoyl group was chosen to be consistent 
with oligodeoxynucleotide synthesis. 
 
   For the first step of this strategy, we were again initially inspired by the procedure 
reported by Choi et al.99 as had previously been used in the case of the thymine 
alkylation (page 99). This involved dissolving commercially available adenine in dry 
DMF in the presence of NaH and propargyl bromide. Following work-up and 
purification by flash chromatography, we obtained 175 in a 36% yield. From the 1H 
NMR spectrum recorded of 175, the alkyne CH proton was observed as a triplet at 3.54 
ppm and the alkyne CH2 protons were seen as a doublet at 5.17 ppm. At this point, we 
needed to verify that the N9 alkylated product had been isolated and this was achieved 
from 2D spectroscopy. It was reasoned that if N7 alkylation had taken place, then cross-
correlation peaks would be seen for the alkyne CH2 group interacting with both H8 and 
the NH2 group [Figure 68]. If on the other hand, N9 alkylation had taken place, then 
cross-correlation peaks would only been seen for the interaction of the CH2 group with 
H8 [Figure 68]. 
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Figure 68. N7 versus N9 alkylation. 
 
From the NOESY* spectrum recorded [Figure 69], we could deduce that the NH2 group 
was on the opposite side of the molecule to the propargyl group. Cross-correlation 
peaks were only observed between the alkyne CH2 group and H8 and therefore, N9 
alkylation was confirmed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*NOESY spectrum obtained from Dr Alan Boyd, Heriot-Watt University
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Figure 69. NOESY* spectrum of alkylated adenine product 175. 
 
   Further, we obtained a crystal structure of 175 which showed that there was only one 
molecule within the asymmetric unit [Figure 70]. The alkyne group was seen to be anti 
rather than syn with respect to the fused ring system. Also, there was one water 
molecule which engaged in hydrogen bonding with N3, and another water molecule, 
generated by symmetry, for every organic molecule.  
 
 
 
 
 
 
*NOESY spectrum obtained from Dr Alan Boyd, Heriot-Watt University.
  110
Results and discussion 
 
 
 
 
 
 
 
Figure 70. Ball and stick representation of the crystal structure of 175 (red = oxygen, 
white = hydrogen, grey = carbon and blue = nitrogen). 
 
   The final step to produce our adenine alkyne analogue, 176, involved benzoylating the 
free amine substituent of 175. This was achieved according to a procedure reported by 
Lindsell et al.105 previously discussed in section 2.3.1 (page 99). 175 was suspended in 
dry pyridine, cooled to 0 oC and BzCl was added. The reaction was stirred at rt for 4 
hours and following work-up and purification by flash chromatography, 176 was 
obtained in a 67% yield. In the crystal structure [Figure 71], we can see that there are 
two molecules within the asymmetric unit and that they differ in orientation of the 
adenine ring system with respect to the carbonyl group. 
 
 
 
 
 
 
 
 
 
Figure 71. Ball and stick representation of the crystal structure of 176 (red = oxygen, 
white = hydrogen, grey = carbon and blue = nitrogen). 
 
From this crystal structure, the distance between the alkyne CH to the N7 position was 
2.283Å. Further, the distance between the CH and the centroid of the phenyl ring was 
2.82Å. The phenyl and alkyne components lie out of the plane formed by the purine unit 
(information obtained from Dr Georgina Rosair, HWU). 
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2.3.4 Guanine alkyne component synthesis 
 
   It is known from the literature that guanine is very difficult to work with, and it has 
been generally accepted that in order to manipulate its structure, it is best to start from 
the commercially available, although expensive, 2-amino-6-chloropurine, 179 [Scheme 
43].106 This intermediate has been shown to improve the regioselectivity of N9 versus 
N7 alkylation. Thus, a synthetic route to guanine alkyne component 183 was devised 
based on this starting material as shown below in Scheme 43. 
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Scheme 43. Reagents and conditions: (i) HC≡CCH2Br, K2CO3, DMF, rt, 24 h; (ii) 
iPrCOCl, DMAP, C5H5N, rt, 4 h; (iii) 2-nitrophenol, DABCO, TEA, DCM, rt, 24 h; (iv) 
1,1,3,3-tetramethylguanidine, 2-nitrobenzaldoxime, CH3CN, rt, 48 h. 
 
The first step in this pathway involved alkylation of the N9 position of 179 with 
propargyl bromide to afford 180 and then protecting the exocyclic NH2 group with a 
isobutyryl group to give 181. Unlike the benzoyl protecting group, in the case of the 
other nucleobases, the isobutyryl group is the desired NH2 protecting group of guanine 
for oligonucleotide chemistry. The next step in the synthetic pathway involved 
replacing the 6-chloro group for an oxygen functionality that would subsequently yield 
the corresponding guanine carbonyl. There are many methods to achieve this, but we 
were inspired by a procedure reported by Howarth et al.106 They successfully achieved 
this substitution quantitatively to afford 185 [Scheme 44], based on work by Reese et 
al.107, 108 and Sproat et al.109 
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Scheme 44. Substitution of the chloro substituent. Reagents and conditions: 2-
nitrophenol, DABCO, TEA, DCM, rt, 24 h.  
 
   The final step in this synthetic pathway involves replacement of the 6-chloro group to 
give the 6-oxygen function required for the guanine alkyne component 182. We were 
again inspired by a procedure reported by Howarth et al.106 in which they had 
successfully achieved this to produce 187 [Scheme 45]. 
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Scheme 45. Regeneration of the carbonyl moiety. Reagents and conditions: 1,1,3,3-
tetramethylguanidine (TMG), 2-nitrobenzaldoxime, CH3CN, rt, 24 h. 
 
   For the first alkylation step in this scheme, we were inspired by a procedure reported 
by Lindsell et al.105 in which they had successfully prepared the same alkylated species 
180 in a 57% yield from 2-amino-6-chloropurine 179 in the presence of propargyl 
bromide and Na2CO3. Thus, a suspension of 179 in dry DMF was treated with propargyl 
bromide in the presence of anhydrous K2CO3. It was decided to employ K2CO3 in place 
of Na2CO3, despite this having been reported by Lindsell et al.105 due to having 
successfully used K2CO3 in the case of our cytosine alkylation (see the previous section 
2.3.2, page 103). After 24 hours at rt, the reaction was worked up and purified by flash 
chromatography, to give 180 in a 77% yield. From the 1H NMR spectrum recorded, the 
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alkyne CH proton was observed as a triplet at 3.48 ppm and the alkyne CH2 protons 
appeared as a doublet at 4.93 ppm. Whilst mass spectrometry and elemental analysis 
data confirmed that mono-alkylation had been achieved, we were unsure whether N9 or 
N7 alkylation had taken place exclusively. Due to there being no protons in the 
corresponding 6 position, it was difficult to confirm the alkylation site from 2D 
spectroscopy. It was hoped that characterisation of subsequent products in the reaction 
pathway would afford us with evidence of N9 alkylation. 
 
   Having successfully produced our alkylated compound 180, the next step was to 
protect the exocyclic amine to give 181. We were inspired by the procedure reported by 
Grǿtli et al.110 in which they had successfully converted 188 into 189 in an 81% yield 
[Scheme 46].  
 
188
O
N
O OCH3
NN
N
O
O2N
H2N
O
iPr2Si
O
iPr2Si O
N
O OCH3
NN
N
O
O2N
N
H O
iPr2Si
O
iPr2Si
O
189
 
 
 
 
 
 
 
Scheme 46. Isobutyryl protection. Reagents and conditions: iPrCOCl, DMAP, C5H5N, 
40 oC, 8h. 
 
   At this point we encountered problems in obtaining isobutyryl chloride quickly from 
our suppliers. In the interest of time, and in order to investigate the final two steps in our 
guanine alkyne component synthetic pathway (Scheme 43, page 109), it was decided to 
employ a different protecting group that could be replaced with an isobutyryl group at a 
later date. Thus, the modified Scheme 47 on the next page was devised and explored.  
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Scheme 47. Modified guanine route. Reagents and conditions: (i) Ac2O, reflux, 3 h; (ii) 
2-nitrophenol, DABCO, TEA, DCM, rt, 24 h; (iii) 5% (v/v) methanolic ammonia, rt, 48 
h; (iv) iPrCOCl, DMAP, C5H5N, 40 oC, 8h; (v) 1,1,3,3-tetramethylguanidine (TMG), 2-
nitrobenzaldoxime, CH3CN, rt, 48 h. 
 
Starting from the alkylated guanine 180, we proposed to protect the exocyclic NH2 
group with an acetyl group to give 190. We then planned to substitute the 6-chloro 
group of 191 with a 2-nitrophenyl group as described before (page 109). The next step 
would then involve removal of the acetyl protecting group to give 192. It was 
rationalised that this could be achieved using a solution of methanolic ammonia, as 
achieved in the case of the cytosine analogue (see the previous section 2.3.2, page 103). 
Subsequent re-protection with the desired isobutyryl protecting group, would then 
afford 182. In the final step, regeneration of the carbonyl moiety could be achieved to 
give the final guanine alkyne component 183 as described before (page 113). 
 
   Thus, having already prepared the alkylated product 180, from Scheme 43 (page 109), 
we needed to protect this with an acetyl group. To achieve this, we were inspired by a 
procedure reported by Lindsell et al.105 in which they had successfully protected the 
exocyclic NH2 group of 180 using acetic anhydride to give 190 in a 32% yield [Scheme 
48].  
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Scheme 48. Exocyclic NH2 protection with acetic anhydride. Reagents and conditions: 
Ac2O, reflux, 3 h. 
 
Thus, a solution of 180 in acetic anhydride was heated to reflux for 3 hours. After 
solvent evaporation in vacuo the crude material obtained was purified by flash 
chromatography to give 190 in an 82% yield. This yield was surprising since it was a lot 
higher than that reported by Lindsell et al.105 They had reported having obtained a 
mixture of both the mono- and diacetylated species (15%), which made us question the 
purity of our product 190. The I.R. spectrum obtained for 190 showed a strong carbonyl 
signal at 1677 cm-1 and a medium NH stretching signal at 3302 cm-1. The 1H NMR 
spectrum recorded of 190 showed a singlet at 2.21 ppm consistent with the CH3 and a 
broad singlet at 10.90 ppm corresponding to the NH of the amide group. Further, the 
mass spectrometry data obtained was consistent with the mono-acetylated compound. 
None of the diacetylated species was detected. 
 
   The next step in our reaction pathway was to introduce a 2-nitrophenyl group into the 
C6 position by displacing the chloro substituent. As described earlier (page 113) we 
were inspired by the procedure reported by Howarth et al.106 Thus, the protected 6-
chloro derivative 190 was dissolved in dry DCM and to this TEA, 2-nitrophenol and 
DABCO were added. The reaction mixture was stirred for 24 hours at rt and following 
work-up and purification by flash chromatography, 195 was isolated in an 89% yield 
[Scheme 49].  
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Scheme 49. Substitution of the chloro substituent. Reagents and conditions: 2-
nitrophenol, DABCO, TEA, DCM, rt, 24 h. 
 
   From the I.R. spectrum recorded for 191, a weak C=O stretching signal at 1623 cm-1 
and a strong signal at 1408 cm-1 were observed. In the 1H NMR spectrum recorded of 
191, the aromatic protons of the 2-nitrophenyl substituent were observed as two 
multiplet signals at 7.42-7.51 ppm and 7.71-7.75 ppm. In the 13C NMR spectrum 
recorded, the two quaternary carbons for the 2-nitrophenyl substituent were observed at 
145 ppm and 151 ppm. Although there was a negligible shift from 159.91 ppm to 
159.10 ppm for the C6 position, there was no indication of the chloro substituent being 
present in the molecular weight obtained from mass spectroscopy data collected. 
 
   The next step in Scheme 47 (page 115), involved removing the acetyl protecting 
group to regenerate the NH2 group of 192. Having successfully achieved the same 
outcome with our cytosine analogue 174, we were inspired to employ the same reaction 
conditions as before (see section 2.3.2, page 107). Thus, 191 was dissolved in a 5% 
(v/v) methanolic ammonia solution and the resulting mixture was left to stir at rt for 24 
h [Scheme 47]. Disappointingly, from TLC analysis and the 1H NMR spectrum 
recorded on the crude product isolated after the work-up, we concluded that no reaction 
had occurred. Thus, another aliquot of methanolic ammonia solution was added and the 
reaction mixture was left for a further 24 hours at rt. Unfortunately, after removing the 
solvent under reduced pressure, still no product 192 was present according to the 1H 
NMR spectrum subsequently recorded. 
 
   Having not been able to remove the acetyl protecting group of 191, we then decided to 
investigate if direct substitution of the chloro substituent from 180 could be achieved to 
afford 192 [Scheme 50]. Not only would this shorten the overall reaction scheme, but 
would also alleviate our problems encountered in removing the acetyl protecting group 
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of 195. Therefore, we exposed our alkylated 2-amino-6-chloropurine derivative, 180, to 
the same reaction conditions as shown in step 2 (Scheme 47, page 117) [Scheme 50]. 
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Scheme 50. Substitution of the chloro substituent. Reagents and conditions: (i) 2-
nitrophenol, DABCO, TEA, DCM, rt, 24 h; (ii) AcCl  or iPrCOCl, DMAP, C5H5N, 40 
oC, 8h. 
 
Thus, 180 was dissolved in dry DCM and to this TEA, 2-nitrophenol and DABCO were 
added. The reaction mixture was stirred for 24 hours at rt and following work-up and 
purification by flash chromatography, 192 was afforded in a 43% yield. The NH2 peak 
was strong at 3293 cm-1. The 1H NMR spectrum again showed, the aromatic protons of 
the 2-nitrophenyl substituent were two multiplet signals at 7.49-7.62 ppm and 7.80-7.89 
ppm. 
 
   Now that we had prepared 192, and isobutyryl chloride had been obtained from our 
suppliers, protection of the NH2 group was attempted using the procedure reported by 
Grǿtli et al.110 (Scheme 46, page 115) [Scheme 51].  
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Scheme 51. NH2 protection. Reagents and conditions: iPrCOCl, DMAP, C5H5N, 40 oC, 
8h. 
  118
Results and discussion 
 
Thus, 192 was taken up in dry pyridine and to this, DMAP and isobutyryl chloride were 
added. Following work-up and purification by flash chromatography, 182 was afforded 
in a 16% yield. From the 1H NMR spectrum recorded, the two CH3 groups from the 
isobutyryl protecting group were observed as a doublet at 1.06 ppm and the CH was 
seen as a septet at 2.95 ppm.  
 
   In order to understand this low yield, it was postulated that perhaps the nature of the 
substituent at the C6 position influenced the nucleophilicity of the N2 amino function, 
and/or steric hindrance was accountable. We therefore decided to revert back to our 
initial guanine synthetic pathway (Scheme 43, page 114) and repeat this step using our 
previously prepared alkylated compound 180 [Scheme 52]. 
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Scheme 52. Exocyclic NH2 protection with isobutyryl chloride. Reagents and 
conditions: iPrCOCl, DMAP, C5H5N, rt, 24 h. 
 
Thus, 180, DMAP and isobutyryl chloride were taken up in dry pyridine at rt and left 
stirring for 24 h [Scheme 52]. Following work-up and purification by flash 
chromatography, 198 was afforded in an 88% yield. The 1H NMR spectrum recorded of 
198, showed a methyl doublet at 1.29 ppm and a septet at 2.93 ppm for the CH of the 
isobutyryl group. The increase in percentage yield obtained when NH2 protection was 
carried out in the presence of a 6-chloro substituent supported our theory that either 
activation of the NH2 group was achieved or that the smaller chloro group provided less 
steric hindrance. 
 
   The next step involved substitution of the 6-chloro substituent for a 2-nitrophenol 
group. This was achieved using the same reaction conditions as shown in Scheme 43 
(page 114) [Scheme 53]. 
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Scheme 53. Substitution of the chloro substituent. Reagents and conditions: 2-
nitrophenol, DABCO, TEA, DCM, rt, 24 h. 
 
   Following work-up and purification by flash chromatography, 182 was afforded in a 
89% yield. Both the I.R. and the 1H NMR spectrum recorded for 182 were consistent 
with the formation of 182. 
 
   The final step to afford our protected guanine alkyne component 183, required us to 
regenerate the carbonyl substituent at the C6 position to give 183. As described earlier 
(page 113) we were inspired by the procedure by Howarth et al.106 Thus, a solution of 
1,1,3,3-tetramethylguanidine (TMG) 200 in dry acetonitrile was added to a stirred 
solution of 182 and 2-nitrobenzaldoxime 199 in dry acetonitrile. The reaction mixture 
was stirred at rt and monitored periodically by TLC over a 48 hour period. TLC and the 
1H NMR spectrum recorded of crude reaction mixture confirmed that the reaction had 
not taken place and, unfortunately, the starting material 182 was recovered 
quantitatively. In attempt to understand this failure, we decided to evaluate a possible 
mechanism behind this specific reaction. 
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Scheme 54. Proposed mechanism for the regeneration of the carbonyl moiety. 
 
Scheme 54 above shows our proposed mechanism for the regeneration of the carbonyl 
function of 183 from 182. 2-Nitrobenzaldoxime 199 and TMG 200 react together to 
form 201 and 202. 201 goes on to substitute the 2-nitrophenol group in the C6-position 
to give 204. Subsequently, excess 200 removes the acidic proton of 204 to afford the 
target compound 183. This mechanism is not simple and may provide the basis from 
which future endeavours into regenerating the carbonyl moiety of guanine can begin.  
 
   Although our efforts at producing our final guanine alkyne component 183 were 
unsuccessful, we were satisfied that having obtained several protected-guanine 
derivatives, namely 182, with the alkyne group present, that this would be sufficient to 
at least attempt our guanine analogue ‘click’ reaction (see the later section 2.4.5, page 
142). It was hypothesised that once the ‘click’ product was obtained, that further 
modification, regeneration of the carbonyl moiety, could then be attempted.  
 
  121
Results and discussion 
 
  122
2.3.5 Conclusions 
 
   The thymine alkyne component was achieved by first protecting the N3 position with 
a benzoyl group to increase the lipophilicity of the compound. Having successfully 
achieved this in a 73% yield, we then alkylated 150 using propargyl bromide to 
regenerate our alkylated thymine monomer 161 in a 55% yield. Our initial failure using 
NaH had led us to substitute this base with K2CO3 which had resulted in this successful 
alkylation. The final (optional) step involved removal of the benzoyl protecting group to 
generate the NH in the N3 position. We had been inspired by conditions reported by 
Maguire et al.102 in which debenzoylation had been achieved using benzyl alcohol. 
Thus, these conditions were applied to 161 and the thymine monomer 162 was afforded 
in an 82% yield. 
 
   Development of the cytosine alkyne component 166 was less straightforward. Our 
initial route towards this target involved benzoylating the exocyclic NH2 group of 
commercially available cytosine. Despite having been unable to verify the structure of 
165 by 1H NMR spectroscopy, due to its poor solubility in any of the deuterated 
solvents available, it was decided to pursue the next step in the pathway and achieve the 
alkylated product 166. A procedure by Guillarme et al.104 was then investigated using 
DBU, however, this reaction failed. In the process of investigating alternative alkylation 
conditions in the literature, we came across the research of Lindsell et al.105 in which 
they advised using commercially available N4-acetylcytosine 171 to prevent competing 
O2 alkylation from occurring when trying to alkylate in the N1 position. Since this 
group of researchers had successfully prepared the same alkylated species 173 using this 
starting material, we decided to replicate their synthetic pathway towards 173. Re-
protection of the ensuing exocyclic NH2 group could then be achieved using the 
benzoylation conditions previously used in the case of our thymine monomer. Thus, the 
alkylated species 166 and then the amine species 174 were afforded in a 40% and 94% 
yield respectively, following their work. Protection of the NH2 group was then achieved 
with a benzoyl group to afford 166 in an 84% yield, in an analogous manner to that 
achieved for the thymine component. 
 
   In the case of developing a synthetic route towards the adenine alkyne component 
176, our approach was slightly different. For purine manipulation, alkylation has to be 
carried out prior to the protection of the exocyclic amine function, contrary to the 
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sequence of steps discussed previously in the case of the two pyrimidine nucleobases. 
Thus, N9 alkylation with propargyl bromide was first investigated. Alkylation 
conditions used in the case of the thymine monomer were applied and the adenine 
alkylated product 175 was afforded in a 36% yield. This yield was comparable to others 
in terms of typical adenine percentage yields. Once we had confirmed that N9 alkylation 
had occurred exclusively, from NOESY spectroscopy, we were then in the position to 
protect the exocyclic NH2 group with a benzoyl group to afford the target adenine 
alkyne component 176. This was achieved in a 67% yield following a procedure by 
Lindsell et al.105 using BzCl in dry pyridine. 
 
   The final nucleobase investigated towards the development of its alkyne component 
was guanine. It is widely accepted in the literature that when manipulating guanine, it is 
best to start from commercially available 2-amino-6-chloropurine 179. Therefore, the 
N9 position of 179 was first alkylated using conditions reported by Lindsell et al.105 in 
which they had successfully prepared the same alkylated species. Thus, 180 was 
obtained in a 77% yield.  
 
   The next step involved protecting the exocyclic amine function with an isobutyryl 
group. However, we experienced problems getting this reagent from our suppliers. In 
light of this, we decided to explore this protection using an alternative group which 
could be replaced with an isobutyryl group once it was available. Lindsell et al.105 had 
opted to protect this function with acetic anhydride and so we decided to reproduce their 
conditions. 190 was obtained in an 82% yield.  
 
   The next investigation involved substituting the 6-chloro group for a 2-nitrophenol 
group. This was achieved using conditions reported by Howarth et al.106 and 191 was 
afforded in an 89% yield.  
 
   It was then attempted to remove the acetyl protecting group, which had been 
successful in the cytosine example described previously. Thus, the same deprotection 
conditions were employed however, unfortunately, no reaction had taken place. 
 
   It was then decided to investigate if direct substitution of the chloro substituent with 
the 2-nitrophenol group could occur from the alkylated compound 180. Therefore, 180 
was subjected to the same substitution conditions previously reported and the desired 
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product 193 was obtained in a 43% yield. At this point, we had managed to obtain 
isobutyryl chloride from our suppliers and therefore, the NH2 protection using this 
reagent was carried out on 182. Although the reaction had been successful, the desired 
product was only obtained in a 16% yield which was unsatisfactory.  
 
   It was then decided to investigate if the nature of the substituent at the C6 position 
influenced the nucleophilicity of the N2 amino function. Thus, the isobutyryl chloride 
conditions were repeated using the 6-chloro alkylated compound 180. In this case, the 
desired product was produced in an 88% yield which confirmed our suspicions that the 
C6 substituent does influence the nucleophilicity of the N2 amino function. In the later 
case, the smaller chloro substituent allowed for easier protection of the NH2 group, and 
in the case of the 2-nitrophenyl substituent in the C6 position, protection was more 
difficult due to steric hindrance. Further, electronic reasons could also influence the 
nucleophilicity of the N2 amino function.  
 
   Substitution of the chloro group for a 2-nitrophenol group was then achieved using the 
same conditions reported previously in the case of the alkylated isobutyryl protected 
compound 198. The desired product 182 was afforded in an 89% yield.  
 
   The next step in the synthetic pathway towards the guanine alkyne-containing 
component was to remove the 2-nitrophenol group and regenerate the carbonyl 
substituent of guanine. To achieve this, we were inspired by the procedure reported by 
Howarth et al.106 By treating 182 with 2-nitrobenzaldoxime 199 and TMG 200 as their 
procedure suggested, unfortunately, resulted in no product 183 being observed. Due to 
time constraints, further investigation into the reaction was not undertaken. However, 
the proposed mechanism (Scheme 54, page 123) is not simple and, upon further 
inspection, may account for the problems we encountered. Instead, the starting materials 
were recovered quantitatively. Despite having not been able to generate the target 
guanine alkyne component 183, we had however, prepared several protected guanine 
intermediates (namely 182) containing an alkyne moiety which could, in theory, be used 
in the ‘click’ reaction. Subsequent modification of the nucleobase component could 
then be achieved following the ‘click’ reaction. 
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2.4 DEVELOPMENT OF THE ‘CLICK’ CHEMISTRY 
 
2.4.1 Introduction 
 
   In 2001, a landmark review was published by Sharpless et al.81 describing a novel 
strategy for organic chemistry, coined ‘click’ chemistry. Dr Sharpless defined ‘click’ 
chemistry as a group of reactions that “…must be modular, wide in scope, give very 
high yields, generate only inoffensive byproducts that can be removed by 
nonchromatographic methods, and be stereospecific (but not necessarily 
enantioselective). The required process characteristics include simple reaction 
conditions (ideally, the process should be insensitive to oxygen and water), readily 
available starting materials and reagents, the use of no solvent or a solvent that is benign 
(such as water) or easily removed, and simple product isolation. Purification, if 
required, must be by non-chromatographic methods, such as crystallisation or 
distillation, and the product must be stable under physiological conditions.”81 
  
   As previously stated, ‘click’ chemistry encompasses a group of reactions and to date, 
these reactions can be classified into four main categories:  
 
(1) Cycloadditions: These are reactions which primarily refer to 1,3-dipolar 
cycloadditions [Scheme 55]. However, they also include hetero-Diels Alder 
cycloadditions.111 
 
R N3 + R'
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N
N
N
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Scheme 55. Cycloadditions (CuI catalysed Huisgen 1,3-dipolar cycloaddition of azides 
and terminal alkynes). 
 
(2) Nucleophilic ring-openings: These are reactions which refer to the opening of 
strained heterocyclic electrophiles, e.g. epoxides, cyclic sulfates, aziridines, aziridinium 
ions and episulfonium ions [Scheme 56].111 
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Scheme 56. Nucleophilic ring openings 
 
(3) Carbonyl chemistry of the non-aldol type: These reactions include for example, 
the formation of hydrazones, ureas, oximes, thioureas, amides, ethers and aromatic 
heterocycles [Scheme 57].111 Aldol type reactions cannot be considered ‘click’ reactions 
due to their thermodynamic driving forces being typically slow, resulting in long 
reaction times, and due to the formation of side products.111 
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Scheme 57. Non-Aldol carbonyl chemistry. 
 
(4) Additions to carbon-carbon multiple bonds: These reactions include for example, 
aziridinations, epoxidations, nitrosyl halide additions, dihydroxylations, sulfonyl halide 
additions and certain Michael additions [Scheme 58].111 
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Scheme 58. Carbon multiple bond additions. 
 
   Amongst these four main classifications, cycloadditions and, in particular, the CuI-
catalysed Huisgen 1,3-dipolar cycloaddition of azides and terminal alkynes is the most 
studied and widely used examplar.111  
 
2.4.2 CuI-catalysed Huisgen 1,3-dipolar cycloaddition of azides and terminal alkynes 
 
   This particular cycloaddition fulfils the ‘click’ chemistry criteria completely and 
results in the formation of 1,2,3-triazoles. CuI-catalysed Huisgen 1,3-dipolar 
cycloadditions are reliable, easy to use and are regiospecific, forming the 1,4-substituted 
product exclusively.111 The reaction can be performed at temperatures between 0 and 
160oC (although the reactions typically do not require heat elevation), over a pH range 
of 5 to 12 and in several different solvents (including water).111 This catalysed version 
proceeds 107 times faster than the uncatalysed version and is unaffected by steric 
factors.111 Primary, secondary, tertiary and aromatic azides all participate in this 
cycloaddition.111 Further, azides and terminal alkynes can both tolerate oxygen, water, 
biological molecules, common organic synthetic conditions, a variety of pHs and 
solvents and the reaction conditions of living systems e.g. hydrolysis, reducing 
environment.111 Although the decomposition of aliphatic azides is thermodynamically 
favoured, they are stable under the aforementioned conditions due to a kinetic barrier 
that exists.111 Thus, they are invisible in solution until they come into contact with a 
dipolarophile, the alkyne.111  
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The mechanism of the CuI-catalysed Huisgen 1,3-dipolar cycloaddition 
 
   Cycloadditions generally proceed in a concerted mechanism, however, both molecular 
modelling and experimental data on this particular cycloaddition has shown it to be a 
stepwise process.111 The catalysed concerted reaction has been shown, using density 
functional theory calculations, to have a greater activation barrier by 1.8 kcal/mol, than 
for the uncatalysed concerted reaction.111 Furthermore, the stepwise-catalysed Huisgen 
1,3-dipolar cycloaddition reaction has an activation barrier which is 11 kcal/mol lower 
than that for the catalysed concerted reaction.111  
 
   Due to these findings, and given that CuI is known to readily insert itself into terminal 
alkynes in a Sonogashira type coupling, it has been proposed that the mechanism of the 
Huisgen 1,3-dipolar cycloaddition is that shown in Scheme 59.111  
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can result.111 π complexation of the CuI serves to lower the pKa of the terminal alkyne 
 
Scheme 59. Proposed mechanism for the CuI catalysed Huisgen 1,3-dipolar 
cycloaddition (redrawn from ref 107). 
 
   From Scheme 59 above, the first step involves π complexation of the CuI dimer 223 to 
the alkyne 224 to afford 225.111 Deprotonation of the terminal hydrogen then occurs, 
which forms the Cu-acetylide 226/227 equilibrium.111 Depending on the reaction 
conditions used, there are a variety of different kinds of Cu-acetylide complexes which 
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he copper catalyst 
 The catalyst required for the 1,3-dipolar cycloaddition of azides and terminal alkynes 
 The catalyst can also be generated by the direct addition of CuI salts to the reaction. 
by up to 9.8 pH units, which allows the deprotonation to occur in the absence of base 
and in aqueous solvent.111 The next step involves displacing one of the ligands, L, from 
the second Cu in the Cu-acetylide 226/227 complex with nitrogen, to form the dicopper 
species 228 which activates the azide for nucleophilic attack.111 N3 is then in close 
enough proximity to attack C4 of the alkyne, resulting in the formation of a 
metallocycle 229.111 This then contracts once the lone pair of electrons on N1 has 
attacked C5, forming the respective triazole in 230.111 The attached Cu dimer then 
complexes to a second terminal alkyne, which cannot undergo a further cycloaddition 
due to the unfavourable structure of the ensuing complex 231, and dissociates upon 
protonations to reform 223.111 A final protonation releases the CuI catalyst to generate 
the 1,2,3-triazole product 232, and allows the catalyst to undergo a second cycle with 
other substrates.111 Although further studies are required to conclusively confirm that 
both these protonations are as a direct result of interactions with protonated external 
base and/or solvent, it is expected.111 
 
T
 
  
can be generated in several different ways. Perhaps the most common of these 
techniques is to reduce CuII salts in situ to produce CuI salts.111 CuSO4·5H2O is 
normally reduced by sodium ascorbate, but other reducing agents including tris(2-
carboxyethyl)phosphine and hydrazine can also be used.111 The reagents in this strategy 
are relatively cheap and the reaction can be carried out in water, which consequently 
prevents the atmosphere having to be deoxygenated.111 The reaction is also therefore, 
environmentally safe.111 By being able to remove the need for using base in the reaction, 
by using water as a solvent, the need for protecting groups is also eliminated.111 The 
major limitation of this method is that the reducing agent may additionally reduce the 
CuII salt to Cu0, although this can normally be prevented by using a correct ratio of 
reducing agent to catalyst or by the addition of a copper stabilising agent such as tris-
(hydroxypropyltriazolylmethyl)amine (THPTA) to the reaction.111  
 
  
The copper salts that can be added include, CuBr, CuI, CuOTf·C6H6 and 
[Cu(NCCH3)4][PF6] for example.111 A reducing agent is not required for this technique, 
but an organic solvent (or a mixed solvent) and hence a deoxygenated atmosphere is 
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 Oxidation of copper metal with an amine salt can also be used to form the active 
 Another way of producing the active catalyst is to use Cu0 nanosize clusters.112 These 
 A catalyst may not always be necessary for this reaction, when the reactant alkyne is 
lick’ chemistry applications 
 Since its debut in 2001, there has been an explosion of growth in publications relating 
comprehensive guide to the recent applications of ‘click’ chemistry. 
necessary.111 Protecting groups are also required along with base.111 Although direct 
addition of CuI salts can be successful, this method is not as reliable as the CuII 
technique described previously. 
 
  
catalyst, albeit with several disadvantages. Longer reaction times as well as large 
quantities of expensive copper are the main problems with this technique.111 Slightly 
acidic environments are also necessary to dissolve the metal, which may be detrimental 
if acid sensitive protecting groups are contained within the reactants.111  
 
  
clusters effectively catalyse the cycloaddition reaction without the need for an amine 
hydrochloride salt.112 The reaction is thought to occur on the surface of the nanoclusters 
rather than in solution and the oxidation state of the copper during this process is likely 
to be CuI.112 Cycloadditions using nanosize Cu0 demonstrate the same broad range of 
high yielding reactions as expected with ‘click’ chemistry however, the major 
disadvantage is that solvation of these nanosize particles necessitates a slightly acidic 
environment.112 Hence, the need for protection of acid sensitive functional groups.112 
Further, Cu0 nanosize clusters are currently not commercially available, and the Cu0 
nanoscale powder required to produce them, is greater than seven times more expensive 
than the other copper sources discussed in this section.112 
 
  
sufficiently electron deficient. However, electron deficient alkynes, are themselves, 
extremely reactive towards nucleophiles and may result in unwanted side reactions 
which would defeat the previously outlined set of criteria for a ‘click’ reaction (page 
125).111 
 
‘C
 
  
to a wealth of applications of ‘click’ chemistry. The fields of bioconjugation, material 
science and drug discovery have perhaps benefited the most from this practical and 
sensible chemical approach. The reader is referred to a review by Moses et al.113 for a 
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‘click’ chemistry and in particular, the 
uI-catalysed Huisgen 1,3-dipolar cycloaddition variant. Firstly, if the diene, the azide 
 when an alkyne reacts 
ith a second alkyne in place of the azide.111  
I-acetylide complex must have physical 
ontact with the azide in order for a successful ‘click’ reaction to result.111 If however, 
he 
tio of nitrogen atoms to carbon atoms exceeds, or is equal to one, in an organic 
l 
onsequences. The side effects of increased copper levels include kidney diseases, 
The problems associated with ‘click’ chemistry 
 
   There are several problems associated with 
C
in this case, is too electron deficient then no reaction will take place.111 This is due to 
the ground state configuration being too low for it to successfully interact with the 
dienophile, the terminal alkyne.111 Similarly, the dienophile cannot be too electron 
rich.111 This circumstance is unlikely though as it would require functional groups not 
commonly found in biological systems or administered drugs.111 
 
   Alkyne homocoupling is a more common problem. This arises
w
 
   Another problem is CuI saturation. The Cu
c
the complex becomes surrounded by terminal alkynes, a chelation effect with the 
alkynes results and the complex becomes saturated.111 Thus, azide functional groups are 
effectively prevented from having contact with the complex and performing the 
displacement.111 Although CuI saturation is rare, it occurs when the dipolarophile 
contains multiple terminal alkynes that are capable of coordinating to a single site.111 
 
   Azide stability may also be a limitation in these cycloaddition reactions. When t
ra
molecule, then the molecule is deemed explosive and therefore, very dangerous.111 A 
slight input of external energy would have disastrous consequences.111 Fortunately, 
large molecules with high carbon content are usually used in pharmaceutical research. 
 
   Despite copper being required in the body, excessive intake can have fata
c
neurological disorders, hepatitis and Alzheimer’s disease.111 Copper is toxic at high 
levels due to it easily accepting and donating single electrons, thereby, changing 
electronic states which allows it to catalyse toxic reactions, such as the in vivo reduction 
of hydrogen peroxide to form hydroxyl free radicals.111 The copper catalyst must 
therefore be completely removed if in vivo applications of ‘click’ chemistry are to be 
found.111  
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first discovered over a decade ago, little information is known about their 
re inconvenience, of ‘click’ chemistry at present is that, 
urrently, many of the ‘click’ building blocks are not commercially available. Although 
ick’ reactions 
otential loss of both our precious serine derived azide 
omponents and nucleobase containing alkyne components, it was decided to first 
   Another challenge to overcome is the biocompatibility of 1,2,3-triazoles. Although 
they were 
biological pathway.111 Individual toxicities of the 1,2,3-triazoles have been extensively 
researched, however, there are currently no reports reviewing their in vivo 
metabolism.111 This is surprising since 1,2,3-triazoles are known bioisosteric 
replacements for amides.111  
 
   The final limitation, or me
c
in the future this will no doubt not be an issue, at the present time it can be seen as a 
daunting task. 
 
2.4.3 Model ‘cl
 
   In order to minimise the p
c
investigate the ‘click’ reaction conditions using structurally similar, readily available 
models. Once the conditions have been optimised, these would be applied to our desired 
‘click’ reactions. From the findings discussed in section 2.4.1 of this chapter (pages 
126-133), it was decided to initially adopt the approach of reducing CuII salts in situ to 
CuI salts using sodium ascorbate. This is the commonest strategy used for 
accomplishing this cycloaddition reaction. We were inspired by the procedure reported 
by Goujon et al.114 in our research group, in which 235 had been prepared from azide 
233 and alkyne 234 in a 76% yield [Scheme 60]. 
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cheme 60. ‘ , CuSO4·5H2O, 
odium ascorbate, DCM/tert-butyl alcohol/H2O, rt, 24 h. 
ying commercially available 
ropargyl alcohol 235, as the substitute thymine-containing alkyne component 161, and 
cheme 61 2O, sodium 
scorbate, DCM/tert-butyl alcohol/H2O. 
suitable alkyne component substitute as it was 
oth commercially available and would prevent complication of the resulting triazole 
 
vailable ethanolamine 236 [Scheme 62].  
O 
 
 
 
 
 
 
 
 
S Click’ conditions. Reagents and conditions: 233, 234
s
 
   The first of our model reactions involved emplo
p
the model azide 238 shown below [Scheme 61]. 
 
 
 
 
S . Model ‘click’ reactions. Reagents and conditions: CuSO4·5H
a
 
Propargyl alcohol 235 was selected as a 
b
proton in the respective 1H NMR spectrum recorded of product 239. It was decided to 
employ the model azide 238 as this would also prevent complication of the 1H NMR 
spectrum obtained for 239 and further, it would allow the silicon lability to be assessed. 
 
   Azide 238 first had to be prepared and this was achieved starting from commercially
a
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cheme 6 ) 
BDMSCl, imidazole, DCM, rt, 24 h; (ii) 152, NaHCO3, CuSO4·5H2O, H2O, MeOH, rt, 
 first step in this synthetic pathway to model azide 238 required us to protect the 
rimary alcohol of 236 with a silicon group to produce 237 and then secondly, to 
ield by treating 236 with TBDMSCl in DCM for 
4 h at rt. From the 1H NMR spectrum recorded of 237, a singlet corresponding to nine 
 to the diazotransfer conditions described previously (see 
ection 2.2.2, page 94). The azide signal was observed at 2114 cm-1 in the crude I.R. 
re then subjected to the ‘click’ conditions reported 
y Goujon et al.114 [Scheme 61]. 238 was taken up in an equal mixture of DCM, tert-
N3 
 
 
S 2. Preparation of the model azide 238. Reagents and conditions: (i
T
24h. 
 
   The
p
convert the amine into azide 238 using the previously prepared ‘diazo donor’ 152 (see 
the previous section 2.2.2, page 94).  
 
   Thus, 237 was afforded in a 53% y
2
tert-butyl protons at 0.31 ppm and a second singlet at 1.14 ppm corresponding to six 
protons of the two CH3 groups attached to the silicon, indicated that successful alcohol 
protection had occurred.  
 
   237 was then subjected
s
spectrum recorded of 238. The crude 1H NMR spectrum recorded showed two singlets 
at 0.09 ppm and 0.91 ppm corresponding to the two and three methyl groups 
respectively on the silicon moiety, and two triplets at 3.27 ppm and 3.80 ppm consistent 
with the protons from the two CH2 groups. There was also a broad singlet at 5.30 ppm 
which indicated that the diazotransfer reaction had not been quantitative, and that some 
starting amine 237 was still present. 
 
   Thus, azide 238 and alkyne 235 we
b
butyl alcohol and H2O and to this, 235, sodium ascorbate, and CuSO4·5H2O (1:2) were 
added. After 24 h stirring at rt, and following work-up and purification by flash 
chromatography, 239 was afforded in a 70% yield. From the 1H NMR spectrum 
recorded of 239, the triazole proton was clearly seen as a singlet at 7.61 ppm. The OH 
O
SiH2N
O
Si
OH
H2N
(i)
236 237 238
(ii)
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was observed as a broad singlet at 3.12 ppm and the silicon moiety was shown to be 
untouched. 
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 The next model reaction involved employing the actual thymine alkyne component 
 
cheme 63. Model reaction using the actual thymine alkyne component 161. Reagents 
hus, the actual thymine alkyne component 161 was subjected to exactly the same 
igure 72. 
  
161 together with the previously prepared model azide 238 [Scheme 63]. 
OTBDMS
N
NO
S
and conditions: 152, CuSO4·5H2O, sodium ascorbate, DCM/tert-butyl alcohol/H2O, rt, 
24 h. 
 
T
conditions as described previously. The reaction mixture was stirred at rt for 24 h, 
worked-up and purified by flash chromatography to afford 240 in a substantially 
reduced yield of 24%. From the 1H NMR spectra recorded of 240, the product was 
identified by a triazole signal at 7.52 ppm and a double doublet at 4.78 ppm 
corresponding to the CH2 group between the triazole and thymine moieties. All other 
protons were consistent with product 240. Despite being confident that the ‘click’ 
conditions employed would favour the formation of the 1,4-regioisomer 240 over the 
1,5-regioisomer 240a [Figure 72], it was decided to carry out NOESY* spectroscopy to 
confirm this.  
 
 
 
 
 
 
 
 
 
F 1,4- and 1,5-regioisomers of 240. 
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elation peaks would be expected resulting 
 
igure 73. NOESY* spectra of product 240. 
 Having been able to form the triazole product 240, it was then decided to employ a 
NOESY spectrum obtained from Dr Alan Boyd, Heriot-Watt University. 
For 1,4-regioisomer formation, two cross-corr
from the interaction between the CH2 groups either side of the triazole moiety, with the 
triazole proton. If the 1,5-regioisomer had formed than only one cross-correlation peak 
should be observed for the interaction of the triazole proton with the CH2 group of the 
nucleobase portion of the molecule. The NOESY* spectrum recorded for 240 is shown 
below in Figure 73. 
N
N
N
N
N
O
O
Ph
O
H
H
H
F
 
  
secondary azide, and investigate the viability of a more sterically hindered azide 242 in 
the ‘click’ reaction with our thymine alkyne component 161 [Scheme 64]. 
 
 
*
OTBDMS
H
H
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chem . Reagents 
 This model azide first had to be prepared from commercially available L-alanine 
cheme 65. Preparation of the model azide 242. Reagents and conditions: 152, 
 Following the procedure by Goddard-Borger et al.96 azide 242 was prepared. The 
 Azide 242 was then subjected to the same ‘click’ conditions reported previously and 
 
 
 
 
 
 
S e 64. Model reaction using the actual thymine alkyne component 161
and conditions: 152, CuSO4·5H2O, sodium ascorbate, DCM/tert-butyl alcohol/H2O, rt, 
24 h. 
 
  
methyl ester 241 [Scheme 65].  
 
 
 
 
 
S
NaHCO3, CuSO4·5H2O, H2O, MeOH, rt, 24h. 
 
  
strong azide signal at 2106 cm-1 in the crude I.R. spectrum recorded of 241 proved that 
the diazotransfer reaction had been successful. Further, the crude 1H NMR also 
confirmed the correct structure of 242. The methyl group was observed as a singlet at 
1.69 ppm, the methoxy CH3 protons were present as a singlet at 3.98 ppm and the 
remaining CH proton was observed as a singlet at 4.07 ppm.  
 
  
following work-up, product 243 was afforded in a 13% yield. The formation of the 
triazole product was confirmed by 1H NMR and NOESY spectroscopy. The triazole 
proton was observed as a singlet at 7.61 ppm, and a double doublet at 4.79 ppm 
confirmed the presence of the CH2 group between the triazole and thymine moieties. It 
was postulated that the poor yield observed for this ‘click’ reaction, and indeed the prior 
example discussed on page 136, may be due to solubility problems of our nucleobase-
OO
H N
N
N
+
BzN
N
O
N
BzN
O
O
O
N3H
O
H
161 242 243
HCl.
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containing alkyne component 161. Despite the yields of these reactions being 
disappointingly low, it was decided in the interest of time to continue to investigate the 
viability of our actual azides 158 and 159 with the substitute alkyne component 235. 
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 Thus, the final model ‘click’ reaction undertaken employed use of our actual azide 
cheme 66. Model ‘c . Reagents and conditions: 
hus, the thymine alkyne substitute 235 was added to a mixture of 158, CuSO4·5H2O, 
.4.4 ‘Click’ studies using serine-derived azide 158 and thymine alkyne 161. 
 We decided that we were now in a position to begin to conduct preliminary 
OTBDMS
  
158 (see the previous section 2.2.2, page 97) and the alkyne substitute, propargyl 
alcohol 235 [Scheme 66]. 
 OTBDMS
+ HO O 
 
 
 
S lick’ reaction with the actual azide 158
CuSO4·5H2O, sodium ascorbate, DCM/tert-butyl alcohol/H2O, rt, 24 h. 
 
T
and sodium ascorbate (1:2) in an equal mixture of DCM, tert-butyl alcohol and H2O. 
Following work-up and purification by flash chromatography, the triazole product 244 
was afforded in a 62% yield. From the 1H NMR spectrum recorded of 244, the OH 
group was seen as a broad singlet at 3.18 ppm, the CH2 group next to the OH group was 
present as a singlet at 4.80 ppm and the triazole signal was observed at 7.92 ppm. The 
silicon portion of the molecule was seen to be intact and the rest of the signals were 
consistent with product 244. 
 
2
 
  
investigations into the ‘click’ reaction using our actual monomers, i.e. the serine-
derived azide 158 and thymine alkyne component 161 [Scheme 67]. 
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cheme 67. Actual ‘click’ reaction. Reagents and conditions: CuSO4·5H2O, sodium 
 We chose to first examine the use of the same reaction conditions as we had 
igure 74. Debenzoylated ‘click’ product 
 None of the product containing fractions contained a click product with the benzoyl 
competing debenzoylation side reaction.  
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161 245
 
 
 
 
 
 
 
S
ascorbate, DCM/tert-butyl alcohol/H2O, rt, 24 h. 
 
  
previously used for our model ‘click’ reactions. Thus, the thymine alkyne component 
161 was added to a mixture of azide 152, CuSO4·5H2O and sodium ascorbate (1:2) in an 
equal mixture of DCM, tert-butyl alcohol and H2O. The reaction mixture was stirred at 
rt for 24 hours, worked-up and purified by flash chromatography. From the 1H NMR 
spectra recorded of the product containing fractions, a ‘click’ product was identified. 
However, this lacked the benzoyl nucleobase protecting group. The debenzoylated 
‘click’ product 246 was formed in the extremely low yield of 15% [Figure 74]. 
 OTBDMS
O NN
 
 
 
 
F 246. 
 
  
group attached (245). At this point, we were not concerned that a debenzoylation side 
reaction had taken place, since removal of this protecting group had been planned for 
the next stage in our synthetic pathway for the synthesis of the thymine monomer. 
However, we felt that the yield of this ‘click’ product was currently unacceptable, and 
so we embarked upon an optimisation strategy in an attempt to improve the yield of the 
desired ‘click’ reaction. We envisaged that this could be achieved in two different ways; 
either through optimisation of the ‘click’ reaction itself or through the elimination of the 
O
N
O
N
NH
O
246
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ception of employing a longer reaction time. 
view by 
ein et al.111 in which it was suggested that the sodium ascorbate:CuII ratio, could be 
 further improve the yield of the ‘click’ reaction involved 
placing the CuSO4·5H2O catalyst for other copper (I) sources. We were inspired by 
   Our initial attempt to optimise the ‘click’ reaction, centred around using the same 
conditions reported previously with the ex
Thus, after 30 h, following work-up and purification by flash chromatography, the 
debenzoylated ‘click’ product 246 was afforded in the improved yield of 44%.  
 
   Whilst looking for further ways to optimise this reaction, we came across a re
H
increased to a 10-fold excess of the reducing agent, thereby increasing the levels of CuI 
in the reaction mixture. It was decided that this was worthy of investigation and, 
therefore, this idea was explored by increasing our ratio from 2:1 sodium ascorbate:CuII 
to 10:1. Unfortunately, the yield of the debenzoylated ‘click’ product 246 achieved for 
this reaction was 37%. 
 
   Our final attempts to
re
the procedure reported by Nahrwold et al.115 in which they had successfully conducted 
the intramolecular 1,3-dipolar cycloaddition using 247 and a copper (I) catalyst, CuI. 
The desired triazole 248 had been afforded in a 32% yield [Scheme 68]. Therefore, we 
decided to apply these conditions to our ‘click’ reaction.  
HO
OH
HO O
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N N
N
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O
O
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N3O
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247 248  
Scheme 68. CuI ‘click’ reaction. Reagents and conditions: CuI, DIPEA, toluene, rt, 20 
h. 
s, the alkyne component 161 was added to a stirred suspension of azide 158, CuI 
nd DIPEA in dry DMF for 24 hours at rt. It was decided to substitute toluene, which 
 
Thu
a
had been utilised in the literature procedure, for DMF in order to enhance the solubility 
of alkyne 161. Following work-up and purification by flash chromatography, the 
triazole product 245 was afforded in a 15% yield. Here, none of the debenzoylated 
‘click’ product 246 was observed in any of the product containing fractions.  
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 using the 
cheme  
uSO4·5H2O, sodium ascorbate, DCM/tert-butyl alcohol/H2O, rt, 30 h. 
esidue afforded 
dicated that the ‘click’ product 246 was present as a singlet appeared at 7.86 ppm 
ed several methods for optimising the ‘click’ reaction and 
limination of the debenzoylation side reaction, the best ‘click’ reaction conditions 
e component ‘click’ reactions 
  
e and adenine alkyne 
ponents 166 and 176, respectively, may require subtle differences in terms of the 
HN
N
   In attempt to eliminate the competing debenzoylation of the thymine moiety side 
reaction from occurring, it was then decided to explore this ‘click’ reaction
deprotected thymine alkyne component 162 (see the previous section 2.3.1, page 103). 
Thus, 162 was subjected to the same reaction conditions as described previously 
[Scheme 69]. 
 
 
OTBDMS
O
+
OTBDMS
 
 
 
 
 
S  69. Debenzoylated thymine ‘click’ reaction. Reagents and conditions:
C
 
Following work-up, the crude 1H NMR spectrum recorded on the r
in
corresponding to the triazole proton. However, this spectrum showed that unreacted 
starting materials were the main components with 246 only being produced in an 
estimated 8% yield. 
 
   Having investigat
e
encountered for our particular azide and alkyne components, involved the in situ 
reduction of CuSO4·5H2O using sodium ascorbate (in a 1:2 ratio) in a 1:1:1 mixture of 
DCM, tert-butyl alcohol and water at rt for 30 h. In the interest of time, it was decided 
to pursue the ‘click’ reactions between our azide 158 and both the cytosine and adenine 
alkyne components 166 and 176. 
 
2.4.5 Cytosine and adenine alkyn
  
   Despite being aware that the ‘click’ reactions with the cytosin
com
‘click’ reaction conditions used with the thymine alkyne component 161 (see the 
previous section 2.4.4, page 140), it was decided to carry out a preliminary investigation 
into these two reactions [Scheme 70].  
ON
N N
O
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cheme 70. ons. Reagents and conditions: (i) 
uSO4·5H2O, sodium ascorbate, DCM/tert-butyl alcohol/H2O, rt, 30 h. 
, CuSO4·5H2O, 
odium ascorbate (1:2) in an equal mixture of DCM, tert-butyl alcohol and H2O. The 
nd adenine ‘click’ reactions could be 
chieved, due to time constraints further investigation into the appropriate conditions 
5 and 246 (see the 
revious section 2.4.4, page 140), the final steps to produce the thymine-containing 
TCNA phosphoramidite monomer 252 were designed and are shown in Scheme 71.  
N
N
 
 
 
 
 
 
 
 
 
 
 
 
 
S Adenine and cytosine ‘click’ reacti
C
 
Thus, alkynes 166 and 176 were added to separate mixtures of azide 158
s
reaction mixtures were stirred at rt and subsequently worked-up. Unfortunately, from 
the crude 1H NMR spectra recorded of 247 and 248, no triazole signals were observed 
in the characteristic region. The alkyne starting materials 166 and 176 were recovered 
quantitatively following flash chromatography. 
 
   Despite being confident that the cytosine a
a
could not be carried out at this stage. Instead, it was decided to pursue the post ‘click’ 
reactions to afford the thymine TCNA phosphoramidite monomer 252. 
 
2.4.6 Synthesis of the thymine TCNA phosphoramidite monomer 
 
   Having successfully obtained the thymine ‘click’ products 24
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4, 
methoxy 9-BBN, THF, 0 oC-rt, 24 h; (ii)DMTrCl, DBU, DCM, rt, 24 h. 
 
   The first step in this post ‘click’ pathway involves reducing the ester of 246 to
then achieved to give 251 which is subsequently 
hosphorylated to afford 252, ready for the incorporation into oligomers.  
thoxy 9-BBN 
as then added to the mixture and the reaction temperature was allowed to warm to rt. 
re was worked-up. 
isappointingly, the 1H NMR spectrum recorded for the crude residue recovered 
Scheme 71. Post ‘click’ reaction pathway. Reagents and conditions: (i)LiBH B-
 the 
primary alcohol 249 followed by re-protection with a DMTr substituent to afford 250. 
Removal of the silicon group is 
p
 
   In order to perform the first step, we selected to employ the same conditions as we 
had used previously for the reduction of 122a to 123a (page 86). Thus, a solution of 246 
in dry THF was added to a solution of LiBH4 in dry THF at 0 oC. B-Me
w
After 24 h, the reaction mixture was worked-up and purified by flash chromatography. 
The desired alcohol was obtained in a 25% yield. The 1H NMR spectrum recorded for 
249 showed the newly generated primary alcohol as a broad singlet at 1.60 ppm. The 
remainder of the peaks were consistent with that expected for 249.  
 
   The next step in this pathway, involved protection of the alcohol of 249 with a DMTr 
group, Thus, alcohol 249 was added to a suspension of DMTrCl in dry DCM in the 
presence of DBU. After 24 h stirring at rt, the reaction mixtu
D
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f our precious azide and alkyne components during the 
reliminary investigation of our ‘click’ reaction, it was decided to carry out some model 
de 238. 235 was chosen as not only was it easy to obtain, but it would also 
llow us to determine the outcome of the ‘click’ reaction easily, by simplifying the 1H 
’ product was only afforded in a 24% yield. This yield was 
nacceptably low and was attributed to poor solubility of the nucleobase-containing 
indicated that this protection reaction had not occurred. This was further confirmed by 
the fact that the alcohol starting material 249 was recovered quantitatively following 
flash chromatography. Due to time constraints, further investigation into this step was 
not carried out, however, it was postulated that perhaps steric hindrance was preventing 
the reaction from occurring and that a different, smaller protecting group could be 
employed instead, in the future. 
 
2.4.7 Conclusions 
 
   In an attempt to prevent loss o
p
reactions.  
 
   The first of these model reactions involved investigating the ‘click’ reaction using 
commercially available propargyl alcohol 235 and a silicon protected ethanolamine-
derived azi
a
NMR region expected for the triazole proton. This azide was chosen due to it being a 
primary azide and also because it allowed us to investigate the stability of the silicon 
group to the ‘click’ conditions. We had been inspired by conditions reported by Goujon 
et al.114 in our research group, and successfully went on to prepare the model ‘click’ 
product 239 in a 70% yield.  
 
   Using this same azide 238, we then attempted the ‘click’ reaction using the same 
conditions as before, except our actual thymine alkyne component 161 was employed. 
In this case, the desired ‘click
u
alkyne component 161. Due to this reaction only being a model, it was decided to 
continue and investigate the ‘click’ reaction between the actual alkyne component 161 
and another model azide. This time, a secondary azide 242 was employed to replicate 
our actual azide, and further, to allow us to evaluate the stability of the methyl ester 
portion of our actual azide 158 during the ‘click’ reaction. Again, although the desired 
‘click’ product 243 was obtained, the yield of 13% was extremely low.  
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 a 62% yield.  
 
ere confident that now we had established reproducible ‘click’ reaction conditions, 
al azide 158 
nd our actual thymine-containing alkyne component 161. Instead, another ‘click’ 
n itself, 
nd secondly, through elimination of the competing debenzoylation side reaction. To 
:1 to 10:1 and the 
utcome was compared. The observed yield form this attempt was 37% however, no 
e previous 
ases, it was decided to explore the direct addition of CuI to the reaction mixture. We 
   The last model reaction investigated involved using our actual azide 158 with 
propargyl alcohol. This successfully produced the triazole product 244 in
 
   Despite our preliminary ‘click’ reactions affording the corresponding triazole product 
in poor yields when the thymine-containing alkyne component 161 was employed. We
w
and knew how to verify if the desired reaction had taken place, that our precious starting 
materials would not be wasted. ‘Click’ studies using the serine-derived azide 158 and 
the thymine-containing alkyne component 161 could now be investigated.  
 
   Thus, using the same conditions described previously in our model ‘click’ reactions, 
no desired triazole-containing product 245 was formed between our actu
a
product, in which the benzoyl group had been cleaved (246) was afforded in a 15% 
yield. Although this result was surprising, the fact that the benzoyl group had been 
removed wasn’t deemed a problem, as its removal had been intended at a later stage, 
prior to the monomers incorporation into oligomers. However, the poor yield was 
unacceptably low and, therefore, an optimisation strategy was embarked upon.  
 
   This investigation centred around two different ways of achieving a greater percentage 
yield of the ‘click’ reaction. Firstly, through optimisation of the ‘click’ reactio
a
optimise the ‘click’ reaction, our first endeavour involved increasing the reaction time. 
The best yield obtained from this investigation was 44% after 30 h.  
 
   Next, we explored the role that the ratio of sodium ascorbate to copper catalyst could 
play in the ‘click’ reaction. Thus, this ratio was increased from 2
o
further investigation into use of different ratios was carried out at this time.  
 
   Our final attempt to optimise the ‘click’ reaction involved using a different source of 
CuI. Instead of reducing CuII to CuI in situ using sodium ascorbate, as in th
c
were inspired by a procedure reported by Nahrwold et al.115 to use CuI. The desired 
Results and discussion 
 
  146
‘click’ optimisation investigation, the highest yield possible of 44%, albeit 
f the debenzoylated species 246, was obtained after 30 h using a 2:1 ratio of sodium 
mpeting debenzoylation side reaction from occurring, 
e previously prepared thymine alkyne component 161, in which the benzoyl group 
r nucleobase-containing alkyne 
omponents in the ‘click’ reaction was then carried out. Azide 158 was subjected to the 
r 161, the next step in the 
ynthetic pathway to afford our TCNA phosphoramidite monomer 252 was to reduce 
‘click’ product 245 was obtained in a 15% yield, but surprisingly, the benzoyl group 
was intact.  
 
   From our 
o
ascorbate to copper (II) catalyst.  
 
   In an attempt to eradicate the co
th
had already been removed, was subjected to these optimised ‘click’ reaction conditions. 
The main constituent of the reaction mixture observed from the crude 1H NMR 
spectrum recorded was the starting materials and the desired triazole-containing ‘click’ 
product 245 was only present in an estimated 8% yield. 
 
   Preliminary investigations into the viability of the othe
c
same optimised ‘click’ reactions discussed previously, with both the cytosine and 
adenine-containing alkyne components 166 and 176. Unfortunately, these initial 
reactions failed and the starting materials were recovered quantitatively in each case. 
Due to these results, the ‘click’ reaction with the guanine alkyne component was not 
attempted. Despite these findings, we are confident that the cytosine, adenine and 
guanine-containing alkyne components will be able to be incorporated into our triazole-
containing monomers in the future. However, due to time constraints, it was not 
possible for us to investigate this here. It was deemed a more appropriate use of the 
remaining time, to investigate the post ‘click’ reactions and develop a route towards our 
thymine-containing TCNA phosphoramidite monomer 252. 
 
   Having obtained our thymine triazole-containing monome
s
the methyl ester to the primary alcohol 249. This was achieved in a 25% yield using 
conditions previously encountered in the development of a synthetic route towards the 
azide component in route B (page 82). Although this yield was poor, no optimisation 
attempts were carried out at this time and instead, it was decided to pursue the next step. 
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 This involved protection of the newly generated primary alcohol with a DMTr group,   
which is a prerequisite for the monomers subsequent incorporation into oligomers. 
Conditions previously used in the development of a synthetic route towards the azide 
component in route A (page 73) were employed. Regrettably, this reaction failed. 
Again, no optimisation attempts were made at this time, however, it was postulated that 
steric hindrance between the ‘click’ alcohol product and the DMTr constituent itself, 
was responsible for this reactions failure. In the future, a smaller protecting group could 
be employed to clarify if this hypothesis is correct, the results of which can then be 
applied to find a suitable alternative or to have the confidence to pursue alternative 
DMTr conditions. 
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Conclusions and future work 
 
3.1 CONCLUSIONS 
 
   The work described in this research project has provided a fundamental basis from 
which our TCNA monomers could, with further development in the future, be prepared 
for incorporation into oligomers for investigations of their potential utility in the field of 
antigene therapy. As outlined in chapter 1 (see the previous section 1.10, pages 67-70), 
the main aims were: (1) to develop a suitable synthetic pathway for the synthesis of the 
azide component; (2) to develop an appropriate synthetic route for the preparation of the 
nucleobase-containing alkyne component; (3) to investigate the use of the ‘click 
reaction’ for coupling our azide and alkyne components, and; (4) to develop a viable 
route for the construction of the TCNA phosphoramidite monomers. The target 
compounds are shown in Figure 75 below. 
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Figure 75. Target compounds. 
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   After investigating several strategies to develop a viable, synthetic scheme towards 
the azide component, this was finally achieved by direct diazotransfer of both the silicon 
protected 158 and natural L-serine methyl ester 159. The novel ‘diazo donor’ imidazole-
1-sulfonyl azide 152, as inspired by Goddard-Borger et al.96, was used in this 
diazotransfer reaction [Scheme 72]. The presence of azides 158 and 159 were confirmed 
by strong signals at 2117 cm-1 and 2110 cm-1 respectively, in the I.R spectra recorded 
(see the previous section 2.2.2, page 97). 
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Scheme 72. Final synthetic route to the azide components 158 and 158. Reagents and 
conditions: 130 or 120, K2CO3, CuSO4·5H2O, MeOH, rt, 16h. 
 
   In parallel to the development of a viable synthetic route to afford our azide 
components, we were also developing the synthesis to afford us with each of the 
nucleobase-containing alkyne components for use in the ‘click’ reaction. Despite the 
structural similarity of the alkyne components, each nucleobase required individual 
investigation into the appropriate conditions to afford such a component.  
 
   The thymine-containing alkyne component 161 was prepared by protecting the N3 
amine function with BzCl to give 160 in a 73% yield (see the previous section 2.3.1, 
page 101). 160 was subsequently alkylated with propargyl bromide in the N1 position to 
give 161 in a 55% yield [Scheme 73]. 
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Scheme 73. Final synthetic route to the thymine-containing alkyne component 161. 
Reagents and conditions: (i) BzCl, CH3CN/C5H5N (1:1), rt, 24 h; (ii) HC≡CCH2Br, 
Cs2CO3, DMF, rt, 24 h. 
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   The cytosine-containing alkyne component 166 was synthesised from commercially 
available N4-acetylcytosine 171 as inspired by Lindsell et al.105 (see the previous 
section 2.3.2, page 104). This reagent was alkylated with propargyl bromide in the 
presence of K2CO3 to afford 173 in a 40% yield. Removal of the acetyl protecting group 
was then carried out by treating 173 with a methanolic ammonia solution to afford 174 
in a 94% yield. Re-protection of the exocyclic NH2 group was then achieved with a 
benzoyl group to afford the target cytosine monomer 166 in a 67% yield [Scheme 74]. 
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Scheme 74. Final synthetic route to the cytosine-containing alkyne component 166.  
Reagents and conditions: (i) HC≡CCH2Br, DMF, K2CO3, rt, 24 h; (ii) 5% (v/v) 
methanolic ammonia solution, 24 h, rt; (iii) BzCl, C5H5N, rt, 24 h. 
 
   The adenine-containing alkyne component 176 was achieved by first alkylating with 
propargyl bromide in the N9 position to give 175 in a 36% yield (see section 2.3.3, page 
109). Protection of the exocyclic amine function was then achieved by treating 175 with 
BzCl in pyridine to afford the target adenine alkyne product 176 in a 67% yield 
[Scheme 75].  
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Scheme 75. Final synthetic route to the adenine-containing alkyne component 176. 
Reagents and conditions: (i) HC≡CCH2Br, DMF, NaH, rt, 24 h; (ii) BzCl, C5H5N, rt, 4 
h. 
 
   The protected guanine-containing alkyne component 182 was successfully prepared 
starting from commercially available 2-amino-6-chloropurine 179 (see the previous 
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section 2.3.4, page 114). Having been inspired by Lindsell et al.105 alkylation in the N9 
position was achieved using propargyl bromide to afford 180 in a 77% yield. The 
exocyclic amine function was then protected using an isobutyryl group to afford 181 in 
an 88% yield. Substitution of the 6-chloro group for a 2-nitrophenol group was then 
successfully carried out in an 89% yield to give 182 [Scheme 76]. This product was 
now suitable to be used in the ‘click’ reaction with our azide component.  
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Scheme 76. Final synthetic route to the protected guanine-containing alkyne 
component 182. Reagents and conditions: (i) HC≡CCH2Br, K2CO3, DMF, rt, 24 h; (ii) 
iPrCOCl, DMAP, C5H5N, rt, 4 h; (iii) 2-nitrophenol, DABCO, TEA, DCM, rt, 24 h. 
 
   Having prepared the azide components and the nucleobase-containing alkyne 
components, we were now in a position to evaluate the ‘click’ reaction. After 
investigating the ‘click’ conditions using model reactions (see the previous section 
2.4.3, pages 134-140), the azide components 158 and 159, together with the thymine-
containing alkyne component 161, were subjected to the same ‘click’ conditions. It was 
found, during our brief attempt to optimise this reaction, that azide 158 and thymine-
containing alkyne component 161 in a 1:1:1 mixture of DCM, tert-butylalcohol and 
H2O in the presence of a 1:2 ratio of CuSO4·5H2O to sodium ascorbate, at room 
temperature for 30 h afforded 246 in a 44% yield [Scheme 77]. 
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Scheme 77. Final conditions for the actual ‘click’ reaction to prepare 246. Reagents 
and conditions: CuSO4·5H2O, sodium ascorbate, DCM/tert-butyl alcohol/H2O, rt, 30 h. 
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   A preliminary investigation into the development of the thymine-containing TCNA 
phosphoramidite monomer 252 was carried out (see the previous section 2.4.6, pages 
144-146). The thymine ‘click’ product was reduced to the corresponding primary 
alcohol 249 in a 25% yield. Due to time constraints, further optimisation of this step and 
indeed investigation into the remaining three steps in this synthetic scheme, towards the 
final target phosphoramidite monomer was not achieved. 
 
3.2 FUTURE WORK 
 
   If time had permitted, a more substantial investigation into the optimisation of the 
‘click’ reaction would have been undertaken, primarily for the improved preparation of 
the thymine monomer, but also for the remaining nucleobase-containing monomers.  
 
   To date, there has been no comprehensive study into the ideal conditions for the CuI-
catalysed azide-alkyne coupling in the literature or indeed in this research, however, the 
results outlined in both suggest that CuI-catalysed azide-alkyne couplings afford 
triazoles under a variety of conditions, underscoring the robustness of the reaction.112 
Typically, ‘click’ reactions take 6-36 hours to occur at ambient temperature, in a variety 
of different solvent mixtures, the catalyst is efficient in a pH range of 4-12 and the 
percentage yields are generally greater than 70%.112 
 
   The problems encountered by other researchers, with the CuI-catalysed Huisgen 1,3-
dipolar cycloaddition variant, have been outlined previously (section 2.4.1 on page 129) 
and are mainly due to; (i) the azide being too electron deficient; (ii) alkyne 
homocoupling occurring; (iii) CuI saturation or fluctuation of appropriate levels of CuI 
in the reaction mixture and; (iiii) poor azide stability.112 It was postulated, in our case, 
that the poor yields and need for the ‘click’ products to be purified was due to the 
combination of poor nucleobase-containing alkyne component solubility in the solvent 
mixtures used and fluctuations in the levels of CuI catalyst throughout the reaction.  
 
   With this in mind, we would have carried out a more thorough investigation into other 
‘click’ conditions that could potentially, have optimised our particular reaction. This 
investigation would have focused on; (i) continued alteration of the copper (II) catalyst 
to sodium ascorbate ratio. Development of a methodical examination into different CuII 
catalysts:sodium ascorbate ratios in the range (1:2) to (1:10), in order to eliminate the 
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fluctuating or insufficient starting levels of CuI in the reaction mixture; (ii) the 
usefulness of oxidating copper metal to CuI or use of Cu0 nanoclusters; (iii) direct 
addition of a variety of different CuI salts (e.g. CuBr, CuCl), using a wide selection of 
nitrogen-containing bases; (iiii) microwave assisted ‘click’ reactions; (v) the use of a 
CuI-stabilising agent (e.g. THPTA) to eliminate CuI saturation and; (vi) the use of 
different solvent mixtures (perhaps employing DMF) to increase the solubility of our 
nucleobase-containing alkyne components.112 
 
   Only when the above analysis has been carried out, with our particular azide and 
nucleobase-containing alkyne components, will comparisons with the literature be able 
to be made. Further, such an investigation would be vital for progressing the work 
described in this thesis, as the poor yields and need for purification encountered here 
would hinder advances towards achieving a triazole-containing nucleic acid oligomer 
for future use in antigene therapy.  
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4. EXPERIMENTAL 
 
4.1 EXPERIMENTAL INTRODUCTION 
 
   Chemicals were purchased from Aldrich, Acros and Alfa Aesar chemical companies 
and were used as supplied without further purification. Standard procedures were used 
to dry organic solvents where stated.  Reactions were routinely carried out under an 
inert atmosphere of argon or N2. ‘Light petroleum’ refers to the fraction boiling between 
40 oC and 60 oC. Analytical thin layer chromatography was performed on aluminium 
backed plates pre-coated with Merck Kieselgel 60 GF254 (Art. 05554). Visualization 
was achieved by ultra-violet light (254 nm) and/or alkaline potassium permanganate 
stain followed by heating. Flash chromatography was performed using DAVISIL® silica 
(60 Å; 35-70 μm) from Fisher (cat. S/0693/60). Fully characterised compounds were 
chromatographically homogeneous (conventional columns). 
 
    1H NMR spectra were recorded at 200 and 400 MHz on Bruker AC200 and DPX400 
spectrometers; 13C NMR spectra were recorded at 50 and 100 MHz on the same 
instruments. Chemical shifts are reported in parts per million (δ in ppm) and are 
referenced against solvent signals (δC 77.16 for chloroform and δC 39.52 for dimethyl 
sulfoxide for 13C spectra; δH 7.26 for chloroform and δH 2.50 methyl sulfoxide for 1H 
spectra). Chemical shift values are accurate to ±0.01 ppm and ±0.1 ppm for 1H NMR 
and 13C NMR spectra, respectively. J values are given in Hz. Multiplicity designations 
used are: s, d, t, q, quint and m for singlet, doublet, triplet, quartet, quintet and multiplet, 
respectively. In 13C NMR spectra, signals corresponding to C, CH, CH2, or CH3 groups 
are assigned from DEPT. High-resolution mass spectra were obtained from the National 
Mass Spectrometry Service Centre, Swansea. Melting points were recorded on a Stuart 
Scientific SMP10 and are uncorrected. Infrared spectra were recorded on a Perkin 
Elmer 1600 FT IR spectrometer. These spectra were recorded as either potassium 
bromide discs, as solutions in CHCl3, or as films between sodium chloride plates. Bands 
are defined as: w, br, m, s, broad, weak, medium, strong, respectively. Microanalytical 
data was recorded on an Exeter CE-440 Elemental Analyser, and [αD] analysis was 
recorded on a Thorn Bendix NPL Automatic Polarimeter type 143D with a yellow 
sodium filter, through the analytical services housed in Chemistry, at Heriot-Watt 
University school of Engineering and Physical Sciences. 
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ed dropwise with 
   (4S)-2,2-Dimethyl-1,3-dioxolane-4-methanol (2.50 g, 18.92 
mmol, 1.00 eq), DMAP (0.13 g, 1.02 mmol, 0.05 eq) and TEA (3 
mL, 21.52 mmol, 1.14 eq) were dissolved in dry DCM (100 mL) 
and to this, TBDPSCl (4.83 mL, 18.85 mmol, 0.99 eq) was add
continual stirring. The mixture was stirred at rt for 24 h and washed with saturated 
NaHCO3 solution (50 mL). The resulting solution was dried over anhydrous Na2SO4 
and the extract was evaporated to dryness in vacuo. The orange residue was purified by 
flash chromatography on a silica column, eluting with light petroleum:EtOAc (80: 20) 
as eluant. Fractions containing product were combined and concentrated in vacuo to 
afford the title compound as a clear, orange/brown oil. (98, 6.56 g, 16.90 mmol, 97%): 
Rf = 0.43 (light petroleum:EtOAc, 80:20); υmax (neat)/cm-1 3071 m, 3050 m, 2931 s, 
2858 s, 1589 w, 1472 m, 1428 m, 1379 m, 1255 m, 1215 m, 1143 m, 1112 m; δH (200 
MHz; CDCl3) 0.92 (9 H, s, (CH3)3C), 1.23 (3 H, s, CH3), 1.24 (3 H, s, CH3), 3.44-3.65 
(2 H, m, C-1H2), 3.74-3.81 (1 H, m, C-2H), 3.89-4.11 (2 H, m, C-3H2), 7.16-7.29 (6 H, 
m, Ar-H), 7.50-7.58 (4 H, m, Ar-H); δc (50 MHz; CDCl3) 19.1 (C), 25.3 (CH3), 26.4 (3 
× CH3), 26.6 (CH3), 64.4 (CH2), 66.6 (CH2), 75.9 (CH), 109.0 (C), 127.6 (4 × CH), 
129.6 (2 × CH), 133.1 (2 × C), 135.4 (4 × CH); m/z (ESI) 388 (M+NH4+, 38%), 293 (M-
(Ph)+, 100%), 43 (M-(C(CH3)2+, 100%); [Found (ESI) 388.2302, C22H34O3SiN requires 
388.2304]; (Found:  C, 71.35; H, 8.24. C22H30O3Si requires C, 71.31; H, 8.16 (c. 19%); 
[α]D24 + 4.02 (19.90 mg / 2 mL in DCM). 
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Attempted preparation of (S)-3-O-(TBDPS)-glycerol (99) 
 
Method A 
 
   98 (0.10 g, 0.28 mmol, 1.00 eq) was dissolved in 60% aqueous acetic 
acid solution (60 mL) and allowed to stir at rt for 4 h. The solvent was 
removed under reduced pressure to afford a clear, colourless oil. 1H 
NMR conducted on this crude residue confirmed that the reaction had failed and that the 
unreacted starting acetal was the sole compound present. 
HO
HO
OTBDPS
C19H26O3Si
1
2
3
 
 
 
 
Experimental 
 
Method B   
 
   The reaction was set up as described in method A except that the reaction was left to 
stir at rt for 24 h instead of 4 h. Subsequently, the solvent was removed under reduced 
pressure to afford a clear, colourless oil. 1H NMR confirmed that the reaction had failed 
and the unreacted starting material was the sole compound present. 
 
Preparation of (S)-3-O-(TBDPS)-glycerol (99)  
 
   To a stirred solution of 98 (1.80 g, 5.05 mmol, 1.00 eq) in a mixture 
of THF/H2O ((4:1) v/v, 180 mL) at 0 oC was added TFA (0.897 mL, 
11.71 mmol, 2.30 eq). The resulting solution was allowed to warm to rt 
before being allowed to stir for 45 h. The solvent was removed in vacuo and a further 
solution of THF/H2O ((4:1) v/v, 180 mL) was added.  The resulting mixture was cooled 
to 0 oC and TFA (0.89 mL, 11.71 mmol, 2.30 eq) was added. The mixture was allowed 
to warm to rt before being allowed to stir for 24 h. The solvent was removed in vacuo 
and a further quantity of THF/H2O ((4:1) v/v, 180 mL) was added. The resulting 
mixture was cooled to 0 oC and TFA (0.89 mL, 11.71 mmol, 2.30 eq) was added. The 
mixture was allowed to warm to rt before being left to stir for 24 h. The solvent was 
removed in vacuo and the residue was purified by flash chromatography on a silica 
column, eluting with (light petroleum:EtOAc:TEA (50:50:1) to light 
petroleum:EtOAc:TEA (25:75:1) to light petroleum:EtOAc:TEA (0:100:1) gradient 
elution). Fractions containing product were combined and concentrated in vacuo to 
afford the title compound as a white solid. (99, 1.02 g, 2.92 mmol, 64%): Rf  = 0.23 
(light petroleum:EtOAc, 50:50); m.p. 51-52 oC; υmax (KBr)/cm-1 3391 br  s (OH), 3071 
w, 2929 m, 2857 m, 1657 w, 1463 w, 1428 w, 1391 w; δH (200 MHz; CDCl3) 0.91 (9 H, 
s, (CH3)3C), 2.26 (2 H, br s, 2 × OH), 3.36-3.67 (5 H, m, C-1,2 and 3H), 7.18-7.33 (6 H, 
m, Ar-H), 7.45-7.53 (4 H, m, Ar-H); δc (50 MHz; CDCl3) 19.0 (C), 26.5 (3 × CH3), 
63.7 (CH2), 65.0 (CH2), 71.6 (CH), 127.7 (4 × CH), 129.8 (2 × CH), 132.6 (2 × C), 
135.3 (4 × CH); m/z (ESI) 348 (M+NH4+, 100%); [Found (ESI) 348.1990, C19H30O3SiN 
requires 348.1989]; (Found:  C, 68.74; H, 7.93. C19H30O3SiN requires C, 69.05; H, 
7.93%); [α]D24 + 6.00 (20.00 mg / 2 mL in DCM). 
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Attempted preparation of (S)-1-O- DMTr -3-O-TBDP S -glycerol (100) 
 
Method A 
 
   The diol, 99 (0.20 g, 0.63 mmol, 1.00 eq) was dissolved in dry 
C5H5N (20 mL) and, to this, DMTrCl (0.21 g, 0.63 mmol, 1.00 eq) 
was added. The reaction mixture was stirred at rt under N2 for 24 h. 
TLC confirmed no reaction had occurred. The reaction mixture was heated gradually to 
a maximum of 70 oC for 12 h, and the solvent was removed in vacuo to afford a 
yellow/orange oil. The crude product was purified by flash chromatography on a silica 
column eluting with dichloromethane:diethyl ether:TEA (50:50:1). None of the 1H 
NMR spectra recorded from the fractions obtained were consistent with formation of the 
desired compound 99; unreacted starting diol was the sole compound present. 
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Method B 
 
   A solution of 99 (0.20 g, 0.63 mmol, 1.00 eq), DMTrCl (0.24 g, 0.69 mmol, 1.10 eq), 
TEA (0.13 mL, 0.95 mmol, 1.50 eq) and  DMAP (0.004 g, 0.03 mmol, 0.04 eq) in dry 
DMF (20 mL) was stirred at rt under N2 for 25 h. The yellow solution was poured into 
ice-H2O (20 mL) and extracted with DCM (4 × 30 mL). The combined organic layers 
were washed with saturated NH4Cl solution (2 × 20 mL) and then H2O (20 mL). The 
separated organic phase was dried over anhydrous MgSO4, filtered and concentrated in 
vacuo to afford a yellow oil. The crude product was purified by flash chromatography 
on a silica column eluting with light petroleum:EtOAc:TEA (50:50:1). None of the 1H 
NMR spectra recorded from the fractions obtained were consistent with formation of the 
desired compound 99; unreacted starting diol was the sole compound present. 
 
Method C 
 
   99 (0.10 g, 0.32 mmol, 1.00 eq) was dissolved in dry DMF (10 mL) and, to this, NaH 
(60% in mineral oil) (0.02 g, 0.35 mmol, 1.10 eq) was added. The reaction mixture was 
stirred at rt under N2 for 20 min. DMTrCl (0.12 g, 0.35 mmol, 1.10 eq) and TEA (0.07 
mL, 0.47 mmol, 1.50 eq) were then added and the reaction mixture was maintained at rt 
for 24 h. A further aliquot of NaH (60% in mineral oil, 0.01 g, 0.14 mmol, 0.42 eq) was 
added and the reaction mixture was maintained at rt for 24 h. The solvent was removed 
under reduced pressure and the crude product was purified by flash chromatography on 
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a silica column eluting with light petroleum:EtOAc:TEA (50:50:1). None of the 1H 
NMR spectra recorded from the fractions obtained were consistent with formation of the 
desired compound 99; unreacted starting diol was the sole compound present. 
 
Method D 
 
   4-Dimethylamino-N-triphenyldimethoxypyridinium chloride, 115 (0.35 g, 0.76 mmol, 
1.20 eq) and diol 99 (0.20 g, 0.63 mmol, 1.00 eq) were dissolved in dry DCM (30 mL) 
before being left to stir at rt under N2 for 24 h. The solvent was removed in vacuo and 
the crude product was purified by flash chromatography on a silica column eluting with 
light petroleum:EtOAc:TEA (50:50:1). None of the 1H NMR spectra recorded from the 
fractions obtained were consistent with formation of the desired compound 99; 
unreacted starting diol was the sole compound present. 
 
Preparation of 4-dimethylamino-N-triphenyldimethoxypyridinium chloride  
(115) 87  
 
   DMTrCl  (0.40 g, 1.19 mmol, 1.10 eq) and DMAP (0.13 g, 1.09 
mmol, 1.00 eq) were mixed in dry DCM (30 mL) before being left to 
stir at rt under N2 for 30 min. Et2O (100 mL) was added and the 
solvent was removed in vacuo to afford an off-white solid. 115 was 
used immediately in the subsequent step to attempt the preparation of 
100 without further purification. 
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Preparation of (S)-1-O-DMTr-3-O-(TBDPS)propan-2-ol (100)  
 
   The diol, 99 (0.25 g, 0.73 mmol, 1.00 eq) was added with stirring 
to a solution of DMTrCl (0.29 g, 0.87 mmol, 1.20 eq) and DBU 
(0.16 g, 1.02 mmol, 1.40 eq) in dry DCM (15 mL). After 27 h at rt 
the reaction was quenched by addition of H2O (20 mL). The organic layer was 
separated, washed with H2O (2 × 20 mL) and dried over anhydrous Na2SO4. Filtration, 
followed by evaporation of the solvent in vacuo afforded a yellow oil. The residue was 
purified by flash chromatography on a silica column, eluting with light 
petroleum:EtOAc:TEA (50:50:1). Fractions containing product were combined and 
concentrated in vacuo to afford the title compound as a white solid. (100, 0.24 g, 0.37 
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mmol, 49%): Rf = 0.45 (light petroleum:EtOAc, 50:50); m.p. 40-42 oC; υmax (KBr)/cm-1 
3564 br s (OH), 3069 m, 2999 m, 2931 s, 2857 m, 2836 m, 1608 s, 1509 s, 1463 m, 
1445 m, 1427 m, 1250 s, 1113 s, 1078 m; δH (200 MHz; CDCl3) 0.97 (9 H, s, (CH3)3C), 
2.44 (1 H, br s, OH), 3.12-3.30 (2 H, m, C-3H2), 3.53-3.69 (6 H, m, C-1H2, C-2H), 3.71 
(3 H, s, OCH3), 6.56-6.83 (5 H, m, Ar-H), 7.06-7.67 (18 H, m, Ar-H); δc (50 MHz; 
CDCl3) 19.4 (C), 27.0 (3 × CH3), 55.4 (2 × CH3), 64.2 (CH2), 65.1 (CH2), 71.4 (CH), 
113.3 (4 × CH), 126.9 (CH),127.2 (2 × CH), 127.9 (8 × CH), 128.3 (2 × CH), 129.9 (2 × 
CH), 130.2 (4 × CH), 133.3 (C), 135.7 (4 × CH), 136.2 (C), 145.1 (C), 158.6 (C); m/z 
(ESI) 655 (M+Na+, 100%), 303 (M-DMTr-O+, 100%); [Found (ESI) 655.2848, 
C40H44O5SiNa requires 655.2850]; (Found:  C, 76.16; H, 6.71. C40H44O5Si requires C, 
75.91; H,  7.01%); [α]D24 + 3.00 (20.00 mg / 2 mL in DCM). 
 
Attempted preparation of (S)-1-O-DMTr-3-O-(TBDPS)propan-2-yl 
methanesulfonate (100a)  
 
   Alcohol 100 (0.62 g, 1.00 mmol, 1.00 eq) was dissolved in dry 
DCM (20 mL) and cooled to 0 oC. To this, TEA (0.84 mL, 6.01 
mmol, 6.00 eq) and CH3SO2Cl (0.23 mL, 3.01 mmol, 3.00 eq) was 
added. The reaction mixture was stirred at rt under N2 for 24 h. The 
reaction mixture was treated with saturated NH4Cl solution (30 mL) and extracted with 
diethyl ether (3 × 40 mL). The combined organic layers were washed with saturated 
NaHCO3 solution (30 mL) followed by saturated NaCl solution (30 mL). The organic 
phase was dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford a 
yellow oil. The crude product was purified by flash chromatography on a silica column, 
eluting with light petroleum:EtOAc:TEA (50:50:1). None of the 1H NMR spectra 
recorded from the fractions obtained were consistent with formation of the desired 
compound 100a, unreacted starting material 100 was the sole compound present. 
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Preparation of (S)-methyl 2-(dibenzylamino)-3-hydroxypropanoate (121)  
 
   L-Serine methyl ester HCl salt (0.25 g, 1.61 mmol, 1.00 eq) was 
dissolved in a mixture of dry THF/DMF ((1:1) v/v, 20 mL) and to this, 
BnBr (0.57 mL, 4.82 mmol, 3.00 eq) and anhydrous NaHCO3 (0.54 g, 
6.423 mmol, 4.00 eq) was added. The mixture was heated to reflux for 14 
h. The reaction mixture was concentrated in vacuo and then H2O (20 mL) was added. 
OH
O
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The aqueous layer was extracted with EtOAc (4 × 40 mL) and the combined organic 
layers were washed with saturated NaCl solution (50 mL) and dried over anhydrous 
MgSO4. Filtration followed by concentration in vacuo afforded a clear, colourless 
liquid. The crude product was purified by flash chromatography on a silica column 
eluting with light petroleum:EtOAc:TEA (80:20:1). Fractions containing product were 
combined and concentrated in vacuo to afford the title compound as a clear, colourless 
oil. (121, 0.44 g, 1.47 mmol, 91%): Rf  = 0.71 (light petroleum:EtOAc, 80:20); υmax 
(neat)/cm-1 3439 br s (OH), 3085 m, 3062 m, 3028 s, 2950 s, 1731 s (C=O), 1667 s, 
1602 m, 1585 w, 1197 s, 1139 s, 1075 s, 699 s; δH (200 MHz; CDCl3) 3.76 (2 H, d J 5.8, 
CH2), 2.95 (1 H, br s, OH), 3.39-3.89 (8 H, m, OCH3, C-2H, and 2 × Benzyl-CH2), 
7.14-7.31 (10 H, m, Ar-H); δc (50 MHz; CDCl3) 51.2 (CH3), 54.5 (2 × CH2), 59.0 
(CH2), 61.4 (CH), 126.6 (2 × CH), 127.2 (4 × CH), 128.3 (4 × CH), 138.4 (2 × C), 
171.5 (C); m/z (ESI) 300 (M+H+, 100%), 234 (M-(CO2CH3)+, 59%); [Found (ESI) 
300.1597, C18H21NO3 requires 300.1594]; (Found: C, 72.02; H, 7.34, N, 4.61. 
C18H21NO3 requires C, 72.22; H, 7.07; N, 4.68%). 
 
Preparation of (S)-methyl 3-O-(TBDMS)-2-(dibenzylamino)propanoate (122)  
 
   121 (0.76 g, 2.54 mmol, 1.00 eq) was dissolved in dry DCM (20 mL) 
and to this imidazole (0.23 g, 3.81 mmol, 1.50 eq) and TBDMSCl 
(0.49 g, 3.30 mmol, 1.30 eq) was added. The reaction mixture was 
stirred at rt for 18 h and then H2O (20 mL) was added to quench the 
reaction. The aqueous phase was extracted with EtOAc (4 × 40 mL) and the combined 
organic layers were washed with saturated NaCl solution (50 mL), dried over anhydrous 
MgSO4, filtered and concentrated in vacuo to afford a clear, colourless liquid. The crude 
product was purified by flash chromatography on a silica column, eluting with light 
petroleum:EtOAc:TEA (80:20:1). Fractions containing product were combined and 
concentrated in vacuo to afford the title compound as a clear, colourless oil. (122, 0.68 
g, 1.64 mmol, 64%): Rf = 0.75 (light petroleum:EtOAc, 80:20); υmax (neat)/cm-1 3086 m, 
3063 s, 3029 s, 1737 s (C=O), 1602 w, 1586 w, 1198 s, 1147 s, 1077 s, 1006 m, 837 s, 
778 s, 698 s; δH (200 MHz; CDCl3) 0.01 (6 H, s, 2 × CH3), 0.87 (9 H, s, (CH3)3C), 3.53-
4.05 (10 H, m, CH3, 2 × Benzyl-CH2, C-2H and C-3H2) 7.12-7.43 (10 H, m, Ar-H); δc 
(50 MHz; CDCl3) 18.2 (CH3), 25.9 (3 × CH3), 33.6 (CH3), 51.1 (CH3), 55.6 (2 × CH2), 
62.8 (CH2), 63.1 (CH), 127.0 (2 × CH), 128.3 (2 × CH), 128.4 (2 × CH), 128.8 (2 × 
2
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CH), 129.1 (2 × CH), 139.9 (2 × C), 172.0 (C); m/z 414 (ESI) (M+H+, 100%), 91 (M-
(PhCH2+,100%); [Found 414.2459, (ESI) C24H35NO3Si requires 414.2458]. 
 
Preparation of (S)-methyl 2-amino-3-O-(TBDMS)propanoate (130)  
 
   L-Serine methyl ester HCl salt (3.00 g, 19.28 mmol, 1.00 eq) was 
suspended in dry DCM (40 mL) and to this, imidazole (1.97 g, 28.92 
mmol, 1.50 eq) and TBDMSCl (3.78 g, 25.06 mmol, 1.30 eq) was 
added. The reaction mixture was stirred at rt for 18 h and then H2O 
(40 mL) was added to quench the reaction. The aqueous phase was extracted with 
EtOAc (4 × 40 mL) and the combined organic layers were washed with saturated NaCl 
solution (50 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo to 
afford the title compound, as a white solid. (130, 3.93 g, 16.78 mmol, 88%): Rf = 0.28 
(light petroleum:EtOAc, 80:20); υmax (KBr)/cm-1 3360 m (NH2), 2929 s, 1749 s (C=O), 
1006 m; δH (200 MHz; CDCl3) 0.02 (6 H, m, 2 × CH3), 0.86 (9 H, s, (CH3)3C), 3.76 (3 
H, s, CH3), 3.90-4.05 (3 H, m, C-2 H and C-3H2), 5.85 (2 H, br s, 2 × NH); δc (50 MHz; 
CDCl3) 17.6 (2 × CH3), 25.1 (3 × CH3), 25.7 (C), 52.0 (CH3), 55.0 (CH), 62.5 (CH2), 
170.2 (C); m/z (ESI) 234 (M+H+, 100%); [Found (ESI) 234.1523, C10H24NO3Si requires 
234.1520]. 
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Preparation of (S)-methyl 2-amino-3-O-(TBDPS)propanoate (135)  
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ous phase was 
   L-Serine methyl ester HCl salt (3.00 g, 19.28 mmol, 1.00 eq) was 
taken up in dry DCM (30 mL) and to this, imidazole (1.99 g, 28.92 
mmol, 1.50 eq) and TBDPSCl (6.89 g, 25.06 mmol, 1.30 eq) was 
added. The reaction mixture was allowed to stir under N2 at rt for 6 h 
and then H2O (30 mL) was added to quench the reaction. The aque
extracted with EtOAc (5 × 50 mL) and the combined organic layers were washed with 
saturated NaCl solution (50 mL), dried over anhydrous MgSO4, filtered and 
concentrated in vacuo to afford a clear, yellow oil. The crude product was purified by 
flash chromatography on a silica column, eluting with light petroleum:EtOAc:TEA 
(50:50:1). Fractions containing product were combined and concentrated in vacuo to 
afford the title compound as a clear, colourless oil. (135, 2.93 g, 8.18 mmol, 43%): Rf = 
0.12 (light petroleum:EtOAc, 50:50); υmax (neat)/cm-1 3386 m (NH2), 1742 s (C=O); δH 
(200 MHz; CDCl3) 0.89 (9 H, s, (CH3)3C), 1.67 (2 H, br s, NH2), 3.56 (1 H, t, J 4.15, 
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7.89, CH), 3.56 (3 H, s, CH3), 3.68–3.87 (2 H, dd, J 13.9, 4.15, 7.89, CH2), 7.18–7.30 (6 
H, m, Ar-H), 7.50–7.52 (4 H, m, Ar-H); δc (50 MHz; CDCl3) 19.2 (CH3), 26.7 (3 × 
CH3), 51.9 (C), 56.4 (CH), 66.1 (CH2), 127.7 (4 × CH), 129.8 (2 × CH), 133.0 (2 × C), 
135.5 (4 × CH), 175.1 (C); m/z 358 (ESI) (M-HCl+, 26%), 715 (M+M+, 100%); [Found 
358.1827, (ESI) C20H28NO3Si requires 358.1833]. 
 
Preparation of (S)-methyl 3-O-(TBDPS)-2-(dibenzylamino)propanoate (122a)  
 
   121 (0.45 g, 1.08 mmol, 1.00 eq) was taken up in dry DCM (20 mL) 
and to this, imidazole (0.110 g, 1.62 mmol, 1.50 eq) and TBDPSCl 
(0.21 g, 1.40 mmol, 1.30 eq) were added. The reaction mixture was 
stirred at rt under N2 for 6 h and H2O (20 mL) was added to quench the 
reaction. The aqueous layer was extracted with EtOAc (4 × 50 mL) and the combined 
organic layers were washed with saturated NaCl solution (50 mL), dried over anhydrous 
MgSO4, filtered and concentrated in vacuo to afford a white oil. The crude product was 
purified by flash chromatography on a silica column, eluting with light 
petroleum:EtOAc:TEA (80:20:1). Fractions containing product were combined and 
concentrated in vacuo to afford the title compound as a clear, colourless oil. (122a, 0.38 
g, 0.71 mmol, 66%): Rf = 0.71 (light petroleum:EtOAc, 80:20); υmax (neat)/cm-1 3069 s, 
3028 s, 1798 s (C=O); δH (200 MHz; CDCl3) 0.89 (9 H, s, (CH3)3C), 3.51–3.65 (6 H, m, 
CH, CH2 and CH3), 3.78–3.96 (4 H, m, 2 × Benzyl-CH2), 7.06–7.34 (16 H, m, Ar-H),  
7.45–7.51 (4 H, m, Ar-H); δc (50 MHz; CDCl3) 19.3 (CH3), 26.8 (CH3), 51.3 (CH), 
55.6 (CH2), 63.2 (CH2), 63.5 (CH2), 127.1 (2 × CH), 127.9 (4 × CH), 128.4 (4 × CH), 
128.9 (4 × CH), 129.9 (2 × CH), 133.3 (2 × C), 135.8 (4 × CH), 139.9 (2 × C) 172.1 
(C); m/z 538 (HNES)  (M+NH4+, 100%); [Found 538.2763, (HNES) 
C34H39NO3Si+NH4+ requires 538.2772]. 
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Attempted preparation of (R)-3-O-(TBDMS)-2-(dibenzylamino)propan-1-ol (123a) 
 
Method A 
 
   122 (0.11 g, 0.26 mmol, 1.00 eq) was dissolved in Et2O (20 mL). The 
solution was cooled to 0 oC and LiBH4 (0.02 g, 1.06 mmol, 4.00 eq) 
and MeOH (0.33 mL) were added. The reaction mixture was heated to 
reflux for 6 h. Saturated NH4Cl solution (20 mL) was added to quench 
the reaction. The aqueous phase was separated and extracted with EtOAc (4 × 40 mL) 
and the combined organic layers were washed with saturated NaCl solution (30 mL), 
dried over MgSO4, filtered and concentrated in vacuo to afford a clear, colourless oil. 
The residue was purified by flash chromatography on a silica column eluting with light 
petroleum:EtOAc:TEA (80:20:1). None of the 1H NMR spectra recorded from the 
fractions obtained were consistent with formation of the desired compound 123; 
unreacted starting material was the sole compound present. 
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Method B 
 
   122 (0.20 g, 0.48 mmol, 1.00 eq) was dissolved in diethyl ether (20 mL). The solution 
was cooled to 0 oC and then LiBH4 (0.04 g, 1.92 mmol, 4.00 eq) and MeOH (0.60 mL) 
were added. The reaction mixture was heated to reflux for 24 h. Saturated NH4Cl 
solution (20 mL) was added to quench the reaction. The aqueous phase was separated 
and extracted with EtOAc (4 × 40 mL) and the combined organic layers were washed 
with saturated NaCl solution (30 mL), dried over MgSO4, filtered and concentrated in 
vacuo to afford a clear, colourless oil. The residue was purified by flash 
chromatography on a silica column, eluting with light petroleum:EtOAc:TEA (80:20:1). 
None of the 1H NMR spectra recorded from the fractions obtained were consistent with 
formation of the desired compound 123, unreacted starting material was the sole 
compound present. 
 
Method C 
 
   NaBH4 (0.99 g, 26.42 mmol, 6.00 eq) was suspended in dry THF (20 mL) in the 
presence of 122 (1.83 g, 4.40 mmol, 1.00 eq) and was heated to reflux for 1 h. MeOH 
(10 mL) was added dropwise down the condenser over 30 min and reflux was 
maintained for a further 4 h. The reaction was quenched with saturated NH4Cl solution 
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(15 mL) before being left to stir at rt for a further 1 h. The organic phase was aqueous 
phase was extracted with EtOAc (4 × 40 mL) and the combined organic layers were 
washed with saturated NaCl solution (30 mL), dried over MgSO4, filtered and 
concentrated in vacuo to afford a clear, yellow liquid. The residue was purified by flash 
chromatography on a silica column eluting with light petroleum ether:EtOAc:TEA 
(80:20:1). None of the 1H NMR spectra recorded from the fractions obtained were 
consistent with formation of the desired compound 123, unreacted starting material was 
the sole compound present. 
 
Method D 
 
   122 (0.68 g, 1.64 mmol, 1.00 eq) in dry THF (10 mL) was added dropwise to a stirred 
solution of LiAlH4 (0.06 g, 1.64 mmol, 1.00 eq) in dry THF (10 mL) at 0 oC under N2. 
The reaction mixture was stirred at rt for 24 h. Subsequently, the reaction was quenched 
by careful addition of an aqueous saturated solution of diethyl ether (20 mL). The 
inorganic precipitates were removed by filtration and washed with EtOAc (50 mL). The 
filtrate was concentrated in vacuo to afford a yellow oil. The crude product was purified 
by flash chromatography on a silica column eluting with light petroleum:EtOAc:TEA 
(50:50:1). None of the 1H NMR spectra recorded from the fractions obtained were 
consistent with formation of the desired compound 123. Starting ester and the 
desilylated alcohol and TBDMSOH were recovered. 
 
Attempted preparation of (R)-3-O-(TBDPS)-2-(dibenzylamino)propan-1-ol (123a) 
 
   A solution of 122a (0.42 g, 0.78 mmol, 1.00 eq) was added slowly to a 
stirred solution of LiAlH4 (0.01 g, 0.39 mmol, 0.50 eq) in dry THF (10 
mL) at 0 oC under N2. The reaction mixture was stirred at rt for 24 h. 
The reaction was quenched by the careful addition of an aqueous 
saturated solution of diethyl ether (20 mL). The resulting solution was dried over 
anhydrous MgSO4, filtered and washed with EtOAc (20 mL). The filtrate was 
concentrated in vacuo to afford a clear, colourless oil. The residue was purified by flash 
chromatography on a silica column, eluting with light petroleum:EtOAc:TEA (50:50:1). 
None of the 1H NMR spectra recorded from the fractions obtained were consistent with 
formation of the desired compound 123a, the ester 122a was the sole compound 
present. 
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Preparation of (R)-3-O-(TBDPS)-2-(dibenzylamino)propan-1-ol (123a)  
 
 
   A solution of 122a (0.27 g, 0.50 mmol, 1.00 eq) in dry THF (5 mL) 
was added to a stirred solution of LiBH4 (0.02 g, 21.78 mmol, 2.00 eq) 
in dry THF (15 mL) at 0 oC under N2. A solution of β−methoxy-9-
borabicyclo[3.3.1]nonane (9-BBN) (1M in hexane, 0.38 mL, 1.10 
mmol, 2.20 eq) was added dropwise to the mixture. The reaction mixture was allowed 
to warm to rt and maintained for 24 h. Solvent was removed in vacuo and H2O (50 mL) 
was added. The aqueous layer was extracted with EtOAc (5 × 50 mL) and the combined 
organic layers were washed with saturated NaCl solution (50 mL), dried over anhydrous 
MgSO4, filtered and concentrated in vacuo to afford a yellow oil. The crude product was 
purified by flash chromatography on a silica column, eluting with light 
petroleum:EtOAc:TEA (50:50:1). Fractions containing product were combined and 
concentrated in vacuo to afford the title compound as a clear, colourless oil. (123a, 0.12 
g, 0.24 mmol, 48%): Rf = 0.67 (light petroleum:EtOAc, 50:50); υmax (neat)/cm-1 3400 w 
(OH), 3069 m, 3028 m; δH (200 MHz; CDCl3) 1.08 (9 H, s, (CH3)3C), 1.65 (1 H, br s, 
OH), 3.18 (1 H, t, J 6, CH), 3.49–4.05 (8 H, m, CH2-OH, CH2 and 2 × Benzyl-CH2), 
7.20–7.49 (16 H, m, Ar-H), 7.57–7.75 (4 H, m, Ar-H); δc (50 MHz; CDCl3) 19.1 (C), 
26.6 (3 × CH3), 53.9 (2 × CH2), 59.4 (CH2), 59.0 (CH2), 61.3 (CH), 127.2 (2 × CH), 
127.8 (4 × CH), 128.6 (4 × CH), 128.9 (4 × CH), 129.6 (2 × CH), 134.8 (2 × C), 135.5 
(4 × CH), 139.4 (2 × C (benzyl)); m/z 510 (HNES)  (M+NH4+, 100%); [Found 
510.2823, (HNES) C33H39NO2Si requires 510.2823]. 
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Preparation of (R)-3-O-(TBDPS)-2-(dibenzylamino)-1-((2-
methoxyethoxy)methoxy)propane (124) 
 
Method A 
 
   123a (1.16 g, 2.28 mmol, 1.00 eq) was taken up in dry THF (20 mL) 
and to this, NaH (60 % in mineral oil) (0.88 g, 2.28 mmol, 1.00 eq) was 
added. The reaction mixture was allowed to stir at rt under N2 for 3 h. 
2-Methoxyethoxymethyl chloride (MEM-Cl) (0.26 mL, 2.28 mmol, 
1.00 eq) was added and the reaction mixture was maintained for 24 h. Solvent was 
removed in vacuo to afford the crude product as a clear, colourless oil. The residue was 
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purified by flash chromatography on a silica column eluting with light 
petroleum:EtOAc:TEA (50:50:1). Fractions containing product were combined and 
concentrated in vacuo to afford the title compound as a clear, colourless oil. (124, 1.00 
g, 1.67 mmol, 98%): Rf = 0.63 (light petroleum:EtOAc, 50:50); υmax (neat)/cm-1 3069 w, 
3028 w, 2928 s, 2856 s; δH (200 MHz; CDCl3) 0.83–0.88 (2 H, ,m, CH2), 1.05–1.08 (9 
H, d, J 6, (CH3)3C), 1.26 (3 H, s, CH3), 3.11 (1 H, t, J 6, CH), 3.36 (2 H, s, CH2), 3.45–
3.95 (10 H, m, Benzyl-CH2, 3 × CH2), 7.18–7.47 (16 H, m, Ar-H), 7.62–7.74 (4 H, m, 
Ar-H); δc (50 MHz; CDCl3) 19.1 (C), 26.6 (3 × CH3), 53.9 (CH2), 55.1 (CH2), 58.9 
(CH), 60.0 (CH2), 61.3 (CH2), 62.6 (CH2), 67.1 (CH2), 71.7 (CH2), 95.6 (CH2), 126.6 (2 
× CH), 128.1 (4 × CH), 128.5 (4 × CH), 129.8 (4 × CH), 129.8 (2 × CH), 134.8 (2 × C), 
135.6 (4 × CH), 140.5 (2 × C); (impurities present in both spectra) m/z 598 (HNES)  
(M+NH4+, 100%), 510 (M-(MEM)+, 54%); [Found 598.3333, (HNES) C37H51N2O4Si 
requires 598.3347]. 
 
Method B 
 
   123a (0.20 g, 0.39 mmol, 1.00 eq) was dissolved in dry DCM (10 mL) and cooled to 0 
oC. To this, MEM-Cl (0.07 mL, 0.59 mmol, 1.50 eq) was added and the reaction 
mixture was stirred at rt under N2 for 24 h. The reaction mixture was cooled to 0 oC and 
quenched with saturated aqueous NaHCO3 solution (6 mL). The pH was increased to 
7.0 using aqueous NaOH solution (10 mL) and the organic phase was separated. The 
aqueous phase was extracted with DCM (4 × 40 mL) and the combined organic layers 
were washed with saturated NaCl solution (40 mL), dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to afford a clear, yellow oil. The residue was purified 
by flash chromatography on a silica column, eluting with light petroleum:EtOAc:TEA 
(50:50:1). Fractions containing product were combined and concentrated in vacuo. 
 
Method C 
 
   123a (0.05 g, 0.19 mmol, 1.00 eq) was dissolved in dry DCM (5 mL) and the reaction 
mixture was cooled to 0 oC. To this, N-ethyldiisopropylamine (DIPEA) (0.05 ml, 0.29 
mmol, 1.50 eq) and MEM-Cl (0.03 mL, 0.29 mmol, 1.50 eq) were added and the 
reaction mixture was allowed to warm to rt before being left to stir under N2 for 24 h. 
The reaction mixture was cooled to 0 oC and quenched with an aqueous NaHCO3 
solution (20%, 1 mL). The aqueous phase was extracted with DCM (4 × 10 mL) and the 
Experimental 
 
combined organic layers were washed with saturated NaCl solution (20 mL), dried over 
anhydrous MgSO4, filtered and concentrated in vacuo to afford a clear, colourless oil. 
The residue was purified by flash chromatography on a silica column eluting with 
dichloromethane:TEA (99:1). Fractions containing product were combined and 
concentrated in vacuo. 1H NMR confirmed that the reaction had failed, with respect to 
the impurities present in the spectra of method A, still being present. 
 
Preparation of (R)-3-O-(TBDPS)-1-((2-methoxyethoxy)methoxy)propan-2-amine 
(125) 
 
   124 (0.48 g, 1.08 mmol, 1.00 eq) was dissolved in EtOH (9 mL). The 
solution was flushed through the H-cube at 0.5 mL/min, 50 oC, 70 bar, 
controlled H2 79 bar, HPLC pump 78 bar. The product was collected 
and concentrated in vacuo to afford the title compound as a clear, 
colourless oil. (125, 0.48 g, 1.15 mmol, 100%): Rf = 0.0 (light 
petroleum:EtOAc, 50:50); υmax (neat)/cm-1 3351 s, 3071 s, 2926 s, 1651 m, 1471 m, 
1427m, 823 m, 700 m. 1H NMR spectroscopy confirmed that the title compound, 125, 
was present (100%) along with the impurities observed in previous steps. 
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Preparation of (R)-2-azido-1-O-((2-methoxyethoxy)methoxy))-3-O-(TBDPS) 
propoxy (126)  
 
   125 (0.29 g, 1.08 mmol, 1.00 eq), imidazole-1-sulfonyl azide HCl 
salt 152 (0.21 g, 1.20 mmol, 1.10 eq), K2CO3 (0.24 g, 1.28 mmol, 1.00 
eq) and copper sulfate pentahydrate (CuSO4·5H2O) (0.003 g, 0.01 
mmol, 0.01 eq) were taken up in dry MeOH (20 mL) and the reaction 
mixture was stirred at rt under N2 for 24 h. The solvent was removed in vacuo and 
subsequently, H2O (20 mL) was added and the resulting solution was extracted with 
EtOAc (4 × 30 mL). The combined organic layers were washed with saturated NaCl 
solution (30 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo. The 
residue was purified by flash chromatography on a silica column, eluting with light 
petroleum:EtOAc:EtOH (25:72:3). Fractions containing product were combined and 
concentrated in vacuo to afford the title compound. υmax (neat)/cm-1 3368 s, 3071 s, 
2930 s, 2096 s,1718 m, 1472 m, 1428m, 823 m, 702 m. 1H NMR spectroscopy 
OTBDPS
OMEM
N3
C23H33N3O4Si
 169
Experimental 
 
confirmed that the title compound, 126 was present along with the impurities observed 
in previous steps. 
 
Preparation of imidazole-1-sulfonyl azide HCl salt (152)96 
 
   Sulfuryl chloride 154 (SO2Cl2) (3.71 mL, 46.15 mmol, 1.00 eq) 
was added dropwise to an ice-cooled suspension of NaN3 (3.00 g, 
46.15 mmol, 1.00 eq) in dry acetonitrile (30 mL) and the reaction 
mixture was stirred at rt for 24 h under N2. Imidazole (5.97 g, 87.69 
mmol, 1.90 eq) was added portion wise to the ice-cooled mixture and the resulting 
slurry was stirred for 3 h at rt. The mixture was diluted with EtOAc (100 mL), washed 
with H2O (2 × 100 mL ) and the aqueous phase was back-extracted with EtOAc (100 
mL). The combined organic layers were washed with saturated NaHCO3 solution (2 × 
100 mL), dried over anhydrous MgSO4 and filtered. A solution of HCl in EtOH 
[obtained by the drop-wise addition of acetyl chloride (CH3COCl) (4.92 mL, 69.23 
mmol, 1.50 eq) to ice-cooled dry EtOH (30mL)] was added drop-wise to the filtrate 
with stirring, the mixture chilled in an ice-bath, filtered and the filter cake was washed 
with EtOAc (3 × 100 mL) to afford the title compound as a white solid. (152, 5.52 g, 
26.33 mmol, 69%): Rf = 0.35 (light petroleum:EtOAc, 50:50); υmax (neat)/cm-1 2172 s, 
1581 s, 1508 s, 1429 s, 1322 s, 1162 s; δH (200 MHz; D2O) 7.59-7.65 (1 H, m, C-4/5H), 
7.98-8.05 (1 H, m, C-4/5H), 9.49-9.55 (1 H, m, C-2H); δc (50 MHz; D2O) 119.9 (CH), 
121.9 (CH), 137.3 (C-2); (Found: C, 17.30; H, 1.92; N, 33.57. C3H4N5O2SCl requires C, 
17.19; H, 1.92; N, 33.41%). 
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Attempted preparation of (S)-methyl 2-azido-3-O-(TBDPS) propanoate (157) 
 
Method A 
 
   135 (0.38 g, 2.17 mmol, 1.00 eq), 152 (0.41 g, 2.39 mmol, 1.10 eq), K2CO3 (0.30 g, 
2.17 mmol, 1.00 eq) and CuSO4·5H2O (0.005 g, 0.02 mmol, 0.01 eq) were taken up in 
dry MeOH (20 mL) and the reaction mixture was stirred at rt under N2 for 24 h. The 
solvent was removed in vacuo and subsequently, H2O (5 mL) was added and the 
resulting solution was extracted with EtOAc (4 × 30 mL). The combined organic layers 
were washed with saturated NaCl solution (30 mL), dried over anhydrous MgSO4, 
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filtered and concentrated in vacuo to afford a blue/green residue. 1H NMR confirmed 
that the reaction had failed. The desilylated compound was recovered (~92%). 
 
Preparation of (S)-methyl 2-azido-3-O-(TBDMS) propanoate (158) 
 
   130 (0.50 g, 2.85 mmol, 1.00 eq), K2CO3 (0.39 g, 2.85 mmol, 1.00 
eq), CuSO4·5H2O (0.007 g, 0.03 mmol, 0.01 eq) and 152 (0.54 g, 3.14 
mmol, 1.10 eq) were suspended in dry MeOH (10 mL) and the 
reaction mixture was stirred at rt under N2 for 24h. (The colour 
changed from green to blue) The reaction mixture was concentrated in 
vacuo and H2O (10 mL) was added. The aqueous phase was extracted with EtOAc (4 × 
40 mL) and the combined organic layers were washed with saturated NaCl solution (30 
mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford a 
yellow/brown oil. The residue was used immediately in the subsequent step; υmax 
(neat)/cm-1 2117 s (N3) (solvent peaks present in spectrum); δH (200 MHz; CDCl3) 0.03 
(6H, s, 2 × CH3), 0.83 (9H, s, 3 × CH3), 3.74 (3H, s, OCH3), 3.81 (1H, s, CH), 3.98-4.02 
(2H, m (confused by solvent), CH2) (solvent/imidazole peaks present on spectrum); δc 
(50 MHz; CDCl3) 13.9 (2 × CH3), 16.4 (C), 25.3 (3 × CH3), 60.1 (CH), 62.8 (CH3), 64.2 
(CH2), 171.1 (C) (solvent/imidazole peaks present on spectrum); m/z (HNESP) 260 
(M+H+, 100%); [Found (HNESP) 260.1429, C10H23N3O3Si requires 260.1425]. 
O
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Preparation of (S)-methyl 2-azido-3-hydroxypropanoate (159) 
 
   L-Serine methyl ester HCl salt (0.50 g, 3.21 mmol, 1.00 eq), K2CO3 
(0.44 g, 3.21 mmol, 1.00 eq) and CuSO4·5H2O (0.01 g, 0.03 mmol, 0.01 
eq) were suspended in dry MeOH (10 mL) before being left to stir at rt 
under N2 for 24 h. The solvent was removed in vacuo and H2O (10 mL) 
was added. The aqueous phase was extracted with EtOAc (4 × 20 mL) and the 
combined organic layers were washed with saturated NaCl solution (30 mL). The 
organic phase was dried over anhydrous MgSO4, filtered and concentrated in vacuo to 
afford a yellow/brown oil. The residue was used immediately in the subsequent; υmax 
(neat)/cm-1 2110 s (N3) (solvent peaks present in spectrum); δH (200 MHz; CDCl3) 3.64 
(3H, s, OCH3), 3.70 (2H, s, CH2), 3.82 (1H, s, CH), 5.74 (1H, br s, OH) 
(solvent/imidazole peaks present on spectrum); δc (50 MHz; CDCl3) 52.5 (CH3), 62.3 
(CH2), 62.9 (CH), 168.9 (C) (solvent/imidazole peaks present on spectrum); m/z 
OH
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(ASAP) 163 (M+NH4+, 100%); [Found (ASAP) 163.0825, C4H11N4O3 requires 
163.0826]. 
 
Preparation of N3-benzoyl thymine (160) 
 
   Benzoyl chloride (BzCl) (1.01 mL, 8.72 mmol, 2.20 eq) was added to 
a mixture of thymine (0.55 g, 4.36 mmol, 1.00 eq) in dry CH3CN/C5H5N 
((5:2) v/v, 20 mL). The mixture was stirred at rt for 24 h, filtered and 
concentrated in vacuo to afford a yellow solid. A solution of anhydrous 
K2CO3 (0.60 g, 4.36 mmol, 1.00 eq) dissolved in dioxane/H2O ((1:1) v/v, 10 mL) was 
used to dissolve the solid and the mixture was allowed to stir for 1 h at rt. The mixture 
was acidified to pH 5.0 using acetic acid and then concentrated in vacuo. The yellow 
solid was taken up in a saturated NaHCO3 solution (30 mL) before being left to stir for 
2 h at rt. Filtration followed by recrystallisation with MeOH/Et2O afforded the title 
compound as an off white solid. (160, 1.34 g, 5.80 mmol, 73%): Rf = 0.39 
(DCM:MeOH, 94:6); m.p. 166-167 oC; υmax (KBr)/cm-1 3180 m, 3054 m, 2825 m, 1734 
s (C=O), 1677 s (C=O), 1460 m, 1452 m, 1421 m; δH (200 MHz; DMSO-d6) 1.86 (3 H, 
s, CH3), 7.45-7.56 (3 H, m, Ar-H), 7.61-7.71 (1 H, m, C-6H), 7.77-7.86 (2 H, m, Ar-H), 
11.58 (1 H, b s, NH); δc (50 MHz; DMSO-d6) 12.4 (CH3), 111.8 (C), 128.8 (2 × C), 
129.8 (2 × C), 133.7 (C), 133.9 (C), 136.1 (C), 149.8 (C), 164.5 (C), 170.5 (C); m/z 
(ESI) 231 (M+H+, 11%), 248 (M-(Methyl)+, 50%); [Found (ESI) 231.0762, C12H11N2O3 
requires 231.0764]; (Found: C, 62.41; H, 4.26; N, 12.09. C12H12N2O3 requires C, 62.61; 
H, 4.38; N 12.17%); The X-Ray crystal structure (Appendix C) was acquired from the 
crystals obtained from Et2O and MeOH. 
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Attempted preparation of 1-(prop-2-ynyl)-N3-benzoyl thymine (161) 
 
   160 (0.170 g, 0.738 mmol, 1.00 eq) was added to dry DMF (20 mL) and to this NaH 
(0.024 g, 1.45 mmol, 1.00 eq) and propargyl bromide (0.067 mL, 7.38 mmol, 0.95 eq) 
was added. The resulting mixture was stirred at rt for 24 h. TLC analysis showed that no 
reaction had occurred. The reaction mixture was heated in increments of 10 oC up to a 
maximum of 80 oC over a 4 h period. The 1H NMR spectrum recorded of the crude 
mixture showed that the reaction had failed. 
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Preparation of 1-(prop-2-ynyl)-N-benzoyl thymine (161) 
 
   160 (1.00 g, 4.34 mmol, 3.00 eq) was added to dry DMF (20 mL) and 
to this propargyl bromide (0.129 mL, 1.45 mmol, 1.00 eq) and Cs2CO3 
(0.94 g, 2.89 mmol, 2.00 eq) was added. The resulting mixture was 
stirred at rt for 48 h. The solvent was removed in vacuo and H2O was 
added (30 mL). The aqueous phase was extracted with EtOAc (4 × 40 
mL) and the combined organic layers were washed with saturated NaCl 
solution (50 mL). The organic phase was dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo to afford a white solid. The crude product was purified by flash 
chromatography on a silica column, eluting with light petroleum:EtOAc:TEA (50:50:1). 
Fractions containing product were combined and concentrated in vacuo to afford the 
title compound as a white solid. (161, 0.64 g, 2.38 mmol, 55%): Rf = 0.19 (light 
petroleum:EtOAc, 50:50); m.p. 178-180 oC; υmax (KBr)/cm-1 3261 m, 3073 w, 2928 w, 
2129 w (alkyne), 1747 s (C=O), 1696 s (C=O), 1644 s (C=O), 1492 w, 1442 s; δH (200 
MHz; CDCl3) 1.01 (3 H, d, J 0.8, CH3), 2.67 (1 H, t, J 2.5, Alkyne-H), 4.56 (2 H, d, J 
2.5, N-CH2), 7.52-7.70 (2 H, m, Ar-H), 7.73-7.96 (4 H, m, Ar-H); δc (50 MHz; CDCl3) 
11.8 (CH3), 37.0 (CH2), 76.3 (C), 77.9 (C), 109.3 (CH), 129.4 (2 × CH), 130.2 (2 × 
CH), 130.9 (C), 135.5 (CH), 141.1 (CH), 148.8 (C), 162.7 (C), 169.5 (C); m/z (ESI) 269 
(M+H+, 71%), 286 (M+(Methyl)+, 100%), 554 (M+(M+Methyl)+, 86%); [Found (ESI) 
269.0922, C15H13N2O3 requires 269.0921]; (Found: C, 66.99; H, 4.48, N, 10.24. 
C15H12N2O3 requires C, 67.16; H, 4.51; 10.44%); The X-Ray crystal structure 
(Appendix D) was acquired from the crystals obtained from Et2O and MeOH. 
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Preparation of 1-(prop-2-ynyl)-thymine(162) 
 
   161 (0.10 g, 0.37 mmol, 1.00 eq) was dissolved in benzyl alcohol 
(BnOH) (1 mL) and heated to 90 oC for 30 h. The solvent was removed in 
vacuo and the residue was purified by flash chromatography on a silica 
column eluting with (light petroleum:EtOAc (100) to light 
petroleum:EtOAc (80:20) to light petroleum:EtOAc (50:50) gradient 
elution). Fractions containing product were combined and concentrated in vacuo to 
afford the title compound as a white solid.(162, 0.05 g, 82%): Rf = 0.44 (light 
petroleum:EtOAc, 50:50); υmax (neat)/cm-1 3251 m, 3014 w, 2934 w, 2125 w (alkyne), 
1701 s (C=O), 1698 s (C=O), 1473 s, 1423 s; δH (400 MHz; CDCl3) 1.95 (3H, d, J 0.8, 
N
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CH3), 2.47 (1H, t, J 2.5, Alkyne-H), 4.51 (2H, d, J 2.49, N-CH2), 7.21 (1H, d, C-6H), 
8.12 (1H, NH); δc (50 MHz; CDCl3) 12.4 (CH3), 36.6 (CH2), 75.2 (C), 77.6 (C), 111.3 
(C), 138.8 (CH), 150.1 (C), 164.3 (C); m/z (ASAP) 165 (M+H+, 100%); [Found (ASAP) 
165.0654, C8H9N2O2 requires 165.0659]. 
 
Preparation of N-benzoyl cytosine (165) 
 
   Cytosine (1.40 g, 12.60 mmol, 1.00 eq) was suspended in dry C5H5N 
(30 mL) and was stirred at rt under N2 in the presence of BzCl (3.45 mL, 
27.72 mmol, 2.20 eq) for 24 h. The reaction mixture was acidified with 
HCl solution to pH 5.0 and stirred for a further 3 h. The precipitate was 
collected and washed with hot EtOH (100 mL). The solid was recrystallised from an 
aqueous acetic acid solution and the title compound was collected as an off-white 
solid.(165, 2.49 g, 92%): υmax (neat)/cm-1 2964 m, 2323 w, 2015 w (alkyne), 1738 s 
(C=O), 1699 s (C=O), 1504 s, 1422 s; (Found: C, 61.47; H, 4.15, N, 19.36. C11H9N3O2 
requires C, 61.39; H, 4.22; N 19.53%). 
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Attempted preparation of 1-(prop-2-ynyl)-N4-benzoyl cytosine(174) 
 
   A suspension of 165 (0.50 g, 2.32 mmol, 1.00 eq) and DBU (0.316 mL, 2.11 mmol, 
0.91 eq) in dry DMF (20 mL) was stirred at rt for 1 h. To this, propargyl bromide (0.248 
mL, 2.32 mmol, 1.00 eq) was added and the reaction mixture was left overnight in the 
dark. The solvent was removed in vacuo and the crude residue was purified by flash 
chromatography on a silica column eluting with light petroleum:EtOAc (60:40). From 
the 1H NMR spectra obtained, the title compound 174 was not observed in any of the 
product containing fractions. 
 
Preparation of 1-(prop-2-ynyl)-4-acetylaminopyrimidin-2(1H)-one105  
 
   A suspension of N4-acetylcytosine 171 (1.00 g, 6.53 mmol, 1.00 eq), 
anhydrous K2CO3 (1.04 g, 7.50 mmol, 1.33 eq) and propargyl bromide 
(80% in toluene, 0.50 mL, 5.64 mmol, 1.00 eq) in dry DMF (20 mL) was 
stirred at rt under N2 for 24 h. The mixture was filtered and the solvent 
was removed in vacuo to afford a brown solid. The residue was dissolved 
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in hot H2O (20 mL) and treated with decolourising charcoal (0.20 g). The mixture was 
filtered through celite© and the clear filtrate was reduced in volume by half, by gentle 
heating. The cooled filtrate precipitated the title compound as an off white solid. (173, 
0.51 g, 2.66 mmol, 40%): Rf = 0.24 (light petroleum:EtOAc, 50:50); υmax (KBr)/cm-1 
3197 s (NH2), 3028 w, 2114 w (Alkyne), 1695 s (C=O), 1659 s (C=O); δH (200 MHz; 
DMSO-d6) 2.09 (3 H, s, CH3), 3.45 (1 H, t, J 3.2, Alkyne-CH), 4.63–4.64 (2 H, d, J 3.4, 
Alkyne-CH2), 7.19–7.22 (1 H, d, J 7.2, CH), 8.13–8.17 (1 H, d, J 7.3, CH), 10.89 (1 H, 
bs, NH); δc (50 MHz; DMSO-d6) 24.3 (CH3), 38.4 (CH2), 76.4 (C), 78.3 (C), 95.7 (CH), 
149.1 (CH), 154.6 (C), 162.6 (C), 170.9 (C); m/z (HNES) 192 (M+NH4+, 100%); 
(Found (HNES) 192.0766, C9H13N4O2 requires 192.0768).  
 
Preparation of 4-amino-1-(prop-2-ynyl)pyrimidin-2(1H)-one (174) 105  
 
   173 (0.19 g, 0.99 mmol, 1.00 eq) was stirred in a methanolic ammonia 
solution (5% v/v, 20 mL) at rt under N2 for 24 h. The solvent was 
removed in vacuo to afford the title compound as an off white solid. 
(174, 0.14 g, 0.94 mmol, 94%); υmax (KBr)/cm-1 3381 s (NH2), 2122 w 
(Alkyne), 1666 s (C=O), 1614 s; δH (200 MHz; DMSO-d6) 3.45 
 (1 H, t, J 2.6, Alkyne-CH), 4.47 (2 H, d, J 2.6, CH2), 5.73 (1 H, d, J 7.3, 
C-5H), 7.16 (2 H, d, NH2), 7.64 (1 H, d, J 7.5, C-6H); δc (50 MHz; DMSO-d6) 37.3 
(CH2), 75.3 (C), 79.4 (C), 94.1 (CH), 144.8 (CH), 155.1 (C), 165.9 (C); m/z (EI) 149 
(M+, 52%), 112 (M-(Propargyl group plus N and NH2 being protonated)+, 94%), 77 (M-
(NH2 and Propargyl group)+, 100%); [Found (EI) 149.0584, C7H7N3O requires 
149.0584]; The X-Ray crystal structure (Appendix E) was acquired from the crystals 
obtained from Et2O and MeOH. 
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Preparation of 4-(benzoylamino)-1-(prop-2-ynyl)pyrimidin-2(1H)-one (166)  
 
   174 (0.26 g, 1.73 mmol, 1.00 eq) was dissolved in dry C5H5N (20 mL) 
and cooled to 0 oC. To this, BzCl (0.30 mL, 2.59 mmol, 1.50 eq) was 
added and the reaction mixture was stirred at rt under N2 for 24 h. The 
solvent was removed in vacuo and the residue was washed with hot 
EtOH (150 mL). The solvent was removed in vacuo and diluted with 
H2O (30 mL). The aqueous phase was extracted with EtOAc (3 × 40 mL) and the 
combined organic layers were washed with saturated NaCl solution (50 mL), dried over 
N
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anhydrous MgSO4 and filtered. Concentration in vacuo afforded the crude product as a 
brown oil. The crude product was purified by flash chromatography on a silica column 
eluting with light petroleum ether:EtOAc (50:50). Fractions containing product were 
combined and concentrated in vacuo to afford the title compound as a pale yellow solid. 
(166, 0.13 g, 0.51 mmol, 84%): Rf = 0.08 (light petroleum ether:EtOAc, 50:50); υmax 
(KBr)/cm-1 3268 m (NH), 2121 w (Alkyne), 1719 s (C=O), 1697 s (C=O), 1657 s; δH 
(400 MHz; DMSO-d6) 3.49 (1 H, t, J 2.4, Alkyne-CH), 4.69 (2 H, d, J 2.5, Alkyne-
CH2), 7.35 (1 H, d, J 7.1, C-5H), 7.46-7.67 (3 H, m, Ar-H), 7.98-8.02 (2 H, m, Ar-H), 
8.23 (1 H, d, J 7.5, CH-6), 11.21 (1H, br s, NH); δc (100 MHz; DMSO-d6) 38.5 (CH2), 
76.4 (C), 78.2 (C), 96.5 (CH), 128.4 (C), 128.7 (2 × CH), 128.8 (CH), 129.1 (C), 132.7 
(CH), 133.1 (C), 133.4 (CH), 149.1 (C), 165.6 (C); m/z (HNESP) 254 (M+NH4+, 
100%); [Found (HNESP) 254.0924, C14H15N4O2 requires 254.0926]; The X-Ray crystal 
structure (Appendix F) was acquired from the crystals obtained from Et2O and MeOH. 
 
Preparation of N2-amino-N9-prop-2-ynyl adenine (175) 
 
   Adenine (2.00 g, 14.80 mmol, 1.00 eq) was taken up in dry DMF (30 mL) 
and stirred at rt under N2 in the presence of NaH (60% in mineral oil, 0.49 g, 
14.80 mmol, 1.00 eq) for 4 h. To this, propargyl bromide (80% in toluene, 
1.58 mL, 14.80 mmol, 1.00 eq) was added dropwise and the reaction 
mixture was maintained for 24 h. Solvent was removed in vacuo and H2O 
(20 mL) was added. The aqueous phase was extracted with EtOAc (5 × 50 mL) and the 
combined organic layers were washed with saturated NaCl solution (50 mL), dried over 
anhydrous MgSO4 and filtered. Concentration in vacuo afforded the title compound as 
an off white solid. (175, 0.93 g, 5.34 mmol, 36%): Rf = 0.14 (light petroleum:EtOAc, 
50:50); υmax (KBr)/cm-1 3584 m, 3148 s, 2111 w (Alkyne), 1420 w, 772 w; δH (400 
MHz; DMSO-d6) 3.53 (1 H, t, J 2.4, Alkyne-CH), 5.16–5.18 (2 H, d, J 2.4, Alkyne-
CH2), 7.29 (2 H, br s, NH2), 7.77 (1 H, s, CH), 8.42 (1 H, s, CH); δc (100 MHz; DMSO-
d6) 32.1 (CH2), 75.7 (C), 78.2 (C), 118.4 (C), 139.9 (CH), 148.9 (C), 152.6 (CH), 155.9 
(C); m/z (HNES) 174 (M+NH4+, 100%); (Found (HNES) 174.0771, C8H7N5 requires 
174.0774); The X-Ray crystal structure (Appendix G) was acquired from the crystals 
obtained from diethyl ether and MeOH. The identity of the product was confirmed by 
NOESY and COSY spectroscopy. 
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Preparation of N-benzoylamino-N-prop-2-ynyl-adenine (176)  
 
   175 (0.05 g, 0.22 mmol, 1.00 eq) was taken up in dry C5H5N (10 mL) 
and cooled to 0 oC. To this, BzCl (0.03 mL, 0.33 mmol, 1.50 eq) was 
added and the mixture was warmed to rt and stirred under N2 for 4 h. 
Solvent was removed in vacuo and the residue was dissolved in DCM 
(20 mL). The residue was washed with an aqueous NaHCO3 solution 
(5%, 20 mL) and the organic phase was dried over anhydrous MgSO4. Filtration 
followed by concentration in vacuo afforded the crude product as a brown/orange solid. 
The residue was purified by flash chromatography on a silica column, eluting with 
MeOH:DCM (3:97). Fractions containing product were combined and concentrated in 
vacuo to afford the title compound as a white solid. (176, 0.04 g, 0.14 mmol, 67%): Rf = 
0.24 (MeOH:DCM, 3:97); m.p. 138-140 oC (turned brown); υmax (KBr)/cm-1 3407 m, 
3207 s, 3054 m, 2982 m, 2125 w (Alkyne), 1691 s (C=O), 1615 s, 1583 s, 1408 s, 1248 
s, 1217 s, 946 w, 752 m; δH (400 MHz; DMSO-d6) 2.67 (1 H, t, J 2.6, Alkyne-CH), 5.33 
(2 H, d, J 2.6, Alkyne-CH2), 7.44-7.56 (3 H, m, Ar-H), 7.96-8.12 (2 H, m, Ar-H), 8.16 
(1 H, s, C-8H), 8.71 (1 H, s, C-2H), 9.51 (1 H, br s, NH); δc (100 MHz; DMSO-d6) 33.3 
(CH2), 75.4 (C), 78.4 (C), 122.9 (C), 127.9 (2 × CH), 128.7 (2 × CH), 132.7 (C), 132.9 
(CH), 142.1 (CH), 149.71 (C), 151.6 (CH), 152.6 (C), 170.4 (C); m/z (HNES) 278 
(M+NH4+, 100%); (Found (HNES) 278.1033, C15H15N6O requires 278.1036); The X-
Ray crystal structure (Appendix H) was acquired from the crystals obtained from Et2O 
and MeOH. 
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Preparation of 9-(prop-2-ynyl)-6-chloro-2-amino-9H-purine (180)  
 
   To a suspension of 2-amino-6-chloropurine 179 (0.50 g, 5.89 mmol, 
1.00 eq) in dry DMF (30 mL) was added anhydrous K2CO3 (0.41 g, 
5.86 mmol, 0.99 eq). The suspension was stirred at rt under N2 for 2 h. 
To this, propargyl bromide (80% in toluene, 0.63 mL, 5.89 mmol, 1.00 
eq) was added and the reaction mixture was left for 24 h. Solvent was 
removed in vacuo to afford the crude product as an orange/yellow solid. The residue 
was purified by flash chromatography on a silica column eluting with MeOH:DCM 
(2:98). Fractions containing product were combined and concentrated in vacuo to afford 
the title compound as a pale yellow solid. (180, 0.47 g, 2.26 mmol, 77%): Rf = 0.17 
(MeOH:DCM, 2:98); m.p. 237-238 oC; υmax (KBr)/cm-1 3457 s (NH2), 3392 w, 3309 s 
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(NH2), 3203 s (NH2), 2127 w (Alkyne), 1404 m, 1139 m, 1000 m; δH (400 MHz; 
DMSO-d6) 3.48 (1 H, t, J 2.5, Alkyne-H), 4.93 (2 H, d, J 2.5, Alkyne-CH2), 7.02 (2 H, 
br s, NH2), 8.18 (1 H, s, C-8H); δc (100 MHz; DMSO-d6) 32.4 (CH2), 76.1 (C), 77.8 
(C), 123.1 (C), 142.3 (CH), 149.5 (CH), 153.6 (C), 159.9 (C); m/z (HNES) 208 
(M+NH4+, 100%); [Found (HNES) 278.1033, C8H8ClN5 requires 208.0384]; (Found:  
C, 46.03; H, 2.72, N, 33.46. C8H8ClN5 requires C, 46.28; H, 2.91; 33.73%). 
 
Preparation of 9-(prop-2-ynyl)-6-chloro-2-acetylamino-9H-purine (190)  
 
   180 (0.13 g, 0.62 mmol, 1.00 eq) was taken up in acetic anhydride 
(Ac2O) (7 mL) and was heated to reflux for 3 h. Solvent was removed 
in vacuo to afford the crude product as a pale yellow solid. The 
residue was purified by flash chromatography on a silica column, 
eluting with MeOH:DCM (3:97). Fractions containing product were 
combined and concentrated in vacuo to afford the title compound as a pale yellow solid. 
(180, 0.12 g, 0.48 mmol, 82%): Rf = 0.16 (MeOH:DCM, 3:97); m.p. 156-157 oC; υmax 
(KBr)/cm-1 3302 m (NH), 2123 w (Alkyne), 1677 s (C=O); δH (200 MHz; DMSO-d6) 
2.21 (3 H, s, CH3), 3.56 (1 H, t, J 3.2, Alkyne-CH), 5.08 (2 H, d, J 3.2, Alkyne-CH2), 
8.58 (1 H, s, CH), 10.90 (1 H, br s, NH); δc (50 MHz; DMSO-d6) 21.9 (CH3), 32.8 
(CH2), 76.5 (C), 77.4 (C), 122.8 (C), 142.8 (CH), 148.3 (CH), 154.2 (C), 159.7 (C), 
170.5 (C); m/z (EI) 249 (M+, 16%), 209 (M-(Propargyl group)+, 30%), 207 (M-
(Acetyl)+, 100%); [Found (EI) 249.0411, C10H10ClN5O requires 249.0412].  
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Preparation of 9-(prop-2-ynyl)-6-(2-nitrophenyl)-2-acetylamino-9H-purine (191)  
 
   To a stirred solution of 190 (0.23 g, 0.99 mmol, 1.00 eq) in dry 
DCM (20 mL) was added TEA (0.4 mL, 2.90 mmol, 3.00 eq), 2-
nitrophenol (0.40 g, 2.90 mmol, 3.00 eq) and 1,4-diazabicyclo-(2,2,2)-
octane (DABCO) (0.11 g, 0.97 mmol, 1.00 eq). The reaction mixture 
was stirred at rt under N2 for 24 h. DCM (20 mL) was added to dilute 
the reaction mixture and the organic phase was washed with saturated 
NaHCO3 solution (60 mL). The aqueous phase was re-extracted with DCM (4 × 60 mL) 
and the combined organic layers were dried over anhydrous MgSO4. Filtration followed 
by evaporation afforded a clear, yellow oil. The residue was purified by flash 
chromatography on a silica column, eluting with EtOAc. Fractions containing product 
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were combined and concentrated in vacuo to afford the title compound as a white foam. 
(191, 0.25 g, 0.71 mmol, 89%): Rf = 0.58 (light petroleum:EtOAc, 50:50); υmax 
(KBr)/cm-1 3385 m (NH), 3237 m (NH), 2122 w (Alkyne), 1677 m, 1624 s (C=O), 1408 
m, 1233 s; δH (400 MHz; CDCl3) 1.29 (3 H, s, CH3), 1.67 (1 H, t, J 2.5, 5.4, Alkyne-H), 
4.07 (2 H, d, J 2.4, Alkyne-CH2), 6.52 (2 H, m, Ar-H), 6.82 (1 H, s, CH), 7.23 (2 H, d, J 
10.8, Ar-H), 7.36 (1 H, br s, NH); δc (100 MHz; CDCl3) 24.6 (CH3), 33.3 (CH2), 60.3 
(CH), 75.3 (C), 75.4 (C), 117.3 (C), 125.4 (CH), 125.7 (CH), 126.7 (CH), 134.8 (CH), 
142.0 (C-8), 145.3 (CH), 151.8 (C), 153.8 (C), 159.1 (C), 171.1 (C); m/z (HNESP) 353 
(M+NH4+, 100%); [Found (HNESP) 353.0995, C16H16N7O4 requires 353.0993]. 
 
Attempted preparation of 9-(prop-2-ynyl)-6-(2-nitrophenyl)-2-amino-9H-purine 
(192)  
 
   191 (0.16 g, 0.45 mmol, 1.00 eq) was stirred in a methanolic ammonia 
solution (5% v/v, 20 mL) at rt under N2 for 48 h. Solvent was removed 
in vacuo to afford a yellow/brown solid. A further aliquot of methanolic 
ammonia solution (5% v/v, 20 mL) was added and the reaction mixture 
was stirred under the same conditions for 24 h. Solvent was removed in 
vacuo. 1H NMR confirmed that the reaction had failed and the starting 
material was the sole compound present. 
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Preparation of 9-(prop-2-ynyl)-6-(2-nitrophenyl)-2-amino-9H-purine (192)  
 
   To a stirred solution of 180 (0.28 g, 1.35 mmol, 1.00 eq) in dry DCM 
(10 mL) was added DABCO (0.15 g, 1.35 mmol, 1.00 eq), TEA (0.56 
mL, 4.05 mmol, 3.00 eq) and 2-nitrophenol (0.56 g, 4.05 mmol, 3.00 
eq). The reaction mixture was stirred at rt under N2 for 24 h. DCM (20 
mL) was added to dilute the mixture and the organic phase was washed 
with a saturated NaHCO3 solution (20 mL). The aqueous phase was re-
extracted with DCM (3 × 20 ml) and the combined organic layers were 
dried over anhydrous MgSO4. Filtration followed by evaporation in vacuo, afforded an 
orange oil. The crude product was purified by flash chromatography on a silica column, 
eluting with EtOAc. Fractions containing product were combined and concentrated in 
vacuo to afford the title compound as a pale yellow solid. (192, 0.18 g, 0.58 mmol, 
43%): Rf = 0.39 (light petroleum:EtOAc, 50:50); υmax (neat)/cm-1 3293 m (NH2), 2124 w 
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(Alkyne), 1626 m, 1576 m, 1527 m, 1407 m, 1238 m; δH (400 MHz; DMSO-d6) 3.47 (1 
H, t, J 2.4, Alkyne-CH), 4.93 (2 H, d, J 2.5, Alkyne-CH2), 6.56 (2 H, br s, NH2), 7.49-
7.62 (2 H, m, Ar-H), 7.80-7.89 (2 H, m, Ar-H), 8.06 (1 H, s, CH); δc (100 MHz; 
DMSO-d6) 32.9 (CH2), 76.5 (C), 78.9 (C), 126.1 (CH), 126.3 (CH), 127.3 (C), 135.4 
(CH), 136.1 (C), 142.3 (CH), 142.7 (C-8), 145.6 (C), 155.7 (C), 159 (C), 160.2 (C); m/z 
(HNESP) 311 (M+NH4+, 100%); [Found (HNESP) 311.0887, C14H14N7O3 requires 
311.0890]. 
 
Preparation of 9-(prop-2-ynyl)-6-chloro-2-isobutyrylamino-9H-purine (198)  
 
   180 (0.27 g, 1.30 mmol, 1.00 eq) was dissolved in dry C5H5N (20 
mL) and to this, DMAP (0.02 g, 0.13 mmol, 0.10 eq) and 
isobutyryl chloride (0.24 g, 2.30 mmol, 1.77 eq) was added. The 
reaction mixture was stirred at rt under N2 for 24 h. MeOH (20 mL) 
was added to quench the reaction and the solvent was removed in 
vacuo. The residue was dissolved in DCM (20 mL) and the solution was washed with 
aqueous NaHCO3 (1 mol dm-3, 20 mL). The organic phase was separated, dried over 
anhydrous MgSO4 and concentrated in vacuo to afford a red oil. The residue was 
purified by flash chromatography on a silica column, eluting with light 
petroleum:EtOAc (50:50). Fractions containing product were combined and 
concentrated in vacuo to afford the title compound as a white oil. (198, 0.31 g, 1.13 
mmol, 88%): Rf = 0.45 (light petroleum:EtOAc, 50:50); υmax (neat)/cm-1 3302 m, 3054 
m, 2981 m, 2306 w (Alkyne), 1722 m (C=O), 1402 m, 1134 m, 1001 w; δH (400 MHz; 
CDCl3) 1.29 (6 H, d, J 6.7, 2 × CH3), 2.56 (1 H, t, J 2.6, Alkyne-H), 2.91 (1 H, sep, J 
6.4, 13.2, CH), 5.02 (2 H, d, J 2.4, Alkyne-CH2), 8.13 (1 H, br s, NH), 8.22 (1 H, s, 
CH); δc (100 MHz; CDCl3) 19.2 (2 × CH3), 33.6 (CH2), 36.2 (CH), 75.1 (C), 75.9 (C), 
128.0 (C), 143.6 (C-8), 151.3 (C), 152.1 (C), 152.3 (C), 175.5 (C); m/z (HNESP) 278 
(M+NH4+, 100%); [Found (HNESP) 278.0803, C12H12ClN5O requires 278.0808]. 
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Preparation of 9-(prop-2-ynyl)-6-(2-nitrophenyl)-2-isobutyrylamino-9H-purine 
(182)  
 
   To a stirred solution of 198 (0.09 g, 0.33 mmol, 1.00 eq) in dry 
DCM (20 mL) was added, TEA (0.14 mL, 0.975 mmol, 3 eq), 2-
nitrophenol (0.14 g, 0.98 mmol, 3.00 eq) and DABCO (0.04 g, 0.33 
mmol, 1.00 eq). The reaction mixture was stirred at rt under N2 for 
24 h. DCM (20 mL) was added to dilute the reaction mixture and 
the organic phase was washed with saturated NaHCO3 solution (30 
mL). The aqueous phase was re-extracted with DCM (4 × 40 mL) 
and the combined organic layers were dried over anhydrous MgSO4. Filtration followed 
by evaporation afforded the crude product as a clear, yellow oil. The residue was 
purified by flash chromatography on a silica column, eluting with EtOAc. Fractions 
containing product were combined and concentrated in vacuo to afford the title 
compound as a yellow oil. (182, 0.11 g, 0.29 mmol, 89%): Rf = 0.21 (light 
petroleum:EtOAc, 50:50); υmax (neat)/cm-1 3465 w (NH), 2985 m, 2122 w (Alkyne), 
1740 s (C=O), 1623 w, 1374 m, 1240 s; δH (400 MHz; CDCl3) 1.06 (6 H, d, J 6.7, 2 × 
CH3), 2.55 (1 H, t, J 2.6, Alkyne-CH), 3.12 (1H, sep, CH), 4.98 (2 H, d, J 2.6, Alkyne-
CH2), 7.42-7.51 (2 H, m, Ar-H), 7.71-7.75 (2 H, m, Ar-H), 8.10 (1 H, br s, NH), 8.15 (1 
H, s, CH); δc (100 MHz; CDCl3) 18.9 (2 × CH3 ), 33.5 (CH2), 34.8 (CH), 75.4 (C), 75.6 
(C), 125.9 (CH), 126.7 (CH), 126.7 (C), 128.4 (CH), 130.1 (CH), 134.9 (C), 142.1 (C-
8), 145.5 (C), 151.8 (C), 159.2 (C), 169.9 (C), 175.9 (C); m/z (HNESP) 381 (M+NH4+, 
100%); [Found (HNESP) 381.1306, C18H20N7O4 requires 381.1308]. 
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Attempted preparation of 9-(prop-2-ynyl)- 2-amino-9H-guanine (183)  
 
 181
 was the sole 
   A solution of 1,1,3,3-tetramethylguanidine (TMG) 200 (0.18 mL, 1.41 
mmol, 9.00 eq) in dry CH3CN (5 mL) was added to a stirred solution of 
182 (0.06 g, 0.16 mmol, 1.00 eq) and 2-nitrobenzaldoxime 199 (0.26 g, 
1.58 mmol, 10.00 eq) in dry CH3CN (5 mL). The reaction mixture was 
stirred at rt under N2 for 48 h. Solvent was removed in vacuo. 1H NMR 
confirmed that the reaction had failed and the starting material, 182,
compound present. 
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Preparation of 2-(TBDMS)ethanamine (237)  
 
   Ethanolamine (1.00 g, 16.37 mmol, 1.00 eq) was taken up in dry 
DCM (20 mL) and to this, imidazole (1.45 g, 24.56 mmol, 1.30 eq) 
and TBDMSCl (3.70 g, 24.56 mmol, 1.50 eq) was added. The reaction mixture was 
stirred at rt under N2 for 24 h. H2O (30 mL) was added to quench the reaction and the 
aqueous phase was separated and extracted with EtOAc (4 × 40 mL). The combined 
organic layers were washed with saturated NaCl solution (30 mL), dried over MgSO4, 
filtered and concentrated in vacuo to afford the title compound as a clear, colourless oil. 
(237, 1.53 g, 8.69 mmol, 53%): Rf  = 0.1 (light petroleum:EtOAc, 50:50); υmax 
(neat)/cm-1 2942 s (NH2), 1736 m, 1590 m; δH (200 MHz; CDCl3) 0.31 (9 H, s, 
(CH3)3C), 1.14 (6 H, s, 2 × CH3), 3.08 (2 H, t, J 5.4, CH2), 3.95 (2 H, t, J 5.4, 10.8, 
CH2), 5.92 (2 H, br s, NH2); δc (50 MHz; CDCl3) 18.4 (2 × CH3), 26.0 (3 × CH3), 43.5 
(CH2), 63.6 (CH2),121.7 (C); m/z (HNESP) 176 (M+NH4+, 100%), 351 (M+(M)+, 73%); 
(Found (HNESP) 176.1462, C8H25N2OSi requires 176.1465). 
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Preparation of (2-azido)-1-o-(TBDMS)ethane (238)  
 
   237 (1.53 g, 8.75 mmol, 1.00 eq) was added to imidazole-1-sulfonyl 
azide HCl salt 152 (1.67 g, 9.62 mmol, 1.10 eq), K2CO3 (1.21 g, 8.75 
mmol, 1.00 eq) and CuSO4·5H2O (0.02 g, 0.09 mmol, 0.01 eq) in 
MeOH (20 mL) and the reaction mixture was stirred at rt under N2 for 24 h. The 
mixture was reduced in volume by concentration in vacuo and then diluted with H2O 
(20 mL). The solution was extracted with EtOAc (4 × 20 mL) and the combined organic 
layers were washed with saturated NaCl solution (20 mL), dried over anhydrous 
MgSO4, filtered and concentrated in vacuo. The pale blue solid was used immediately in 
the subsequent step. υmax (neat)/cm-1 2114 m (N3) (solvent peaks on spectrum); δH (200 
MHz; CDCl3) 0.09 (6H, s, 2 × CH3), 0.91 (9H, s, 3 × CH3), 3.27 (2H, t, J 5.0, CH2), 
3.80 (2H, t, J 5.4, CH2), (solvent peaks present on spectrum); δc (50 MHz; CDCl3) -5.50 
(2 × CH3), 25.7 (3 × CH3), 53.2 (CH2), 60.4 (C), 62.6 (CH2) (solvent peaks present on 
spectrum); m/z (ASAP) 202 (M+H+, 100%); [Found (ASAP) 202.1368, C8H20N3OSi 
requires 202.1370]. 
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Preparation of (1-O-(TBDMS ethane)-1H-1,2,3-triazol-4-yl)methanol (239) 
 
   238 (0.57 g, 2.85 mmol, 1.00 eq) was taken up in a mixture of 
DCM/tert-butyl alcohol/H2O ((1:1:1) v/v, 6 mL) and to this, sodium 
ascorbate (0.57 mL, 0.57 mmol, 0.20 eq), CuSO4·5H2O (0.01 g, 0.26 
mmol, 0.09 eq) and propargyl alcohol (0.18 mL, 3.11 mmol, 1.09 
eq) were added. The reaction mixture was stirred under N2 at rt for 
24 h. H2O (10 mL) was added to quench the reaction and the 
aqueous phase was extracted with EtOAc (4 × 20 mL). The combined organic layers 
were washed with saturated NaCl solution (20 mL), dried over anhydrous MgSO4, 
filtered and concentrated in vacuo to afford the title compound as a yellow/brown oil. 
(239, 0.48 g, 1.99 mmol, 70%) Rf = 0.42 (light petroleum:EtOAc, 50:50); υmax 
(neat)/cm-1 3269 w (OH), 1471 w, 1361 m, 1182 m, 1111 m; δH (200 MHz; CDCl3) -
0.139 (6H, s, 2 × CH3), 0.737 (9H, s, 3 × CH3), 3.12 (1H, br s, OH), 3.87 (2H, t, J 5.0, 
CH2), 4.36 (2H, t, J 5.0, CH2), 4.65 (2H, s, CH2), 7.61 (1H, s, triazole-H); δc (50 MHz; 
CDCl3) -5.9 (2 × CH3), 25.4 (3 × CH3), 52.5 (CH3), 56.1 (CH2), 61.7 (CH2), 63.3 (CH2), 
64.0 (CH),123.1 (CH); m/z (HNESP) 258 (M+H+, 100%); [Found (HNESP) 258.1630, 
C11H24N3O2Si requires 258.1632]. 
N
O
Si
N
N
OH
C11H23N3O2Si
 
Preparation of 3-benzoyl-1-((1-(2-(tert-butyldimethylsilyloxy)ethyl)-1H-1,2,3-
triazol-4-yl)methyl)-5-methylpyrimidine-2,4(1H,3H)-dione (240)  
 
   238 (1.76 g, 8.74 mmol, 1.00 eq) in EtOAc (6 mL) was added 
to a mixture of DCM/tert-butyl alcohol/H2O ((1:1:1) v/v, 6 mL) 
and to this, 161 (1.85 g, 8.02 mmol, 1.09 eq), CuSO4·5H2O (0.19 
g, 0.79 mmol, 0.09 eq) and sodium ascorbate (2.19 mL, 1.75 
mmol, 0.20 eq) were added. The deep yellow solution was 
stirred for 24 h at rt. The solvent was removed in vacuo and H2O 
(20mL) was added. The solution was extracted with EtOAc (4 × 30 mL) and the 
combined organic layers were washed with saturated NaCl solution (30 mL), dried over 
anhydrous MgSO4, filtered and concentrated in vacuo to afford a yellow/brown oil. The 
residue was purified by flash chromatography on a silica column, eluting with light 
petroleum:EtOAc (50:50). Fractions containing product were combined and 
concentrated in vacuo to afford the title compound as a clear, yellow oil. (240, 0.94 g, 
2.06 mmol, 24%): Rf = 0.15 (light petroleum:EtOAc, 50:50); υmax (neat)/cm-1 2929m, 
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1748 s (C=O), 1699 s (C=O), 1658 s (C=O), 1461 m, 1440 s; δH (400 MHz; CDCl3) -
0.28 (6 H, s, 2 × CH3), 0.59 (9 H, s, 3 × CH3), 1.71 (3 H, d, J 1.2, CH3), 3.75 (2 H, t, J 
4.7, CH2), 4.23 (2 H, t, J 5.2, CH2), 4.78 (2 H, s, CH2), 7.24-7.29 (3 H, m, Ar-H), 7.39-
7.44 (1 H, m, Ar-H), 7.52 (1 H, s, Triazole-CH), 7.67-7.71 (2 H, m, Ar-H); δc (100 
MHz; CDCl3) -5.9 (2 × CH3), 12.2 (CH3), 17.9 (CH), 25.5 (3 × CH3), 42.8 (CH2), 52.7 
(CH2), 61.6 (CH2), 110.8 (C), 124.7 (Triazole-CH), 130.2 (2 × CH), 130.3 (2 × CH), 
131.4 (C), 134.8 (CH), 139. 9 (CH), 141.2 (C), 149.6 (C=O), 162.9 (C=O), 168.8 
(C=O); m/z (HNESP) 470 (M+NH4+, 100%), 939 (M+(M+), 44%); [Found (HNESP) 
470.2208, C23H35N6O4Si requires 470.2218]; The identity of the product was confirmed 
by NOESY spectroscopy. 
 
Preparation of (R)-methyl 2-azidopropanoate (242)  
 
   L-Alanine methyl ester HCl salt (1.00 g, 7.16 mmol, 1.00 eq) was added 
to a mixture of imidazole-1-sulfonyl azide HCl salt  152 (1.36 g, 7.88 
mmol, 1.10 eq), K2CO3 (0.99 g, 7.16 mmol, 1.00 eq) and CuSO4·5H2O  
H
N3
O
O
C4H7N3O2
(0.02 g, 0.07 mmol, 0.01 eq) and the reaction mixture was stirred for 24 h at rt under N2. 
The mixture was reduced in volume by concentration in vacuo and then diluted with 
H2O (20 mL). The solution was extracted with EtOAc (4 × 20 mL) and the combined 
organic layers were washed with saturated NaCl solution (20 mL). The organic phase 
was dried over anhydrous MgSO4, filtered and reduced in volume by concentration in 
vacuo. The residue was used immediately in the subsequent step; υmax (neat)/cm-1 2106 s 
(N3), 1738 s (C=O) (solvent peaks on spectrum); δH (200 MHz; CDCl3) 1.69 (3H, s, 
CH3), 3.98 (3H, s, OCH3), 4.07 (1H, s, CH) (solvent/imidazole peaks present on 
spectrum); δc (50 MHz; CDCl3) 16.4 (CH3), 52.3 (CH), 56.7 (CH3), 151.1 (C) (solvent 
peaks present on spectrum); m/z (ASAP) 147 (M+NH4+, 100%); [Found (ASAP) 
147.0877, C4H15N5O2 requires 147.0877]. 
 
Preparation of (R)-methyl 2-(4-((3-benzoyl-5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)methyl)-1H-1,2,3-triazol-1-yl)propanoate (243)  
 
   242 (0.59 g, 3.05 mmol, 1.00 eq) in EtOAc (6.5 mL) was 
added to a mixture of DCM/tert-butyl alcohol/H2O ((1:1:1) v/v, 
6 mL) and to this, 161 (0.89 g, 3.32 mmol, 1.09 eq), N
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CuSO4·5H2O (0.02 g, 0.65 mmol, 0.09 eq) and sodium ascorbate (0.74 mL, 0.61 mmol, 
0.20 eq) were added. The deep yellow solution was stirred for 24 h at rt. The solvent 
was removed in vacuo and H2O (10 mL) was added. The solution was extracted with 
EtOAc (6 × 15 mL) and the combined organic layers were washed with saturated NaCl 
solution (20 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo to 
afford a yellow/brown oil. The residue was purified by flash chromatography on a silica 
column, eluting with light petroleum:EtOAc (80:20). Fractions containing product were 
combined and concentrated in vacuo to afford the title compound as a clear, colourless 
oil. (243, 0.18 g, 0.45 mmol, 13%): Rf = 0.34 (light petroleum:EtOAc, 80:20); υmax 
(neat)/cm-1 2922 s, 1746 s (C=O), 1697 s (C=O), 1656 s (C=O), 1461 s, 1377 s; δH (400 
MHz; CDCl3) 1.61 (3 H, d, J 7.5, CH3-CH), 1.71 (3 H, d, J 1.25, Thymine-CH3), 3.55 
(3 H, s, OCH3), 4.79 (2 H, ab, J 14.9, CH2), 5.22 (1 H, q, J 7.5, CH3-CH), 7.22-7.30 (3 
H, m, 3 × Ar-CH), 7.38-7.47 (1 H, m, Ar-CH), 7.61 (1 H, s, Triazole-CH), 7.66-7.72 (2 
H, m, 1 × Ar-CH and Thymine-CH); δc (100 MHz; CDCl3) 12.7 (CH3), 18.2 (CH3), 
43.4 (CH2), 53.5 (OCH3), 58.6 (CH), 111.5 (C), 123.4 (CH), 129.4 (2 × CH), 130.7 (2 × 
CH), 131.8 (C), 135.3 (CH), 140.3 (CH), 142.1 (C), 150.1 (C=O), 163.3 (C=O), 169.3 
(C=O), 169.7 (C=O); m/z (HNESP) 398 (M+NH4+, 100%); [Found (HNESP) 398.1459, 
C19H23N6O5 requires 398.1459]; The identity of the product was confirmed by NOESY 
spectroscopy. 
Preparation of (S)-methyl 3-(tert-butyldimethylsilyloxy)-2-(4-(hydroxymethyl)-1H-
1,2,3-triazol-1-yl)propanoate (244) 
 
   158 (0.74 g, 2.85 mmol, 1.00 eq), CuSO4·5H2O (0.06 g, 0.26 mmol, 
0.09 eq), propargyl alcohol (0.18 mL, 3.11 mmol, 1.09 eq) and sodium 
ascorbate (0.92 mL, 0.57 mmol, 0.20 eq) were suspended in a mixture 
of DCM/tert-butyl alcohol/H2O ((1:1:1) v/v, 6 mL) and stirred at rt 
under N2 for 24 h. Solvent was removed in vacuo and H2O (10 mL) 
was added. The aqueous phase was extracted with EtOAc (6 × 20 mL) 
and the combined organic layers were washed with saturated NaCl 
solution (30 mL). The organic phase was dried over anhydrous MgSO4, filtered and 
concentrated in vacuo to afford a yellow/brown oil. The residue was purified by flash 
chromatography on a silica column eluting with (light petroleum:EtOAc (80:20) to light 
petroleum:EtOAc (50:50) to light petroleum:EtOAc (30:70) gradient elution). Fractions 
containing product were combined and concentrated in vacuo to afford the title 
compound as a clear, yellow oil. (244, 0.56 g, 1.76 mmol, 62%): Rf = 0.15 (light 
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petroleum:EtOAc, 30:70); υmax (neat)/cm-1 3286 w (OH), 1749 s, (C=O), 1362 m, 1253 
s; δH (200 MHz; CDCl3) 0.02 (6H, s, 2 × CH3), 0.85 (9H, s, 3 × CH3), 3.18 (1H, br s, 
OH), 3.78 (3H, s, OCH3), 4.02 (1H, d, J 10.4, CH2-OTBDPS), 4.37 (1H, d, J 10.4, CH2-
OTBDPS), 4.80 (2H, s, CH2-OH), 5.53-5.57 (1H, m, CH), 7.92 (1H, s, triazole-H); δc 
(50 MHz; CDCl3) 17.7 (2 × CH3), 25.2 (3 × CH3), 27.8 (C), 52.7 (CH3), 56.0 (CH2), 
63.3 (CH2), 64.0 (CH), 122.6 (CH), 147.1 (C), 167.1 (C); m/z (HNESP) 316 (M+H+, 
100%); [Found (HNESP) 316.1688, C13H26N3O4Si requires 316.1687]; (Found C, 
49.46; H, 8.05; N, 13.56. C13H25N3O4Si requires C, 49.50; H, 7.99; N, 13.32%). 
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reparation of (S)-methyl 3-(tert-butyldimethylsilyloxy)-2-(4-((5-methyl-2,4-dioxo-
 158 (1.62 g, 6.26 mmol, 1.00 eq), CuSO4·5H2O (0.14 g, 0.56 mmol, 
P
3,4-dihydropyrimidin-1(2H)-yl)methyl)-1H-1,2,3-triazol-1-yl)propanoate (246) 
 
  
0.09 eq), sodium ascorbate (2.02 mL, 1.25 mmol, 0.2 eq) and 161 
(1.83 g, 6.82 mmol, 1.09 eq) were suspended in a mixture of 
DCM/tert-butyl alcohol/H2O ((1:1:1) v/v, 12 mL) and stirred at rt 
under N2 for 30 h. Solvent was removed in vacuo and H2O (30 mL) 
was added. The aqueous phase was extracted with EtOAc (6 × 40 mL) 
and the combined organic layers were washed with saturated NaCl 
solution (50 mL). The organic phase was dried over anhydrous 
MgSO4, filtered and concentrated in vacuo to afford a yellow/brown 
oil. The residue was purified by flash chromatography on a silica colu
(light petroleum:EtOAc (75:25) to light petroleum:EtOAc (50:50) to light 
petroleum:EtOAc (0:100) gradient elution). Fractions containing product were 
combined and concentrated in vacuo to afford the title compound as a clear, yellow oil. 
(246, 1.17 g, 0.93 mmol, 44%): R
Si
mn eluting with 
f = 0.25 (light petroleum:EtOAc, 50:50); υmax 
(neat)/cm-1 2956 w, 2858 w, 1754 w, 1674 s, 1470 w, 1126 w; δH (200 MHz; CDCl3) -
0.15 (6H, s, 2 × CH3), 0.66 (9H, s, 3 × CH3), 1.74 (3H, s, thymine-CH3), 3.65 (3H, s, 
OCH3), 3.92-3.95 (1H, d, J 13.3, CH2-OTBDMS), 4.18-4.25 (1H, d, J 13.3, CH2-
OTBDMS), 4.82-4.98 (2H, dd, J 13.3, CH2), 5.42-5.46 (1H, m, CH), 7.26 (1H, s, 
thymine-CH), 7.91 (1H, s, triazole-CH), 10.08 (1H, br s, NH); δc (50 MHz; CDCl3) -6.1 
(CH3), -5.9 (CH3), 12.1 (CH3), 17.8 (C), 25.3 (3 × CH3), 42.4 (CH2), 52.9 (OCH3), 63.3 
(CH2), 64.4 (CH), 110.9 (C), 124.6 (triazole-CH), 140.0 (CH), 141.8 (C), 150.9 (C=O), 
164.4 (C=O), 166.9 (C=O); m/z (HNESP) 424 (M+H+, 100%); [Found (HNESP) 
O
ON
N N
O
O
N
NH
O
C18H29N5O5Si
Experimental 
 
424.2007, C18H30N5O5Si requires 424.2011]. The identity of the product was confirmed 
by NOESY and COSY spectroscopy. 
 
Preparation of (2S)-methyl 2-(4-((3-benzoyl-5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)methyl)-4,5-dihydro-1,2,3-triazol-1-yl)-3-(tert-
butyldimethylsilyloxy)propanoate (245) 
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uid. The residue 
   158 (0.74 g, 2.85 mmol, 1.00 eq), CuI (0.82 g, 4.28 mmol, 1.50 eq), 
161 (0.77 g, 2.85 mmol, 1.00 eq) and DIPEA (4.96 mL, 28.50 mmol, 
10.00 eq) were suspended in dry DMF (7 mL). The reaction mixture 
was stirred at rt under N2 for 30 h. The dark green mixture was taken 
up in EtOAc (100 mL) and H2O (100 mL) and the layers were 
separated. The aqueous phase was extracted with EtOAc (3 × 50 mL) 
and the combined organic layers were washed with saturated NaCl 
solution (50 mL). The organic phase was dried over anhydrous 
MgSO4, filtered and concentrated in vacuo to afford a brown/yellow liq
was purified by flash chromatography on a silica column eluting with light 
petroleum:EtOAc (75:25) to light petroleum:EtOAc (50:50) to light petroleum:EtOAc 
(25:75) gradient elution. Fractions containing product were combined and concentrated 
in vacuo to afford the title compound as a clear, yellow oil. (245, 0.14 g, 0.27 mmol, 
15%): Rf = 0.29 (light petroleum:EtOAc, 50:50); υmax (neat)/cm-1 1746 s (C=O), 1698 s 
(C=O), 1599 s (C=O), 1435 m,  1250 s, 1224 s; δH (400 MHz; CDCl3) -0.04 (6H, s, 2 × 
CH3), 0.77 (9H, s, 3 × CH3), 1.92 (3H, s, CH3-thymine), 3.77 (3H, s, OCH3), 3.99-4.05 
(1H, dd, J 13.7, CH2), 4.33-4.38 (1H, d, J 13.7, CH2), 4.89-5.13 (2H, d, J 16.6, CH2), 
5.55 (1H, m, CH), 7.41-7.51 (3H, m, Ar-CH), 7.57-7.66 (1H, m, thymine-CH), 7.86-
7.92 (2H, m, Ar-CH), 8.00 (1H, s, triazole-CH); δc (100 MHz; CDCl3) -5.9 (CH3), -5.7 
(CH3), 12.3 (CH3), 17.9 (C), 25.4 (3 × CH3), 42.8 (CH2), 53.0 (OCH3), 63.4 (CH2), 64.6 
(CH), 111.0 (C), 127.3 (C), 128.5 (C), 129.0 (2 × CH), 130.3 (2 × CH), 131.6 (CH), 
134.8 (CH), 139.8 (CH), 149.7 (C=O), 163.0 (C=O), 167.0 (C=O), 168.8 (C=O); m/z 
(HNESP) 528 (M+NH4+, 100%); [Found (HNESP) 528.2259, C25H37N6O6Si requires 
528.2263]. The identity of the product was confirmed by NOESY and COSY 
spectroscopy. 
O
Si
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N
N
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C25H33N5O6Si
 
 
 
Experimental 
 
Attempted preparation of (S)-methyl 2-(4-((4-benzamido-2-oxopyrimidin-1(2H)-
yl)methyl)-1H-1,2,3-triazol-1-yl)-3-(tert-butyldimethylsilyloxy)propanoate (247) 
 
   158 (0.166 g, 0.641 mmol, 1.00 eq), in EtOAc (3 mL) was added to 
a mixture of DCM/tert-butyl alcohol/H2O ((1:1:1) v/v, 6 mL) and to 
this, 166 (0.177 g, 0.699 mmol, 1.09 eq), CuSO4·5H2O (0.015 g, 0.06 
mmol, 0.09 eq) and sodium ascorbate (0.21 mL, 0.013 mmol, 0.20 eq) 
were added. The deep yellow solution was stirred for 30 h at rt. The 
solvent was removed in vacuo and H2O (10mL) was added. The 
solution was extracted with EtOAc (4 × 30 mL) and the combined 
organic layers were washed with saturated NaCl solution (30 mL), 
dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford a 
yellow/brown oil. The residue was purified by flash chromatography on a silica column, 
eluting (light petroleum:EtOAc (80:20) to light petroleum:EtOAc (50:50) to light 
petroleum:EtOAc (20:80) gradient elution). 1H NMR confirmed that none of the 
fractions contained the title compound 247 and the starting materials 158 and 166 were 
recovered. 
O
N
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Attempted preparation of (S)-methyl 2-(4-((6-benzamido-9H-purin-9-yl)methyl)-
1H-1,2,3-triazol-1-yl)-3-(tert-butyldimethylsilyloxy)propanoate (248)  
 
   158 (0.59 g, 1.90 mmol, 1.00 eq), in EtOAc (3 mL) was added to a 
mixture of DCM/tert-butyl alcohol/H2O ((1:1:1) v/v, 6 mL) and to 
this, 176 (0.58 g, 2.07 mmol, 1.09 eq), CuSO4·5H2O (0.04 g, 0.17 
mmol, 0.09 eq) and sodium ascorbate (0.74 mL, 0.38 mmol, 0.20 eq) 
were added. The deep yellow solution was stirred for 30 h at rt. The 
solvent was removed in vacuo and H2O (10mL) was added. The 
solution was extracted with EtOAc (4 × 30 mL) and the combined 
organic layers were washed with saturated NaCl solution (30 mL), 
dried over anhydrous MgSO4, filtered and concentrated in vacuo to 
afford a yellow/brown oil. The residue was purified by flash 
chromatography on a silica column, eluting (light petroleum:EtOAc (80:20) to light 
petroleum:EtOAc (50:50) to light petroleum:EtOAc (20:80) gradient elution). 1H NMR 
confirmed that none of the fractions contained the title compound 248 and the starting 
materials 158 and 176 were recovered. 
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Experimental 
 
Preparation of (R)-1-((1-(3-(tert-butyldimethylsilyloxy)-1-hydroxypropan-2-yl)-
1H-1,2,3-triazol-4-yl)methyl)-5-methylpyrimidine-2,4(1H,3H)-dione (249) 
 
   246 (0.10 g, 0.19 mmol, 1.00 eq) was added to a stirred solution of 
LiBH4 (0.01 g, 0.38 mmol, 2.00 eq) in dry THF (10 mL) at 0 oC under 
N2. To this, 9-BBN (1M in hexane, 0.14 mL, 0.42 mmol, 2.20 eq) was 
added dropwise to the mixture. The reaction mixture was allowed to 
warm to rt and maintained for 24 h. The solvent was removed in 
vacuo and H2O (10 mL) was added. The aqueous phase was extracted 
with EtOAc (4 × 20 mL) and the combined organic layers were 
washed with saturated NaCl solution (20 mL). The organic phase was 
dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford a clear, 
colourless oil. The residue was purified by flash chromatography on a silica column 
eluting with (light petroleum:EtOAc (70:30) to light petroleum:EtOAc (50:50) to light 
petroleum:EtOAc (30:70) gradient elution). Fractions containing product were 
combined and concentrated in vacuo to afford the title compound as a clear, yellow oil. 
(249, 0.02 g, 0.10 mmol, 25%): Rf = 0.52 (light petroleum:EtOAc, 50:50); υmax 
(neat)/cm-1  2985 s, 1740 s, 1373 m, 1240 s; δH (400 MHz; CDCl3) -0.03 (6H, s, 2 × 
CH3), 0.81 (9H, s, 3 × CH3), 1.60 (1H, br s, OH), 1.90 (3H, s, thymine-CH3), 4.01-4.05 
(2H, m, CH2-OTBDMS), 4.11-4.18 (2H, m, CH2OH), 4.61-4.68 (1H, m, CH), 4.97 (2H, 
s, CH2), 7.33 (1H, s, thymine-CH), 7.86 (1H, s, triazole-CH), 8.46 (1H, br s, NH); δc 
(100 MHz; CDCl3) -5.8 (CH3), -5.7 (CH3), 12.3 (CH3), 18.0 (C), 25.6 (3 × CH3), 42.8 
(CH2), 62.0 (CH2), 63.1 (CH2), 64.2 (CH), 111.2 (C), 124.3 (CH), 140.1 (CH), 141.6 
(C), 150.6 (C), 163.8 (C); m/z (HNESP) 396 (M+H+, 100%); [Found (HNESP) 
396.2059, C17H30N5O4Si requires 396.2062]. 
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Experimental 
 
Attempted preparation (R)-1-((1-(3-(bis(4-methoxyphenyl)(phenyl)methoxy)-1-
(tert-butyldimethylsilyloxy)propan-2-yl)-1H-1,2,3-triazol-4-yl)methyl)-5-
methylpyrimidine-2,4(1H,3H)-dione (250) 
 
   249 (0.01 g, 2.53×10-3 mmol, 1.00 eq) and DMTrCl (0.01 g, 
3.03×10-3 mmol, 1.20 eq) was suspended in dry DCM (3 mL) 
and to this, DBU (0.01 mL, 3.54×10-3 mmol, 1.40 eq) was 
added. The reaction mixture was stirred at rt under N2 for 24 h. 
TLC confirmed no reaction had occurred and the reaction 
mixture was maintained for a further 24 h. H2O (3 mL) was 
added and the organic phase was separated and washed with 
H2O (2 × 6 mL), dried over anhydrous MgSO4, filtered and 
concentrated in vacuo to afford a clear, colourless oil. 1H NMR showed no product 250 
was present and the starting material was the sole compound present.
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Appendix A. The Genetic code 
 
 T C A G 
T 
TTT Phe (F) 
TTC Phe (F) 
TTA Leu (L) 
TTG Leu (L) 
TCT Ser (S) 
TCC Ser (S) 
TCA Ser (S) 
TCG Ser (S)  
TAT Tyr (Y) 
TAC  
TAA STOP 
TAG STOP
TGT Cys (C) 
TGC  
TGA STOP 
TGG Trp (W) 
C 
CTT Leu (L) 
CTC Leu (L) 
CTA Leu (L) 
CTG Leu (L) 
CCT Pro (P) 
CCC Pro (P) 
CCA Pro (P) 
CCG Pro (P) 
CAT His (H) 
CAC His (H) 
CAA Gln (Q) 
CAG Gln (Q) 
CGT Arg (R) 
CGC Arg (R) 
CGA Arg (R) 
CGG Arg (R) 
A 
ATT Ile (I) 
ATC Ile (I) 
ATA Ile (I) 
ATG Met (M) 
START
ACT Thr (T) 
ACC Thr (T) 
ACA Thr (T) 
ACG Thr (T) 
AAT Asn (N) 
AAC Asn (N)  
AAA Lys (K) 
AAG Lys (K) 
AGT Ser (S) 
AGC Ser (S) 
AGA Arg (R) 
AGG Arg (R) 
G 
GTT Val (V) 
GTC Val (V) 
GTA Val (V) 
GTG Val (V) 
GCT Ala (A) 
GCC Ala (A) 
GCA Ala (A) 
GCG Ala (A) 
GAT Asp (D) 
GAC Asp (D) 
GAA Glu (E) 
GAG Glu (E) 
GGT Gly (G) 
GGC Gly (G) 
GGA Gly (G) 
GGG Gly (G) 
 
Table 11. The genetic code. 
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Appendix B. Table of the Amino acid structures 
H2N
H
C C
CH3
OH
O
Ala
Glu
Leu
Ser
Arg
Gln
Lys
Thr
Asn
Gly
Met
Trp
Asp
His
Phe
Tyr
Cys
Ile
Pro
Val
H2N CH C
CH2
OH
O
CH2
CH2
NH
C
NH2
NH
H2N CH C
CH2
OH
O
C
NH2
O
H2N CH C
CH2
OH
O
C
OH
O
H2N CH C
CH2
OH
O
SH
A
la
A
rg
A
sn
A
sp
C
ys
 G
lu
 G
ln
 G
ly
 H
is
 Il
e
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u
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s
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P
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r
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p
Ty
r
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Acids
H2N CH C
CH2
OH
O
CH2
C
OH
O
H2N CH C
CH2
OH
O
CH CH3
CH3
H2N CH C
CH2
OH
O
OH
H2N CH C
CH2
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O
CH2
C
NH2
O
H2N CH C
CH2
OH
O
CH2
CH2
CH2
NH2
H2N CH C
CH
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O
OH
CH3
H2N CH C
H
OH
O
H2N CH C
CH2
OH
O
N
NH
H2N CH C
CH
OH
O
CH3
CH2
CH3
H2N CH C
CH2
OH
O
CH2
S
CH3
H2N CH C
CH2
OH
O
HN
H2N CH C
CH2
OH
O
HN
C OH
O
H2N CH C
CH
OH
O
CH3
CH3
H2N CH C
CH2
OH
O
OH
 
Table 12. Amino acid structure 
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Appendix C. 160 crystal structure 
 
here are two molecules in the asymmetric unit with small differences in the orientation 
ata was collected by Dr Georgina Rosair on a Bruker X8 Apex 2 CCD single crystal 
able 13.  Crystal data and structure refinement for 160.
 
T
of the phenyl and methyl groups. 
 
D
diffractometer at 100 K. 
 
T  
N2 O3 
 
 
  
nsions (8) Å α= 90°. 
olume 2113(3) 
t 
or data collection 
 
entification code  x82556o Id
Empirical formula  C12 H14 
Formula weight  234.25 
Temperature  100(2) K
Wavelength  0.71073 Å
Crystal system Orthorhombic 
Space group  Pca2(1) 
Unit cell dime a = 9.485
 b = 8.678(8) Å β= 90°. 
 c = 25.67(2) Å γ = 90°. 
V Å3 
Z 8 
Density (calculated) 1.473 Mg/m3 
Absorption coefficien 0.107 mm-1 
F(000) 992 
Crystal size 0.64 x 0.30 x 0.04 mm3 
Theta range f 2.35 to 26.53°. 
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0<=k<=10, -32<=l<=32 
llected 
s (int) = 0.1411] 
25.00° 
atrix least-squares on F2 
ameters 
 
d hole 
able 14.   Bond lengths [Å] and angles [°] for 160.
Index ranges -10<=h<=11, -1
Reflections co 25634 
Independent reflection 2191 [R
Completeness to theta = 98.3 %  
Absorption correction None 
Refinement method Full-m
Data / restraints / par 2191 / 1 / 309 
Goodness-of-fit on F2 1.125 
Final R indices [I>2sigma(I)] R1 = 0.0777, wR2 = 0.1946
R indices (all data) R1 = 0.1628, wR2 = 0.2665 
Largest diff. peak an 0.410 and -0.498 e.Å-3 
 
T  
(1A)-C(2A)  1.395(12) 
 
) 
 
  ) 
) 
C(12A)-C(13A)  1.386(18) 
) 
) 
 
2) 
 
 
N
N(1A)-C(6A)  1.399(13) 
N(1A)-C(7A)  1.460(13) 
C(2A)-O(2A)  1.243(13) 
C(2A)-C(3A)  1.451(14) 
C(3A)-C(4A)  1.354(15) 
C(3A)-C(14A) 1.476(13) 
C(4A)-N(5A)  1.375(14) 
C(4A)-H(4A)  0.9500 
N(5A)-C(6A)  1.349(13
C(6A)-O(6A)  1.243(12) 
C(7A)-O(7A)  1.222(13) 
C(7A)-C(8A)  1.467(16) 
C(8A)-C(9A)  1.398(14) 
C(8A)-C(13A) 1.405(14) 
C(9A)-C(10A)  1.404(15) 
C(9A)-H(9A)  0.9500 
C(10A)-C(11A) 1.372(15
C(10A)-H(10A)  0.9500 
C(11A)-C(12A)  1.381(16
C(11A)-H(11A)  0.9500 
C(12A)-H(12A)  0.9500 
C(13A)-H(13A)  0.9500 
C(14A)-H(14A)  0.9800 
C(14A)-H(14B)  0.9800 
C(14A)-H(14C)  0.9800 
N(1B)-C(6B)  1.388(13
N(1B)-C(2B)  1.420(11
N(1B)-C(7B)  1.477(12) 
C(2B)-O(2B)  1.228(13) 
C(2B)-C(3B)  1.443(14) 
C(3B)-C(4B)  1.342(16) 
C(3B)-C(14B) 1.514(13) 
C(4B)-N(5B)  1.403(13) 
C(4B)-H(4B)  0.9500 
N(5B)-C(6B)  1.368(12) 
C(6B)-O(6B)  1.229(1
C(7B)-O(7B)  1.208(12) 
C(7B)-C(8B)  1.471(15) 
C(8B)-C(9B)  1.392(15) 
C(8B)-C(13B) 1.408(15) 
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)  
A) 12
A) 11
1) 
0) 
0) 
) 
) 
C(9B)-C(10B) 1.400(16) 
C(9B)-H(9B)  0.9500 
C(10B)-C(11B) 1.397(16) 
C(10B)-H(10B 0.9500 
C(11B)-C(12B)  1.392(16) 
C(11B)-H(11B)  0.9500 
C(12B)-C(13B)  1.375(16) 
C(12B)-H(12B)  0.9500 
C(13B)-H(13B)  0.9500 
C(14B)-H(14D)  0.9800 
C(14B)-H(14E)  0.9800 
C(14B)-H(14F)  0.9800 
C(2A)-N(1A)-C(6 4.4(8) 
C(2A)-N(1A)-C(7 9.2(8) 
C(6A)-N(1A)-C(7A) 115.7(8) 
O(2A)-C(2A)-N(1A) 117.7(9) 
O(2A)-C(2A)-C(3A) 125.4(9) 
N(1A)-C(2A)-C(3A) 116.9(9) 
C(4A)-C(3A)-C(2A) 116.2(9) 
C(4A)-C(3A)-C(14A) 124.6(9) 
C(2A)-C(3A)-C(14A) 119.1(10) 
C(3A)-C(4A)-N(5A) 124.9(10) 
C(3A)-C(4A)-H(4A) 117.5 
N(5A)-C(4A)-H(4A) 117.5 
C(6A)-N(5A)-C(4A) 121.0(9) 
O(6A)-C(6A)-N(5A) 123.7(9) 
O(6A)-C(6A)-N(1A) 120.1(9) 
N(5A)-C(6A)-N(1A) 116.3(9) 
O(7A)-C(7A)-N(1A) 117.9(10) 
O(7A)-C(7A)-C(8A) 126.5(10) 
N(1A)-C(7A)-C(8A) 115.5(9) 
C(9A)-C(8A)-C(13A) 120.2(10) 
C(9A)-C(8A)-C(7A) 121.2(9) 
C(13A)-C(8A)-C(7A) 118.5(10) 
C(8A)-C(9A)-C(10A) 119.4(10) 
C(8A)-C(9A)-H(9A) 120.3 
C(10A)-C(9A)-H(9A) 120.3 
C(11A)-C(10A)-C(9A) 119.7(10) 
C(11A)-C(10A)-H(10A) 120.2 
C(9A)-C(10A)-H(10A) 120.2 
C(10A)-C(11A)-C(12A) 121.2(1
C(10A)-C(11A)-H(11A) 119.4 
C(12A)-C(11A)-H(11A) 119.4 
C(11A)-C(12A)-C(13A) 120.5(1
C(11A)-C(12A)-H(12A) 119.7 
C(13A)-C(12A)-H(12A) 119.7 
C(12A)-C(13A)-C(8A) 119.0(1
C(12A)-C(13A)-H(13A) 120.5 
C(8A)-C(13A)-H(13A) 120.5 
C(3A)-C(14A)-H(14A) 109.5 
C(3A)-C(14A)-H(14B) 109.5 
H(14A)-C(14A)-H(14B) 109.5 
C(3A)-C(14A)-H(14C) 109.5 
H(14A)-C(14A)-H(14C) 109.5 
H(14B)-C(14A)-H(14C) 109.5 
C(6B)-N(1B)-C(2B) 127.1(8
C(6B)-N(1B)-C(7B) 115.7(7
C(2B)-N(1B)-C(7B) 117.0(8) 
O(2B)-C(2B)-N(1B) 118.9(9) 
O(2B)-C(2B)-C(3B) 126.3(9) 
N(1B)-C(2B)-C(3B) 114.8(9) 
C(4B)-C(3B)-C(2B) 118.4(9) 
C(4B)-C(3B)-C(14B) 123.3(9) 
C(2B)-C(3B)-C(14B) 118.2(9) 
C(3B)-C(4B)-N(5B) 123.5(10) 
C(3B)-C(4B)-H(4B) 118.2 
N(5B)-C(4B)-H(4B) 118.2 
C(6B)-N(5B)-C(4B) 122.0(9) 
O(6B)-C(6B)-N(5B) 125.5(9) 
O(6B)-C(6B)-N(1B) 120.4(9) 
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) 
) 
) 
able 15.  Torsion angles [°] for 160.
N(5B)-C(6B)-N(1B) 114.1(9) 
O(7B)-C(7B)-C(8B) 125.6(9) 
O(7B)-C(7B)-N(1B) 120.7(9) 
C(8B)-C(7B)-N(1B) 113.8(9) 
C(9B)-C(8B)-C(13B) 119.7(10) 
C(9B)-C(8B)-C(7B) 118.5(10) 
C(13B)-C(8B)-C(7B) 121.8(10) 
C(8B)-C(9B)-C(10B) 120.4(10) 
C(8B)-C(9B)-H(9B) 119.8 
C(10B)-C(9B)-H(9B) 119.8 
C(11B)-C(10B)-C(9B) 119.3(11) 
C(11B)-C(10B)-H(10B) 120.4 
C(9B)-C(10B)-H(10B) 120.4 
C(12B)-C(11B)-C(10B) 120.0(11
C(12B)-C(11B)-H(11B) 120.0 
C(10B)-C(11B)-H(11B) 120.0 
C(13B)-C(12B)-C(11B) 121.0(11
C(13B)-C(12B)-H(12B) 119.5 
C(11B)-C(12B)-H(12B) 119.5 
C(12B)-C(13B)-C(8B) 119.6(10
C(12B)-C(13B)-H(13B) 120.2 
C(8B)-C(13B)-H(13B) 120.2 
C(3B)-C(14B)-H(14D) 109.5 
C(3B)-C(14B)-H(14E) 109.5 
H(14D)-C(14B)-H(14E) 109.5 
C(3B)-C(14B)-H(14F) 109.5 
H(14D)-C(14B)-H(14F) 109.5 
H(14E)-C(14B)-H(14F) 109.5
 
T  
(6A)-N(1A)-C(2A)-O(2A) -177.0(9) 
 
C
C(7A)-N(1A)-C(2A)-O(2A) -7.8(14) 
C(6A)-N(1A)-C(2A)-C(3A) 4.7(14) 
C(7A)-N(1A)-C(2A)-C(3A) 174.0(9) 
O(2A)-C(2A)-C(3A)-C(4A) -179.1(10) 
N(1A)-C(2A)-C(3A)-C(4A) -1.0(15) 
O(2A)-C(2A)-C(3A)-C(14A) 2.6(17) 
N(1A)-C(2A)-C(3A)-C(14A) -179.4(9) 
C(2A)-C(3A)-C(4A)-N(5A) -0.3(17) 
C(14A)-C(3A)-C(4A)-N(5A) 177.9(10) 
C(3A)-C(4A)-N(5A)-C(6A) -1.9(17) 
C(4A)-N(5A)-C(6A)-O(6A) -175.2(10) 
C(4A)-N(5A)-C(6A)-N(1A) 5.1(14) 
C(2A)-N(1A)-C(6A)-O(6A) 173.5(9) 
C(7A)-N(1A)-C(6A)-O(6A) 3.9(14) 
C(2A)-N(1A)-C(6A)-N(5A) -6.7(14) 
C(7A)-N(1A)-C(6A)-N(5A) -176.4(9) 
C(2A)-N(1A)-C(7A)-O(7A) 102.3(11) 
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C(6A)-N(1A)-C(7A)-O(7A)                             -87.5(12) 
C(2A)-N(1A)-C(7A)-C(8A)                             -76.3(11) 
C(6A)-N(1A)-C(7A)-C(8A)                               93.9(11) 
O(7A)-C(7A)-C(8A)-C(9A)                             172.4(10) 
N(1A)-C(7A)-C(8A)-C(9A)                                -9.2(14) 
O(7A)-C(7A)-C(8A)-C(13A)                              -7.4(16) 
N(1A)-C(7A)-C(8A)-C(13A)                              171.0(9) 
C(13A)-C(8A)-C(9A)-C(10A)                             -2.2(14) 
C(7A)-C(8A)-C(9A)-C(10A)                               178.0(9) 
C(8A)-C(9A)-C(10A)-C(11A)                               2.1(15) 
C(9A)-C(10A)-C(11A)-C(12A)                            -0.8(17) 
C(10A)-C(11A)-C(12A)-C(13A)                          -0.4(17) 
C(11A)-C(12A)-C(13A)-C(8A)                              0.2(16) 
C(9A)-C(8A)-C(13A)-C(12A)                                1.1(15) 
C(7A)-C(8A)-C(13A)-C(12A)                             -179.2(9) 
C(6B)-N(1B)-C(2B)-O(2B)                                  179.6(10) 
C(7B)-N(1B)-C(2B)-O(2B)                                      3.1(14) 
C(6B)-N(1B)-C(2B)-C(3B)                                       1.2(14) 
C(7B)-N(1B)-C(2B)-C(3B) -175.3(8) 
O(2B)-C(2B)-C(3B)-C(4B) 179.1(10) 
N(1B)-C(2B)-C(3B)-C(4B) -2.6(14) 
O(2B)-C(2B)-C(3B)-C(14B) -1.3(16) 
N(1B)-C(2B)-C(3B)-C(14B) 176.9(9) 
C(2B)-C(3B)-C(4B)-N(5B) 1.5(17) 
C(14B)-C(3B)-C(4B)-N(5B) -178.1(10) 
C(3B)-C(4B)-N(5B)-C(6B) 1.5(16) 
C(4B)-N(5B)-C(6B)-O(6B) 174.1(10) 
C(4B)-N(5B)-C(6B)-N(1B) -2.9(14) 
C(2B)-N(1B)-C(6B)-O(6B) -175.6(9) 
C(7B)-N(1B)-C(6B)-O(6B) 1.0(14) 
C(2B)-N(1B)-C(6B)-N(5B) 1.5(14) 
C(7B)-N(1B)-C(6B)-N(5B) 178.1(8) 
C(6B)-N(1B)-C(7B)-O(7B) 82.4(11) 
C(2B)-N(1B)-C(7B)-O(7B) -100.6(11) 
C(6B)-N(1B)-C(7B)-C(8B) -98.8(10) 
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ymmetry transformations used to generate equivalent atoms: 
C(2B)-N(1B)-C(7B)-C(8B) 78.1(10) 
O(7B)-C(7B)-C(8B)-C(9B) 15.0(15) 
N(1B)-C(7B)-C(8B)-C(9B) -163.6(9) 
O(7B)-C(7B)-C(8B)-C(13B) -164.4(10) 
N(1B)-C(7B)-C(8B)-C(13B) 17.0(13) 
C(13B)-C(8B)-C(9B)-C(10B) -2.7(15) 
C(7B)-C(8B)-C(9B)-C(10B) 177.9(9) 
C(8B)-C(9B)-C(10B)-C(11B) 1.6(16) 
C(9B)-C(10B)-C(11B)-C(12B) 1.1(16) 
C(10B)-C(11B)-C(12B)-C(13B) -2.7(16) 
C(11B)-C(12B)-C(13B)-C(8B) 1.6(15) 
C(9B)-C(8B)-C(13B)-C(12B) 1.1(14) 
C(7B)-C(8B)-C(13B)-C(12B) -179 
 
S  
onor --- H....Acceptor [    ARU  ]      D - H      H...A      D...A  D - H...A 
 
3
 
D
C(13B)--H(13B) ..O(2B)  [  -1/2+x,-y,z]     0.95       2.54  3.432(12)    156'
C(14B)--H(14F) ..O(7B)  [  -1/2+x,-y,z]       0.98       2.58  3.326(13)        13
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Appendices 
 
Appendix D. 161 crystal structure 
 
 
Data was collected by Dr Georgina Rosair on a Bruker X8 Apex 2 CCD single crystal 
diffractometer at 100 K. 
 
Table 16.  Crystal data and structure refinement for 161. 
 
Identification code  x82469o 
Empirical formula  C15 H12 N2 O3 
Formula weight  268.27 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pna2(1) 
Unit cell dimensions a = 11.656(2) Å α= 90°. 
 b = 12.237(2) Å β= 90°. 
 c = 9.2778(16) Å γ = 90°. 
Volume 1323.4(4) Å3 
Z 4 
Density (calculated) 1.346 Mg/m3 
Absorption coefficient 0.096 mm-1 
F(000) 560 
Crystal size 0.58 x 0.44 x 0.40 mm3 
Theta range for data collection 2.41 to 30.76°. 
Index ranges -16<=h<=16, -17<=k<=17, -13<=l<=13 
Reflections collected 29233 
Independent reflections 2173 [R(int) = 0.0360] 
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Completeness to theta = 25.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.962 and 0.863 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2173 / 1 / 182 
Goodness-of-fit on F2 1.106 
Final R indices [I>2sigma(I)] R1 = 0.0444, wR2 = 0.1176 
R indices (all data) R1 = 0.0543, wR2 = 0.1234 
Largest diff. peak and hole 0.333 and -0.185 e.Å-3 
 
Table 17.   Bond lengths [Å] and angles [°] for 161. 
 
C(1)-O(1)  1.232(3) 
C(1)-N(2)  1.412(3) 
C(1)-C(6)  1.446(3) 
N(2)-C(3)  1.385(3) 
N(2)-C(7)  1.476(3) 
C(3)-O(3)  1.223(3) 
C(3)-N(4)  1.375(3) 
N(4)-C(5)  1.376(3) 
N(4)-C(14)  1.470(3) 
C(5)-C(6)  1.343(3) 
C(5)-H(5)  0.9500 
C(6)-C(17)  1.503(3) 
C(7)-O(7)  1.205(3) 
C(7)-C(8)  1.465(3) 
C(8)-C(9)  1.395(3) 
C(8)-C(13)  1.412(3) 
C(9)-C(10)  1.386(3) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.385(4) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.391(4) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.379(4) 
C(12)-H(12)  0.9500 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.471(4) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-C(16)  1.179(4) 
C(16)-H(16)  0.9500 
C(17)-H(17A)  0.9800 
C(17)-H(17B)  0.9800 
C(17)-H(17C)  0.9800 
O(1)-C(1)-N(2) 118.9(2) 
O(1)-C(1)-C(6) 126.4(2) 
N(2)-C(1)-C(6) 114.74(19) 
C(3)-N(2)-C(1) 126.54(18) 
C(3)-N(2)-C(7) 116.07(18) 
C(1)-N(2)-C(7) 117.29(19) 
O(3)-C(3)-N(4) 123.8(2) 
O(3)-C(3)-N(2) 122.0(2) 
N(4)-C(3)-N(2) 114.24(18) 
C(3)-N(4)-C(5) 122.02(19) 
C(3)-N(4)-C(14) 117.97(19) 
C(5)-N(4)-C(14) 120.0(2) 
C(6)-C(5)-N(4) 123.6(2) 
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C(6)-C(5)-H(5) 118.2 
N(4)-C(5)-H(5) 118.2 
C(5)-C(6)-C(1) 118.32(19) 
C(5)-C(6)-C(17) 122.9(2) 
C(1)-C(6)-C(17) 118.8(2) 
O(7)-C(7)-C(8) 125.6(2) 
O(7)-C(7)-N(2) 118.4(2) 
C(8)-C(7)-N(2) 115.92(18) 
C(9)-C(8)-C(13) 119.8(2) 
C(9)-C(8)-C(7) 122.1(2) 
C(13)-C(8)-C(7) 118.1(2) 
C(10)-C(9)-C(8) 119.5(2) 
C(10)-C(9)-H(9) 120.2 
C(8)-C(9)-H(9) 120.2 
C(11)-C(10)-C(9) 120.3(2) 
C(11)-C(10)-H(10) 119.9 
C(9)-C(10)-H(10) 119.9 
C(10)-C(11)-C(12) 120.7(2) 
C(10)-C(11)-H(11) 119.6 
C(12)-C(11)-H(11) 119.6 
C(13)-C(12)-C(11) 119.6(2) 
C(13)-C(12)-H(12) 120.2 
C(11)-C(12)-H(12) 120.2 
C(12)-C(13)-C(8) 120.0(2) 
C(12)-C(13)-H(13) 120.0 
C(8)-C(13)-H(13) 120.0 
N(4)-C(14)-C(15) 112.68(18) 
N(4)-C(14)-H(14A) 109.1 
C(15)-C(14)-H(14A) 109.1 
N(4)-C(14)-H(14B) 109.1 
C(15)-C(14)-H(14B) 109.1 
H(14A)-C(14)-H(14B) 107.8 
C(16)-C(15)-C(14) 179.3(3) 
C(15)-C(16)-H(16) 180.0 
C(6)-C(17)-H(17A) 109.5 
C(6)-C(17)-H(17B) 109.5 
H(17A)-C(17)-H(17B) 109.5 
C(6)-C(17)-H(17C) 109.5 
H(17A)-C(17)-H(17C) 109.5 
H(17B)-C(17)-H(17C) 109.5 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
 
Table 18.  Torsion angles [°] for 161. 
 
O(1)-C(1)-N(2)-C(3) -176.24(19) 
C(6)-C(1)-N(2)-C(3) 4.0(3) 
O(1)-C(1)-N(2)-C(7) 0.0(3) 
C(6)-C(1)-N(2)-C(7) -179.74(18) 
C(1)-N(2)-C(3)-O(3) -178.6(2) 
C(7)-N(2)-C(3)-O(3) 5.1(3) 
C(1)-N(2)-C(3)-N(4) 2.5(3) 
C(7)-N(2)-C(3)-N(4) -173.76(18) 
O(3)-C(3)-N(4)-C(5) 174.3(2) 
N(2)-C(3)-N(4)-C(5) -6.9(3) 
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O(3)-C(3)-N(4)-C(14) -5.2(3) 
N(2)-C(3)-N(4)-C(14) 173.64(18) 
C(3)-N(4)-C(5)-C(6) 4.6(3) 
C(14)-N(4)-C(5)-C(6) -175.9(2) 
N(4)-C(5)-C(6)-C(1) 2.6(3) 
N(4)-C(5)-C(6)-C(17) -178.7(2) 
O(1)-C(1)-C(6)-C(5) 173.9(2) 
N(2)-C(1)-C(6)-C(5) -6.4(3) 
O(1)-C(1)-C(6)-C(17) -4.9(3) 
N(2)-C(1)-C(6)-C(17) 174.8(2) 
C(3)-N(2)-C(7)-O(7) 86.3(3) 
C(1)-N(2)-C(7)-O(7) -90.3(3) 
C(3)-N(2)-C(7)-C(8) -94.6(2) 
C(1)-N(2)-C(7)-C(8) 88.7(2) 
O(7)-C(7)-C(8)-C(9) 178.4(2) 
N(2)-C(7)-C(8)-C(9) -0.6(3) 
O(7)-C(7)-C(8)-C(13) -0.5(4) 
N(2)-C(7)-C(8)-C(13) -179.5(2) 
C(13)-C(8)-C(9)-C(10) 1.3(3) 
C(7)-C(8)-C(9)-C(10) -177.5(2) 
C(8)-C(9)-C(10)-C(11) -2.1(4) 
C(9)-C(10)-C(11)-C(12) 1.3(5) 
C(10)-C(11)-C(12)-C(13) 0.3(5) 
C(11)-C(12)-C(13)-C(8) -1.0(4) 
C(9)-C(8)-C(13)-C(12) 0.2(4) 
C(7)-C(8)-C(13)-C(12) 179.1(2) 
C(3)-N(4)-C(14)-C(15) 82.2(3) 
C(5)-N(4)-C(14)-C(15) -97.3(3) 
N(4)-C(14)-C(15)-C(16)                                       -132(27) 
  
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Appendix E. 174 crystal structure 
 
Displacement ellipsoids drawn at the 50% probability level 
 
Data was collected by Dr Georgina Rosair on a Bruker X8 Apex 2 CCD single crystal 
diffractometer at 100 K. 
 
Table 19.  Crystal data and structure refinement for 174. 
 
Identification code  x82673 
Empirical formula  C7 H7 N3 O 
Formula weight  149.16 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 5.3400(11) Å α= 90°. 
 b = 17.674(4) Å β= 97.46(3)°. 
 c = 6.9390(14) Å γ = 90°. 
Volume 649.3(2) Å3 
Z 4 
Density (calculated) 1.526 Mg/m3 
Absorption coefficient 0.109 mm-1 
F(000) 312 
Crystal size 0.38 x 0.22 x 0.03 mm3 
Theta range for data collection 2.30 to 25.18°. 
Index ranges -6<=h<=6, 0<=k<=21, 0<=l<=8 
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Reflections collected 1169 
Independent reflections 1169 [R(int) = 0.0000] 
Completeness to theta = 25.00° 97.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.997 and 0.819 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1169 / 2 / 108 
Goodness-of-fit on F2 0.942 
Final R indices [I>2sigma(I)] R1 = 0.0824, wR2 = 0.2029 
R indices (all data) R1 = 0.1903, wR2 = 0.2799 
Largest diff. peak and hole 0.460 and -0.439 e.Å-3 
 
Table 20.   Bond lengths [Å] and angles [°] for  174. 
 
N(1)-C(6)  1.341(8) 
N(1)-C(2)  1.381(8) 
N(1)-C(7)  1.467(8) 
C(2)-O(2)  1.235(7) 
C(2)-N(3)  1.363(8) 
N(3)-C(4)  1.317(8) 
C(4)-N(4)  1.330(8) 
C(4)-C(5)  1.404(8) 
N(4)-H(41)  0.89(2) 
N(4)-H(42)  0.90(2) 
C(5)-C(6)  1.354(9) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
C(7)-C(8)  1.459(9) 
C(7)-H(7A)  0.9900 
C(7)-H(7B)  0.9900 
C(8)-C(9)  1.151(9) 
C(9)-H(9)  0.9500 
 
C(6)-N(1)-C(2) 119.3(5) 
C(6)-N(1)-C(7) 123.0(5) 
C(2)-N(1)-C(7) 117.7(5) 
O(2)-C(2)-N(3) 122.7(6) 
O(2)-C(2)-N(1) 118.2(6) 
N(3)-C(2)-N(1) 119.0(5) 
C(4)-N(3)-C(2) 121.0(5) 
N(3)-C(4)-N(4) 119.7(5) 
N(3)-C(4)-C(5) 121.2(6) 
N(4)-C(4)-C(5) 119.1(6) 
C(4)-N(4)-H(41) 116(4) 
C(4)-N(4)-H(42) 124(4) 
H(41)-N(4)-H(42) 118(6) 
C(6)-C(5)-C(4) 116.7(6) 
C(6)-C(5)-H(5) 121.6 
C(4)-C(5)-H(5) 121.6 
N(1)-C(6)-C(5) 122.6(5) 
N(1)-C(6)-H(6) 118.7 
C(5)-C(6)-H(6) 118.7 
C(8)-C(7)-N(1) 112.1(5) 
C(8)-C(7)-H(7A) 109.2 
N(1)-C(7)-H(7A) 109.2 
C(8)-C(7)-H(7B) 109.2 
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N(1)-C(7)-H(7B) 109.2 
H(7A)-C(7)-H(7B) 107.9 
C(9)-C(8)-C(7) 177.1(7) 
C(8)-C(9)-H(9) 180.0 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
  
Table 21.  Torsion angles [°] for 174. 
 
C(6)-N(1)-C(2)-O(2) 179.2(5) 
C(7)-N(1)-C(2)-O(2) 1.2(8) 
C(6)-N(1)-C(2)-N(3) 0.0(8) 
C(7)-N(1)-C(2)-N(3) -177.9(5) 
O(2)-C(2)-N(3)-C(4) 179.4(6) 
N(1)-C(2)-N(3)-C(4) -1.4(8) 
C(2)-N(3)-C(4)-N(4) -179.4(5) 
C(2)-N(3)-C(4)-C(5) 0.2(8) 
N(3)-C(4)-C(5)-C(6) 2.4(9) 
N(4)-C(4)-C(5)-C(6) -178.0(6) 
C(2)-N(1)-C(6)-C(5) 2.8(9) 
C(7)-N(1)-C(6)-C(5) -179.4(6) 
C(4)-C(5)-C(6)-N(1) -4.0(9) 
C(6)-N(1)-C(7)-C(8) 16.4(8) 
C(2)-N(1)-C(7)-C(8) -165.8(5) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
  
Table 22.  Hydrogen bonds for 174  [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
______________________________________________________________________  
 N(4)-H(41)...O(2)#1 0.89(2) 2.05(3) 2.924(7) 166(6) 
 N(4)-H(42)...N(3)#2 0.90(2) 2.08(3) 2.946(7) 162(6) 
______________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x,y,z-1    #2 -x+3,-y+1,-z+1       
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Appendix F. 166 crystal structure 
 
 
 
Displacement ellipsoids drawn at the 50% probability level 
 
Data was collected by Dr Georgina Rosair on a Bruker X8 Apex 2 CCD single crystal 
diffractometer at 100 K. 
 
Table 23.  Crystal data and structure refinement for 166 
 
Identification code  2009src0266 
Empirical formula  C14 H11 N3 O2 
Formula weight  253.26 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
Unit cell dimensions a = 12.8138(3) Å α= 90°. 
 b = 6.0048(2) Å β= 90.599(2)°. 
 c = 15.2212(4) Å γ = 90°. 
Volume 1171.12(6) Å3 
Z 4 
Density (calculated) 1.436 Mg/m3 
Absorption coefficient 0.100 mm-1 
F(000) 528 
Crystal size 0.21 x 0.1 x 0.03 mm3 
Theta range for data collection 3.18 to 27.48°. 
Index ranges -16<=h<=16, -7<=k<=6, -19<=l<=17 
Reflections collected 14858 
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Independent reflections 2669 [R(int) = 0.0504] 
Completeness to theta = 25.00° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.997 and 0.721 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2669 / 0 / 175 
en Goodness-of-fit on F2 1.118 
Final R indices [I>2sigma(I)] R1 = 0.0593, wR2 = 0.1063 
R indices (all data) R1 = 0.0830, wR2 = 0.1187 
Largest diff. peak and hole 0.264 and -0.270 e.Å-3 
 
Table 24.   Bond lengths [Å] and angles [°] for  166. 
 
N(1)-C(6)  1.352(3) 
N(1)-C(2)  1.400(3) 
N(1)-C(14)  1.483(3) 
C(2)-O(2)  1.239(2) 
C(2)-N(3)  1.366(3) 
N(3)-C(4)  1.326(2) 
C(4)-N(4)  1.392(3) 
C(4)-C(5)  1.410(3) 
N(4)-C(7)  1.388(2) 
N(4)-H(4N)  0.87(3) 
C(5)-C(6)  1.353(3) 
C(5)-H(5)  0.9500 
C(6)-H(6)  0.9500 
C(7)-O(7)  1.220(2) 
C(7)-C(8)  1.491(3) 
C(8)-C(9)  1.391(3) 
C(8)-C(13)  1.399(3) 
C(9)-C(10)  1.388(3) 
C(9)-H(9)  0.9500 
C(10)-C(11)  1.379(3) 
C(10)-H(10)  0.9500 
C(11)-C(12)  1.379(4) 
C(11)-H(11)  0.9500 
C(12)-C(13)  1.384(3) 
C(12)-H(12)  0.9500 
C(13)-H(13)  0.9500 
C(14)-C(15)  1.463(3) 
C(14)-H(14A)  0.9900 
C(14)-H(14B)  0.9900 
C(15)-C(16)  1.186(3) 
C(16)-H(16)  0.9500 
C(6)-N(1)-C(2) 120.99(18) 
C(6)-N(1)-C(14) 118.82(18) 
C(2)-N(1)-C(14) 120.14(17) 
O(2)-C(2)-N(3) 122.1(2) 
O(2)-C(2)-N(1) 120.04(19) 
N(3)-C(2)-N(1) 117.87(17) 
C(4)-N(3)-C(2) 120.08(18) 
N(3)-C(4)-N(4) 113.74(18) 
N(3)-C(4)-C(5) 123.18(19) 
N(4)-C(4)-C(5) 123.06(18) 
C(7)-N(4)-C(4) 126.80(18) 
C(7)-N(4)-H(4N) 118.7(16) 
C(4)-N(4)-H(4N) 114.3(16) 
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C(6)-C(5)-C(4) 116.22(19) 
C(6)-C(5)-H(5) 121.9 
C(4)-C(5)-H(5) 121.9 
N(1)-C(6)-C(5) 121.6(2) 
N(1)-C(6)-H(6) 119.2 
C(5)-C(6)-H(6) 119.2 
O(7)-C(7)-N(4) 122.0(2) 
O(7)-C(7)-C(8) 121.10(18) 
N(4)-C(7)-C(8) 116.90(18) 
C(9)-C(8)-C(13) 119.0(2) 
C(9)-C(8)-C(7) 124.60(19) 
C(13)-C(8)-C(7) 116.38(19) 
C(10)-C(9)-C(8) 119.9(2) 
C(10)-C(9)-H(9) 120.0 
C(8)-C(9)-H(9) 120.0 
C(11)-C(10)-C(9) 120.5(2) 
C(11)-C(10)-H(10) 119.7 
C(9)-C(10)-H(10) 119.7 
C(10)-C(11)-C(12) 120.1(2) 
C(10)-C(11)-H(11) 119.9 
C(12)-C(11)-H(11) 119.9 
C(11)-C(12)-C(13) 119.9(2) 
C(11)-C(12)-H(12) 120.0 
C(13)-C(12)-H(12) 120.0 
C(12)-C(13)-C(8) 120.5(2) 
C(12)-C(13)-H(13) 119.8 
C(8)-C(13)-H(13) 119.8 
C(15)-C(14)-N(1) 112.24(17) 
C(15)-C(14)-H(14A) 109.2 
N(1)-C(14)-H(14A) 109.2 
C(15)-C(14)-H(14B) 109.2 
N(1)-C(14)-H(14B) 109.2 
H(14A)-C(14)-H(14B) 107.9 
C(16)-C(15)-C(14) 177.5(2) 
C(15)-C(16)-H(16) 180.0 
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_________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
  
Table 25.  Torsion angles [°] for 166 
 
C(6)-N(1)-C(2)-O(2) 179.44(19) 
C(14)-N(1)-C(2)-O(2) -3.2(3) 
C(6)-N(1)-C(2)-N(3) -0.5(3) 
C(14)-N(1)-C(2)-N(3) 176.89(18) 
O(2)-C(2)-N(3)-C(4) 179.47(19) 
N(1)-C(2)-N(3)-C(4) -0.6(3) 
C(2)-N(3)-C(4)-N(4) -176.44(18) 
C(2)-N(3)-C(4)-C(5) 1.7(3) 
N(3)-C(4)-N(4)-C(7) -167.77(19) 
C(5)-C(4)-N(4)-C(7) 14.1(3) 
N(3)-C(4)-C(5)-C(6) -1.7(3) 
N(4)-C(4)-C(5)-C(6) 176.3(2) 
C(2)-N(1)-C(6)-C(5) 0.5(3) 
C(14)-N(1)-C(6)-C(5) -177.0(2) 
C(4)-C(5)-C(6)-N(1) 0.6(3) 
C(4)-N(4)-C(7)-O(7) 0.8(3) 
C(4)-N(4)-C(7)-C(8) -179.44(19) 
O(7)-C(7)-C(8)-C(9) 171.7(2) 
N(4)-C(7)-C(8)-C(9) -8.1(3) 
O(7)-C(7)-C(8)-C(13) -6.5(3) 
N(4)-C(7)-C(8)-C(13) 173.73(19) 
C(13)-C(8)-C(9)-C(10) 1.0(3) 
C(7)-C(8)-C(9)-C(10) -177.1(2) 
C(8)-C(9)-C(10)-C(11) -0.3(3) 
C(9)-C(10)-C(11)-C(12) -0.6(4) 
C(10)-C(11)-C(12)-C(13) 0.7(4) 
C(11)-C(12)-C(13)-C(8) 0.1(3) 
C(9)-C(8)-C(13)-C(12) -0.9(3) 
C(7)-C(8)-C(13)-C(12) 177.4(2) 
C(6)-N(1)-C(14)-C(15) -61.5(3) 
C(2)-N(1)-C(14)-C(15) 121.1(2) 
________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
  
Table 26.  Hydrogen bonds for 166  [Å and °]. 
______________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
______________________________________________________________________  
 N(4)-H(4N)...O(2)#1 0.87(3) 2.21(3) 3.056(2) 164(2) 
______________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
  
. 
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Appendices 
 
Appendix G. 175 crystal structure. 
 
The Alkyne group is anti rather than syn to the fused ring system. There is a water 
solvent molecule which engages in hydrogen bonding with N8 and with another water 
molecule generated by symmetry. There is one water molecule per organic molecule. 
 
Data was collected by Dr Georgina Rosair on a Bruker X8 Apex 2 CCD single crystal 
diffractometer at 100 K. 
 
Table 27.  Crystal data and structure refinement for 175. 
 
Identification code  x82526 LT304 
Empirical formula  C8 H9 N5 O 
Formula weight  191.20 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 6.826(2) Å α= 90°. 
 b = 26.976(9) Å β= 96.104(14)°. 
 c = 4.8221(15) Å γ = 90°. 
Volume 882.9(5) Å3 
Z 4 
Density (calculated) 1.438 Mg/m3 
Absorption coefficient 0.103 mm-1 
F(000) 400 
Crystal size 0.38 x 0.08 x 0.06 mm3 
Theta range for data collection 3.00 to 24.82°. 
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Index ranges -8<=h<=7, -31<=k<=31, -5<=l<=5 
Reflections collected 13197 
Independent reflections 1520 [R(int) = 0.0572] 
Completeness to theta = 24.82° 99.3 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9938 and 0.9618 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1520 / 6 / 139 
Goodness-of-fit on F2 1.040 
Final R indices [I>2sigma(I)] R1 = 0.0541, wR2 = 0.1217 
R indices (all data) R1 = 0.0873, wR2 = 0.1371 
Largest diff. peak and hole 0.438 and -0.203 e.Å-3 
 
Table 28.   Bond lengths [Å] and angles [°] for 175. 
 
N(1)-C(9)  1.362(4) 
N(1)-C(2)  1.369(4) 
N(1)-C(10)  1.455(4) 
C(2)-N(3)  1.315(4) 
C(2)-H(2)  0.9500 
N(3)-C(4)  1.379(4) 
C(4)-C(9)  1.395(4) 
C(4)-C(5)  1.399(4) 
C(5)-N(5)  1.335(4) 
C(5)-N(6)  1.380(4) 
N(5)-H(51)  0.903(17) 
N(5)-H(52)  0.887(17) 
N(6)-C(7)  1.322(4) 
C(7)-N(8)  1.345(4) 
C(7)-H(7)  0.9500 
N(8)-C(9)  1.346(4) 
C(10)-C(11)  1.472(4) 
C(10)-H(10A)  0.9900 
C(10)-H(10B)  0.9900 
C(11)-C(12)  1.169(4) 
C(12)-H(12)  0.9500 
O(1)-H(11W)  0.903(17) 
O(1)-H(12W)  0.881(17) 
C(9)-N(1)-C(2) 106.4(2) 
C(9)-N(1)-C(10) 124.8(2) 
C(2)-N(1)-C(10) 128.5(2) 
N(3)-C(2)-N(1) 114.0(3) 
N(3)-C(2)-H(2) 123.0 
N(1)-C(2)-H(2) 123.0 
C(2)-N(3)-C(4) 103.2(2) 
N(3)-C(4)-C(9) 111.4(3) 
N(3)-C(4)-C(5) 132.1(3) 
C(9)-C(4)-C(5) 116.5(3) 
N(5)-C(5)-N(6) 120.3(3) 
N(5)-C(5)-C(4) 122.5(3) 
N(6)-C(5)-C(4) 117.2(3) 
C(5)-N(5)-H(51) 119.4(18) 
C(5)-N(5)-H(52) 120.2(19) 
H(51)-N(5)-H(52) 120(3) 
C(7)-N(6)-C(5) 119.3(2) 
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N(6)-C(7)-N(8) 129.0(3) 
N(6)-C(7)-H(7) 115.5 
N(8)-C(7)-H(7) 115.5 
C(7)-N(8)-C(9) 110.2(3) 
N(8)-C(9)-N(1) 127.2(3) 
N(8)-C(9)-C(4) 127.8(3) 
N(1)-C(9)-C(4) 105.0(2) 
N(1)-C(10)-C(11) 111.7(2) 
N(1)-C(10)-H(10A) 109.3 
C(11)-C(10)-H(10A) 109.3 
N(1)-C(10)-H(10B) 109.3 
C(11)-C(10)-H(10B) 109.3 
H(10A)-C(10)-H(10B) 107.9 
C(12)-C(11)-C(10) 178.0(3) 
C(11)-C(12)-H(12) 180.0 
H(11W)-O(1)-H(12W) 110(3) 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
 
Table 29.  Torsion angles [°] for 175. 
 
C(9)-N(1)-C(2)-N(3)  1.4(3) 
C(10)-N(1)-C(2)-N(3) 175.5(2) 
N(1)-C(2)-N(3)-C(4)  -1.0(3) 
C(2)-N(3)-C(4)-C(9)  0.2(3) 
C(2)-N(3)-C(4)-C(5)  -177.2(3) 
N(3)-C(4)-C(5)-N(5)  -2.6(5) 
C(9)-C(4)-C(5)-N(5)  -179.9(3) 
N(3)-C(4)-C(5)-N(6)  176.4(3) 
C(9)-C(4)-C(5)-N(6)  -0.9(4) 
N(5)-C(5)-N(6)-C(7)  -179.6(2) 
C(4)-C(5)-N(6)-C(7)  1.3(4) 
C(5)-N(6)-C(7)-N(8)  -0.9(4) 
N(6)-C(7)-N(8)-C(9)  -0.1(4) 
C(7)-N(8)-C(9)-N(1)  -177.7(3) 
C(7)-N(8)-C(9)-C(4)  0.7(4) 
C(2)-N(1)-C(9)-N(8)  177.5(3) 
C(10)-N(1)-C(9)-N(8)  3.1(4) 
C(2)-N(1)-C(9)-C(4)  -1.1(3) 
C(10)-N(1)-C(9)-C(4)  -175.5(2) 
N(3)-C(4)-C(9)-N(8)  -178.0(2) 
C(5)-C(4)-C(9)-N(8)  -0.2(4) 
N(3)-C(4)-C(9)-N(1)  0.6(3) 
C(5)-C(4)-C(9)-N(1)  178.4(2) 
C(9)-N(1)-C(10)-C(11)  -175.1(2) 
C(2)-N(1)-C(10)-C(11)  11.8(4) 
N(1)-C(10)-C(11)-C(12)  -107(10) 
________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
 
Table 30.  Hydrogen bonds for 175 [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
_________________________________________________________________ 
 N(5)-H(51)...N(3)#1 0.903(17) 2.20(2) 3.065(3) 161(3) 
 N(5)-H(52)...N(6)#2 0.887(17) 2.131(18) 3.014(3) 173(3) 
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 O(1)-H(11W)...N(8) 0.903(17) 1.941(18) 2.837(3) 171(3) 
 O(1)-H(12W)...O(1)#3 0.881(17) 1.861(18) 2.741(2) 176(3) 
 
Symmetry transformations used to generate equivalent atoms:  
#1 -x,-y+1,-z+1    #2 -x+1,-y+1,-z    #3 x,-y+3/2,z+1/2      
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Appendix H. 176 crystal structure 
 
 
There are two molecules in the asymmetric unit. They differ by the orientation of the 
adenine ring system with respect to the carbonyl. 
 
Data was collected by Dr Georgina Rosair on a Bruker X8 Apex 2 CCD single crystal 
diffractometer at 100 K. 
 
Table 31.  Crystal data and structure refinement for 176. 
 
Identification code  x82562_0m 
Empirical formula  C15 H11 N5 O 
Formula weight  277.29 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.2899(6) Å α= 78.615(3)°. 
 b = 12.2253(10) Å β= 77.172(4)°. 
 c = 13.6802(11) Å γ = 75.627(4)°. 
Volume 1294.58(18) Å3 
Z 4 
Density (calculated) 1.423 Mg/m3 
Absorption coefficient 0.096 mm-1 
F(000) 576 
Crystal size 0.62 x 0.35 x 0.04 mm3 
Theta range for data collection 2.58 to 29.10°. 
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Index ranges -10<=h<=8, -16<=k<=15, -18<=l<=16 
Reflections collected 17848 
Independent reflections 5488 [R(int) = 0.0528] 
Completeness to theta = 25.00° 94.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9962 and 0.7464 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5488 / 0 / 387 
Goodness-of-fit on F2 0.980 
Final R indices [I>2sigma(I)] R1 = 0.0516, wR2 = 0.0984 
R indices (all data) R1 = 0.1473, wR2 = 0.1285 
Largest diff. peak and hole 0.273 and -0.307 e.Å-3 
 
Table 32. Bond lengths [Å] and angles [°] for 176. 
 
N(1A)-C(9A)  1.377(3) 
N(1A)-C(2A)  1.380(3) 
N(1A)-C(19A)  1.465(3) 
C(2A)-N(3A)  1.316(3) 
C(2A)-H(2A)  0.9500 
N(3A)-C(4A)  1.392(3) 
C(4A)-C(9A)  1.383(3) 
C(4A)-C(5A)  1.393(3) 
C(5A)-N(6A)  1.338(3) 
C(5A)-N(10A)  1.388(3) 
N(6A)-C(7A)  1.351(3) 
C(7A)-N(8A)  1.338(3) 
C(7A)-H(7A)  0.9500 
N(8A)-C(9A)  1.337(3) 
N(10A)-C(11A)  1.377(3) 
N(10A)-H(10A)  0.85(3) 
C(11A)-O(18A)  1.218(3) 
C(11A)-C(12A)  1.492(3) 
C(12A)-C(13A)  1.387(3) 
C(12A)-C(17A)  1.392(3) 
C(13A)-C(14A)  1.384(3) 
C(13A)-H(13A)  0.9500 
C(14A)-C(15A)  1.382(4) 
C(14A)-H(14A)  0.9500 
C(15A)-C(16A)  1.379(3) 
C(15A)-H(15A)  0.9500 
C(16A)-C(17A)  1.384(4) 
C(16A)-H(16A)  0.9500 
C(17A)-H(17A)  0.9500 
O(18B)-C(11B)  1.226(3) 
C(19A)-C(20A)  1.462(4) 
C(19A)-H(19A)  0.9900 
C(19A)-H(19B)  0.9900 
C(20A)-C(21A)  1.184(4) 
C(21A)-H(21A)  0.9500 
N(1B)-C(9B)  1.369(3) 
N(1B)-C(2B)  1.371(3) 
N(1B)-C(19B)  1.468(3) 
C(2B)-N(3B)  1.315(3) 
C(2B)-H(2B)  0.9500 
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N(3B)-C(4B)  1.396(3) 
C(4B)-C(9B)  1.391(3) 
C(4B)-C(5B)  1.394(3) 
C(5B)-N(6B)  1.349(3) 
C(5B)-N(10B)  1.385(3) 
N(6B)-C(7B)  1.346(3) 
C(7B)-N(8B)  1.334(3) 
C(7B)-H(7B)  0.9500 
N(8B)-C(9B)  1.348(3) 
N(10B)-C(11B)  1.386(3) 
N(10B)-H(10B)  0.89(3) 
C(11B)-C(12B)  1.484(3) 
C(12B)-C(17B)  1.396(3) 
C(12B)-C(13B)  1.398(3) 
C(13B)-C(14B)  1.381(4) 
C(13B)-H(13B)  0.9500 
C(14B)-C(15B)  1.381(3) 
C(14B)-H(14B)  0.9500 
C(15B)-C(16B)  1.388(4) 
C(15B)-H(15B)  0.9500 
C(16B)-C(17B)  1.387(3) 
C(16B)-H(16B)  0.9500 
C(17B)-H(17B)  0.9500 
C(19B)-C(20B)  1.469(4) 
C(19B)-H(19C)  0.9900 
C(19B)-H(19D)  0.9900 
C(20B)-C(21B)  1.179(3) 
C(21B)-H(21B)  0.9500 
C(9A)-N(1A)-C(2A) 105.3(2) 
C(9A)-N(1A)-C(19A) 126.2(2) 
C(2A)-N(1A)-C(19A) 128.1(2) 
N(3A)-C(2A)-N(1A) 114.2(2) 
N(3A)-C(2A)-H(2A) 122.9 
N(1A)-C(2A)-H(2A) 122.9 
C(2A)-N(3A)-C(4A) 103.29(19) 
C(9A)-C(4A)-N(3A) 111.1(2) 
C(9A)-C(4A)-C(5A) 117.2(2) 
N(3A)-C(4A)-C(5A) 131.7(2) 
N(6A)-C(5A)-N(10A) 122.0(2) 
N(6A)-C(5A)-C(4A) 119.2(2) 
N(10A)-C(5A)-C(4A) 118.7(2) 
C(5A)-N(6A)-C(7A) 117.2(2) 
N(8A)-C(7A)-N(6A) 129.2(2) 
N(8A)-C(7A)-H(7A) 115.4 
N(6A)-C(7A)-H(7A) 115.4 
C(9A)-N(8A)-C(7A) 111.0(2) 
N(8A)-C(9A)-N(1A) 127.8(2) 
N(8A)-C(9A)-C(4A) 126.2(2) 
N(1A)-C(9A)-C(4A) 106.0(2) 
C(11A)-N(10A)-C(5A) 130.0(2) 
C(11A)-N(10A)-H(10A) 117.6(18) 
C(5A)-N(10A)-H(10A) 112.3(18) 
O(18A)-C(11A)-N(10A) 122.5(2) 
O(18A)-C(11A)-C(12A) 122.2(2) 
N(10A)-C(11A)-C(12A) 115.3(2) 
C(13A)-C(12A)-C(17A) 118.3(2) 
C(13A)-C(12A)-C(11A) 123.9(2) 
C(17A)-C(12A)-C(11A) 117.8(2) 
C(14A)-C(13A)-C(12A) 120.8(2) 
C(14A)-C(13A)-H(13A) 119.6 
C(12A)-C(13A)-H(13A) 119.6 
C(15A)-C(14A)-C(13A) 120.4(2) 
C(15A)-C(14A)-H(14A) 119.8 
C(13A)-C(14A)-H(14A) 119.8 
C(16A)-C(15A)-C(14A) 119.4(2) 
C(16A)-C(15A)-H(15A) 120.3 
C(14A)-C(15A)-H(15A) 120.3 
C(15A)-C(16A)-C(17A) 120.3(3) 
C(15A)-C(16A)-H(16A) 119.8 
C(17A)-C(16A)-H(16A) 119.8 
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C(16A)-C(17A)-C(12A) 120.8(2) 
C(16A)-C(17A)-H(17A) 119.6 
C(12A)-C(17A)-H(17A) 119.6 
C(20A)-C(19A)-N(1A) 114.6(2) 
C(20A)-C(19A)-H(19A) 108.6 
N(1A)-C(19A)-H(19A) 108.6 
C(20A)-C(19A)-H(19B) 108.6 
N(1A)-C(19A)-H(19B) 108.6 
H(19A)-C(19A)-H(19B) 107.6 
C(21A)-C(20A)-C(19A) 173.2(3) 
C(20A)-C(21A)-H(21A) 180.0 
C(9B)-N(1B)-C(2B) 105.91(19) 
C(9B)-N(1B)-C(19B) 126.3(2) 
C(2B)-N(1B)-C(19B) 127.76(19) 
N(3B)-C(2B)-N(1B) 114.2(2) 
N(3B)-C(2B)-H(2B) 122.9 
N(1B)-C(2B)-H(2B) 122.9 
C(2B)-N(3B)-C(4B) 103.4(2) 
C(9B)-C(4B)-C(5B) 116.2(2) 
C(9B)-C(4B)-N(3B) 110.5(2) 
C(5B)-C(4B)-N(3B) 133.2(2) 
N(6B)-C(5B)-N(10B) 117.3(2) 
N(6B)-C(5B)-C(4B) 118.9(2) 
N(10B)-C(5B)-C(4B) 123.8(2) 
C(7B)-N(6B)-C(5B) 118.2(2) 
N(8B)-C(7B)-N(6B) 129.0(2) 
N(8B)-C(7B)-H(7B) 115.5 
N(6B)-C(7B)-H(7B) 115.5 
C(7B)-N(8B)-C(9B) 110.5(2) 
N(8B)-C(9B)-N(1B) 126.9(2) 
N(8B)-C(9B)-C(4B) 127.1(2) 
N(1B)-C(9B)-C(4B) 106.0(2) 
C(5B)-N(10B)-C(11B) 123.4(2) 
C(5B)-N(10B)-H(10B) 114.8(17) 
C(11B)-N(10B)-H(10B) 117.1(16) 
O(18B)-C(11B)-N(10B) 122.5(2) 
O(18B)-C(11B)-C(12B) 122.4(2) 
N(10B)-C(11B)-C(12B) 115.1(2) 
C(17B)-C(12B)-C(13B) 119.1(2) 
C(17B)-C(12B)-C(11B) 118.8(2) 
C(13B)-C(12B)-C(11B) 121.9(2) 
C(14B)-C(13B)-C(12B) 119.9(2) 
C(14B)-C(13B)-H(13B) 120.1 
C(12B)-C(13B)-H(13B) 120.1 
C(13B)-C(14B)-C(15B) 120.6(2) 
C(13B)-C(14B)-H(14B) 119.7 
C(15B)-C(14B)-H(14B) 119.7 
C(14B)-C(15B)-C(16B) 120.4(2) 
C(14B)-C(15B)-H(15B) 119.8 
C(16B)-C(15B)-H(15B) 119.8 
C(17B)-C(16B)-C(15B) 119.3(2) 
C(17B)-C(16B)-H(16B) 120.4 
C(15B)-C(16B)-H(16B) 120.4 
C(16B)-C(17B)-C(12B) 120.8(2) 
C(16B)-C(17B)-H(17B) 119.6 
C(12B)-C(17B)-H(17B) 119.6 
N(1B)-C(19B)-C(20B) 112.1(2) 
N(1B)-C(19B)-H(19C) 109.2 
C(20B)-C(19B)-H(19C) 109.2 
N(1B)-C(19B)-H(19D) 109.2 
C(20B)-C(19B)-H(19D) 109.2 
H(19C)-C(19B)-H(19D) 107.9 
C(21B)-C(20B)-C(19B) 179.5(3) 
C(20B)-C(21B)-H(21B) 180.0 
_____________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
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Table 33.  Torsion angles [°] for 176. 
 
C(9A)-N(1A)-C(2A)-N(3A)  -0.5(3) 
C(19A)-N(1A)-C(2A)-N(3A)  -174.3(2) 
N(1A)-C(2A)-N(3A)-C(4A)  0.6(3) 
C(2A)-N(3A)-C(4A)-C(9A)  -0.5(3) 
C(2A)-N(3A)-C(4A)-C(5A)  177.3(3) 
C(9A)-C(4A)-C(5A)-N(6A)  -2.4(3) 
N(3A)-C(4A)-C(5A)-N(6A)  179.8(2) 
C(9A)-C(4A)-C(5A)-N(10A)  176.8(2) 
N(3A)-C(4A)-C(5A)-N(10A)  -0.9(4) 
N(10A)-C(5A)-N(6A)-C(7A)  -177.8(2) 
C(4A)-C(5A)-N(6A)-C(7A)  1.5(3) 
C(5A)-N(6A)-C(7A)-N(8A)  0.4(4) 
N(6A)-C(7A)-N(8A)-C(9A)  -1.1(4) 
C(7A)-N(8A)-C(9A)-N(1A)  179.6(2) 
C(7A)-N(8A)-C(9A)-C(4A)  -0.1(3) 
C(2A)-N(1A)-C(9A)-N(8A)  -179.6(2) 
C(19A)-N(1A)-C(9A)-N(8A)  -5.7(4) 
C(2A)-N(1A)-C(9A)-C(4A)  0.1(3) 
C(19A)-N(1A)-C(9A)-C(4A)  174.1(2) 
N(3A)-C(4A)-C(9A)-N(8A)  180.0(2) 
C(5A)-C(4A)-C(9A)-N(8A)  1.8(4) 
N(3A)-C(4A)-C(9A)-N(1A)  0.2(3) 
C(5A)-C(4A)-C(9A)-N(1A)  -178.0(2) 
N(6A)-C(5A)-N(10A)-C(11A)  -9.0(4) 
C(4A)-C(5A)-N(10A)-C(11A)  171.7(2) 
C(5A)-N(10A)-C(11A)-O(18A)  4.4(4) 
C(5A)-N(10A)-C(11A)-C(12A)   
-175.9(2) 
O(18A)-C(11A)-C(12A)-C(13A)   
-169.8(2) 
N(10A)-C(11A)-C(12A)-C(13A)  
10.4(3) 
O(18A)-C(11A)-C(12A)-C(17A)  9.1(3) 
N(10A)-C(11A)-C(12A)-C(17A)  
-170.7(2) 
C(17A)-C(12A)-C(13A)-C(14A)  1.7(4) 
C(11A)-C(12A)-C(13A)-C(14A)  
-179.5(2) 
C(12A)-C(13A)-C(14A)-C(15A)  -0.6(4) 
C(13A)-C(14A)-C(15A)-C(16A)  -0.5(4) 
C(14A)-C(15A)-C(16A)-C(17A)  0.6(4) 
C(15A)-C(16A)-C(17A)-C(12A)  0.5(4) 
C(13A)-C(12A)-C(17A)-C(16A)  -1.6(4) 
C(11A)-C(12A)-C(17A)-C(16A)  
179.5(2) 
C(9A)-N(1A)-C(19A)-C(20A)  120.0(3) 
C(2A)-N(1A)-C(19A)-C(20A)  -67.4(3) 
C(9B)-N(1B)-C(2B)-N(3B)  -0.2(3) 
C(19B)-N(1B)-C(2B)-N(3B)  177.5(2) 
N(1B)-C(2B)-N(3B)-C(4B)  0.7(3) 
C(2B)-N(3B)-C(4B)-C(9B)  -1.0(3) 
C(2B)-N(3B)-C(4B)-C(5B)  -178.2(3) 
C(9B)-C(4B)-C(5B)-N(6B)  -0.1(3) 
N(3B)-C(4B)-C(5B)-N(6B)  177.1(2) 
C(9B)-C(4B)-C(5B)-N(10B)  -177.7(2) 
N(3B)-C(4B)-C(5B)-N(10B)  -0.6(4) 
N(10B)-C(5B)-N(6B)-C(7B)  177.5(2) 
C(4B)-C(5B)-N(6B)-C(7B)  -0.3(3) 
C(5B)-N(6B)-C(7B)-N(8B)  1.1(4) 
N(6B)-C(7B)-N(8B)-C(9B)  -1.4(4) 
C(7B)-N(8B)-C(9B)-N(1B)  -177.9(2) 
C(7B)-N(8B)-C(9B)-C(4B)  0.9(3) 
C(2B)-N(1B)-C(9B)-N(8B)  178.5(2) 
C(19B)-N(1B)-C(9B)-N(8B)  0.8(4) 
C(2B)-N(1B)-C(9B)-C(4B)  -0.5(2) 
C(19B)-N(1B)-C(9B)-C(4B)  -178.2(2) 
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C(5B)-C(4B)-C(9B)-N(8B)  -0.3(4) 
N(3B)-C(4B)-C(9B)-N(8B)  -178.1(2) 
C(5B)-C(4B)-C(9B)-N(1B)  178.69(19) 
N(3B)-C(4B)-C(9B)-N(1B)  0.9(3) 
N(6B)-C(5B)-N(10B)-C(11B)  139.6(2) 
C(4B)-C(5B)-N(10B)-C(11B)  -42.7(3) 
C(5B)-N(10B)-C(11B)-O(18B)  -12.7(4) 
C(5B)-N(10B)-C(11B)-C(12B)  167.2(2) 
O(18B)-C(11B)-C(12B)-C(17B)   
-33.7(3) 
N(10B)-C(11B)-C(12B)-C(17B)  
146.4(2) 
O(18B)-C(11B)-C(12B)-C(13B)  
141.3(2) 
N(10B)-C(11B)-C(12B)-C(13B)   
-38.7(3) 
C(17B)-C(12B)-C(13B)-C(14B)  1.3(3) 
C(11B)-C(12B)-C(13B)-C(14B)   
-173.6(2) 
C(12B)-C(13B)-C(14B)-C(15B)  -0.7(4) 
C(13B)-C(14B)-C(15B)-C(16B)  -0.8(4) 
C(14B)-C(15B)-C(16B)-C(17B)  1.7(4) 
C(15B)-C(16B)-C(17B)-C(12B)  -1.1(4) 
C(13B)-C(12B)-C(17B)-C(16B)  -0.4(3) 
C(11B)-C(12B)-C(17B)-C(16B)  
174.7(2) 
C(9B)-N(1B)-C(19B)-C(20B)  -84.7(3) 
C(2B)-N(1B)-C(19B)-C(20B)  98.0(3) 
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________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
  
Table 34.  Hydrogen bonds for 176 [Å and °]. 
 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
______________________________________________________________________ 
 N(10A)-H(10A)...N(3A) 0.85(3) 2.61(3) 2.991(3) 109(2) 
 N(10B)-H(10B)...N(6B)#10.89(3) 2.15(3) 3.020(3) 166(2) 
 
Symmetry transformations used to generate equivalent atoms:  
#1-x+1,-y+1,-z+1       
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